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Abstract 
Despite many advances in technology and significant levels of funding, the 
genetic factors that regulate blood pressure in the population remain unclear. 
The public health implications of this lack of knowledge are conspicuous and a 
better understanding of the mechanisms behind hypertension would lead to 
better management of this important risk factor. The myriad of physiological 
systems involved in maintaining blood pressure can be variably dysregulated in 
patients with hypertension. Therefore, taking more account of hypertension as a 
heterogeneous condition may be a useful approach. Given the lack of success in 
dissecting the genetic factors to date, it seems reasonable to refocus attention 
on more carefully phenotyped groups of subjects, with the aim of identifying 
mechanisms specific to them. 
 Hypertension with inappropriate aldosterone level for salt and volume status, as 
measured by the use of the aldosterone to renin ratio, is one such sub-
phenotype and is present in around 10% of hypertensive patients. This sub-
phenotype has been associated with both altered adrenal corticosteroid 
production and genetic variation in the aldosterone synthase (CYP11B2) and 11β-
hydroxylase (CYP11B1) genes. However, the mechanisms behind this genotype-
phenotype relationship are not apparent. It has been proposed that inefficient 
11β-hydroxylation leads to increased ACTH drive in order to maintain cortisol, 
and that this subtle increase over time leads to hyperplasia of the zona 
glomerulosa of the adrenal gland and an increased capacity for aldosterone 
production. Alternatively, as it is known that the aldosterone synthase and 11β-
hydroxylase genes are in a locus of high linkage disequilibrium. It may be that 
functional changes in the aldosterone synthase gene are co-inherited with 
functional changes in 11β-hydroxylase and this digenic phenomenon leads to the 
phenotype observed.  In order to test this second hypothesis, a number of 
investigations were carried out and are reported in this thesis.  
Firstly, the pattern of linkage disequilibrium in the promoter region of the 
aldosterone synthase gene is examined in chapter 3. Polymorphic variation in 
this region has previously been reported but the degree to which these 
variations are inherited in a “haplotype block” was unclear. In this study, it is 
demonstrated that the -344 polymorphism in CYP11B2, which has been widely 
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investigated in the past and is associated with hypertension and an elevated 
aldosterone to renin ratio, can serve as a surrogate for at least 5 other single 
nucleotide polymorphisms within 2 kilo bases of the transcriptional start site of 
the aldosterone synthase gene. As such, any of these polymorphisms could be 
responsible for alteration in transcriptional activity of the gene.  
In order to investigate the transcriptional activity of aldosterone synthase, a 
suitable in vitro model system is required. In chapter 4 the H295R cell line is 
assessed for this purpose. This cell line has been extensively used to explore a 
variety of aspects of adrenal function; it is the only human cell line capable of 
expressing the required steroidogenic enzymes and responding to trophins of 
steroid production. The investigations in chapter 4 confirm the presence of those 
characteristics of this cell line necessary for use as a model of transcriptional 
activity of the aldosterone synthase gene, as well as describing some of the 
limitations of this in vitro system. These include variation in steroidogenesis and 
enzyme expression over time in culture as well as the clear differences in terms 
of regulation of steroidogenesis from the in vivo system. In particular, the lack 
of zone-specific gene expression in the H295R cells in contrast to the normal 
adrenal gland is noted. 
Having validated a model of aldosterone production, chapter 5 describes the use 
of this model for investigations of the functional effects of variation in the 
aldosterone synthase promoter region. A sequence of experiments is described in 
this chapter. Initially, a bioinformatic search was undertaken to prioritise 
further investigations. This confirmed the theoretical possibility that single base 
changes in this region may lead to altered transcription factor binding. Using this 
data, a single site of variation in CYP11B2 (-1651 rs13268025) was selected for 
further study. Differential transcriptional activity was confirmed using gene 
reporter assays. This demonstrated that the C allele at -1651 of the promoter 
region of CYP11B2 was associated with greater transcriptional activity that the T 
allele at this site. It was hypothesised that this was due to altered transcription 
factor binding. Therefore, the next investigation was an assessment of DNA: 
protein interaction in the presence of the T or C allele at -1651. An 
electromobility shift assay demonstrated that a larger (less mobile) complex of 
radiolabelled DNA and nuclear protein from H295R cells was formed in the 
presence of the T allele than the C allele. This indicated that a previously 
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unidentified protein that bound more avidly to this region of the gene in the 
presence of the T allele could act as a transcriptional repressor. In order to 
identify this protein, biotinylated probes bond in a protein: DNA complex were 
captured by streptavidin beads and, following trypsin digestion, analysed by 
mass spectroscopy. This analysis suggested that a transcription factor called 
APE1 was detectable in the presence of the T allele but not the C allele. In order 
to test whether APE1 could act as a transcriptional repressor, it was inhibited in 
a further reporter gene assay. This confirmed that when APE1 was inhibited, 
there was greater transcriptional activity of aldosterone synthase promoter and 
that this inhibition was greater in the presence of the T allele. In summary, the 
evidence presented in this chapter suggests that the polymorphic variation at 
position -1651 of CYP11B2 is associated with allelic-dependant variation in 
transcriptional activity mediated by APE1. 
Finally, the effects of variation of the aldosterone synthase gene in human 
subjects were considered. Normal volunteers were studied under standardised 
conditions of posture and salt intake. Plasma responses to trophins of 
corticosteroid production were assessed as well as 24 hour urine collections for 
metabolites of corticosteroids. Data presented in Chapter 6 confirm that 
subjects homozygous for the T allele at -1651 have a lower excretion rate of 
aldosterone metabolites than subjects homozygous for the C allele. This is 
consistent with the notion that these individuals have less transcriptional 
activity of the aldosterone synthase gene. No allele-dependant difference was 
observed in response to salt intake or in response to trophins of aldosterone was 
observed, and some of the possible reasons for this are discussed.  
In summary, this work confirms that the linkage disequilibrium across the 
aldosterone synthase gene promoter region is high, as is the linkage 
disequilibrium across the entire CYP11B1/CYP11B2 locus. It demonstrates that a 
number of polymorphisms are co-inherited with the -344 SNP in CYP11B2. 
Variation at -1651 of CYP11B2 is shown to be associated with allele-dependant 
variation in transcriptional activity of the aldosterone synthase promoter region. 
Data are presented to support the hypothesis that the transcription factor APE1 
binds more avidly to the T allele at -1651 and acts as a transcriptional repressor. 
This is supported by the data from normal volunteers confirming that the T 
allele is associated with reduced aldosterone production. These findings 
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demonstrate how a common polymorphic variant might lead to a functional 
change in gene expression that translates into an important physiological 
phenotype. Further work is required to establish precisely how APE1 functions to 
alter transcriptional activity of this gene and whether this knowledge can be 
utilised to improve clinical care. 
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1. Introduction 
1.1 Hypertension 
1.1.1 Historical context 
 Hypertension remains the most significant modifiable risk factor for 
cardiovascular disease and makes a major contribution to the global burden of 
disease (World Health Organisation, 2002). Despite advances in understanding of 
the pathophysiology of hypertension as well as a significant expansion in 
therapies available, the effect of uncontrolled disease on morbidity and 
mortality continues to rise.  
 Historically, many of the consequences of high blood pressure have been 
recognised for hundreds of years, but it was only with the invention of accurate 
methods of measurement of blood pressure that the study of blood pressure 
advanced. Our current understanding of blood pressure began in the age of 
Enlightenment: this era inspired reasoned enquiry in the field of natural 
philosophy in general, and the study of cardiovascular physiology and blood 
pressure was not left behind. The spirit of the age was embodied by the 
Reverend Stephen Hale, who was the first to physically demonstrate blood 
pressure in 1733 (Hales, 1733). He inserted one end of a brass tube into the 
artery of a horse and attached a vertical glass tube, to the other. Blood pressure 
was demonstrated when the artery which had been tied off was released and 
blood rose in the tube to a height of eight feet three inches above the left 
ventricle of the heart. Despite this clear demonstration of physiology, it was not 
until 1896 that this was used in a practical sense when an Italian physician, Dr 
Scipione Riva-Rocci, developed an inflatable rubber cuff that occluded the 
artery of the upper arm (Riva-Rocci S., 1896). Systolic blood pressure 
corresponded to the pressure at which the brachial pulse could no longer be 
palpated and his device was strongly promoted by Dr Harvey Cushing the 
neurosurgeon and one of the founding fathers of endocrinology (Cushing H, 
1903). However, the measurement of systolic and diastolic blood pressure did 
not become a common clinical measurement until 1905, when Dr Korotkoff 
described the systolic and diastolic sounds that can be heard with a stethoscope, 
just below the levels that Riva-Rocci palpated using his inflatable cuff (Korotkoff 
NC, 1905). Thus, having established a more accurate measurement technique, 
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the debate began regarding what was considered normal blood pressure, and 
was the stimulus to a rapid expansion in the investigation of the pathogenesis of 
the elevated blood pressure values. From a clinical perspective, it became 
possible for the first time to identify patients with elevated blood pressure prior 
to developing end organ damage as well as monitor treatment.   
1.1.2 Hypertension: The clinical definition 
 Although the advances made by the pioneers of blood pressure measurement 
allowed physicians to objectively monitor blood pressure, blood pressure targets 
and the threshold for intervention has been a subject of controversy since that 
time. Hypertension could be defined as a “blood pressure level above which 
investigation and treatment do more good than harm”; a definition that was first 
used by Evans and Rose in 1971 (Evans and Rose, 1971) and this remains a useful 
tenet today. To that end, the concept of cardiovascular risk has gained 
prominence and an estimation of this can be calculated based on extensive 
epidemiological data gathered from the Framingham study (Anderson et al., 
1991) or other sources (Woodward et al., 2007). This allows the synthesis of 
numerous risk factors (e.g. age, gender, cholesterol, blood pressure) in 
considering the prevention of cardiovascular disease. Nevertheless, cut off 
values are required, however arbitrary, and the British Hypertension Society 
gives clear guidelines regarding the thresholds for treatment as well as targets, 
in the context of overall cardiovascular risk (Williams et al., 2004) (see Table 
1-1). Blood pressure targets are based on resting clinic blood pressure 
measurements, using instruments based on Riva-Rocci and Korotkoff’s 
observations with standardised techniques in order to increase reproducibility 
and minimise error (Williams et al., 2004) (see Table 1-2). 
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CATEGORY SYSTOLIC BLOOD 
PRESSURE 
(mmHG) 
DIASTOLIC BLOOD 
PRESSURE 
(mmHG) 
Optimal blood pressure 
Normal blood pressure 
High-normal blood pressure 
 
<120 
<130 
130–139 
<80 
<85 
85–89 
Grade 1 Hypertension (mild) 
Grade 2 Hypertension (moderate) 
Grade 3 Hypertension (severe) 
140–159 
160–179 
>180 
90–99 
100–109 
>110 
Isolated systolic hypertension 
(Grade 1) 
140–159 <90 
Isolated systolic hypertension 
(Grade 2) 
>160 <90 
Table 1-1 British Hypertension Society classification of blood pressure levels.  
Report of the fourth working party of the British Hypertension Society, 2004—BHS IV 
(Williams et al., 2004). 
 
GUIDELINES FOR BLOOD PRESSURE MEASUREMENT 
 
Use a properly maintained, calibrated and validated device 
 
Measure sitting blood pressure routinely: standing blood pressure 
should be recorded at the initial estimation in elderly and diabetic 
patients 
 
Remove tight clothing, support arm at heart level, ensure hand 
relaxed and avoid talking during the measurement procedure 
 
Use cuff of appropriate size 
 
Lower mercury column slowly (2 mm/s) 
 
Read blood pressure to the nearest 2 mmHg 
 
Measure diastolic as disappearance of sounds (phase V) 
 
Take the mean of at least two readings; more recordings are needed 
if marked differences between initial measurements are found. 
 
Do not treat on the basis of an isolated reading 
 
Table 1-2 Guidelines for blood pressure measurement. 
 Report of the fourth working party of the British Hypertension Society, 2004—BHS IV 
(Williams et al., 2004) 
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 There is an awareness that blood pressure measurements as one-off, office 
assessments may not reflect the day-to-day blood pressure of patients and 
alternatives to this have been proposed including ambulatory monitoring, and 
home blood pressure monitoring (O'Brien et al., 2003; Stergiou and Bliziotis, 
2011; Hodgkinson et al., 2011). It should be borne in mind that the thresholds 
for diagnosing hypertension are lower using these methods. There is mounting 
evidence to support both ambulatory and home monitoring as efficacious and 
cost effective in terms of diagnosis (Lovibond et al., 2011), and this has resulted 
in a recent change to the NICE guidelines (http://guidance.nice.org.uk/CG127) 
published in August 2011, to support the use of use of ambulatory blood pressure 
monitors to confirm the diagnosis of hypertension.  However, there are limited 
data to inform clinicians regarding appropriate targets for treatment using this 
method of monitoring.  
 In addition, given the current and appropriate focus on blood pressure as a 
function of overall cardiovascular risk (British Cardiac Society, 2005), interest 
has been shown in measurements that may better reflect this. For example, 
pulse wave analysis as an indication of central pressure measurements has been 
proposed as a prognostic marker which could assist in cardiovascular assessment 
(Task Force Members: et al., 2007). Measurement of this index has been 
hampered by the invasive nature of the gold standard method of measuring 
central pulse pressure or by controversy over the relevance of surrogate 
markers. Williams et al have recently proposed a novel method of measurement 
and analysis of radial artery pulse wave velocity and recommend its clinical 
utility in assisting in identifying and monitoring disturbances of blood pressure 
(Williams et al., 2011). However, a lack of outcome data with all these 
measurements hinders their use in clinical practice and measurements seated in 
the clinician’s consulting room, using the traditional brachial cuff instrument, 
developed over 100 years ago, remain the cornerstone of blood pressure 
management.  
1.1.3 Aetiology of essential hypertension 
Although distinct values have been determined for the diagnosis of hypertension, 
it is recognised that blood pressure is a continuous variable with a normal 
distribution and it has been many years since the continuous association 
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between increasing blood pressure values and increased cardiovascular risk was 
confirmed (Hamilton et al., 1964). In around 5% of patients with elevated blood 
pressure a clear pathophysiological mechanism can be identified but in the 
remainder, it is very likely that multiple genetic and environmental influences 
combine to determine blood pressure. This thesis will focus on the role of 
genetic variation in a candidate gene, aldosterone synthase, and its role in 
hypertension and relative aldosterone excess. However, I will first discuss some 
of the other contributing factors to the development of hypertension as well as a 
brief overview of investigations to date exploring relevant physiological and 
genetic factors leading to hypertension. 
Lifestyle factors  
 The majority of this thesis will focus on genetic and pathophysiological 
mechanisms for the development of hypertension. However it is important to 
mention in brief the lifestyle mechanisms that have contributed to the 
significant increase in global burden of hypertension.  
 Weight gain is associated with a rise in blood pressure (Masuo et al., 2000) and 
strategies to lose weight have been shown to result in lower blood pressure. A 
meta-analysis of 25 randomised controlled trials included 4874 participants from 
different ethnic populations and showed a blood pressure reduction of 4.4/-3.6 
mm Hg for around 5kg weight loss either by energy restriction, increased 
physical activity, or both (Neter et al., 2003). Exercise, even in the absence of 
weight loss improved blood pressure parameters. A further meta-analysis of 54 
trials showed that blood pressure reduction of 3.8 mmHg SBP (95% CI 2.7 to 5.0 
mm Hg, p <0.001) and 2.6 mmHg DBP (95% CI 1.8 to 3.4 mm Hg, p < 0.001) with 
regular aerobic exercise. This effect was achieved in people regardless of their 
initial blood pressure, weight or ethnicity (Whelton et al., 2002).   
 Placebo-controlled studies have shown that reduced sodium intake lowers blood 
pressure and increases response to pharmacological therapy (Cappuccio et al., 
1997; Elliott, 1989; Cutler and Stamler, 1997).  However, until very recently, 
evidence of long term benefit was lacking. This has now been addressed in a 
recent major long term follow up study (Cook et al., 2007) where reduction in 
dietary sodium intake is associated with a reduced risk of cardiovascular 
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morbidity and mortality (relative risk 0.75, 95% CI 0.57 to 0.99, p=0.04 adjusted 
for trial, clinic, age, race, and sex). The interaction of potassium and sodium 
status has been proposed as an important factor in the regulation of blood 
pressure. Epidemiological data provide support for this view in that those 
societies with low sodium/ high potassium diets have lower blood pressure than 
industrialised societies (Adrogue and Madias, 2007). Potassium supplementation 
is associated with a  reduction in blood pressure (Whelton et al., 1997) and the 
need for antihypertensive medication (Siani et al., 1991). In addition, the DASH 
trial (Appel et al., 1997) demonstrated that a fruit and vegetable rich diet 
containing a potassium content more than twice that of an average American 
diet, reduced blood pressure to a greater extent than controls with a similar 
level of sodium.  
Genetic factors 
Clearly environmental influences must be taken into account both by the 
patient, their physician, as well as public health organisations. However, 
environmental factors only account for part of blood pressure variation and 
genetic factors are estimated to account for 15-40%.  
 
Figure 1-1 Interaction of genetic and environmental factors leading to elevated blood 
pressure.  
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The search for genes responsible for blood pressure variation remains ongoing. 
While some rare monogenic conditions have a large impact on an individual’s 
blood pressure, more common genetic variations at multiple loci with smaller 
effects on blood pressure are likely to have a cumulative effect. Strategies for 
investigation of hypertension based on these approaches will be discussed in 
more detail in section 1.1.5 to 1.1.8.  
 As most investigation of culprit genes has focused on those involved in 
physiological systems known to regulate blood pressure, a brief overview of 
some of the homeostatic systems of blood pressure control will now follow.  
1.1.4 Physiological regulation of blood pressure. 
 Normal control of blood pressure depends on a number of complementary 
neural, endocrine and paracrine mechanisms and the development of 
hypertension can result from perturbation of any or all of these. Blood pressure 
depends on cardiac output which is a function of heart rate and stroke volume 
multiplied by peripheral resistance. While systems that modulate all three of 
these variables will be discussed in the following section, the main focus will be 
on the renin- angiotensin- aldosterone system (RAAS) and in particular, 
aldosterone, which will be discussed at greater length in this work. 
Renin-angiotensin- aldosterone system 
The RAAS plays a crucial role in the regulation of blood volume. The classical 
mechanisms of homeostatic control mediated by the RAAS are demonstrated in 
Figure 1-2. Angiotensinogen, mainly synthesised in the liver, is cleaved by renin 
to form angiotensin I. Renin (encoded by the REN gene on chromosome 1) is 
released from the juxtaglomerular cells in the kidney in both an active and 
inactive form in response to signals from baroreceptors in the afferent arteriole, 
sympathetic neural activity and circulating catecholamines as well as 
chemoreceptor in the macula densa of the distal tubule. Prorenin (the inactive 
form) is cleaved to form active renin in vivo (Hsueh and Baxter, 1991) (this 
reaction requires recognition as cryoactivation of prorenin to renin can be a 
source of measurement errors unless samples are properly handled). Increased 
pressure to the juxtaglomerular cells inhibits renin release, thus forming a 
conventional negative feedback loop and maintaining homeostasis.  
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 The angiotensin I peptide is the substrate for angiotensin converting enzyme 
(ACE), which cleaves angiotensin I to the biologically active angiotensin II 
(AngII). There are at least two subtypes of AngII receptors: the cardiovascular 
actions are effected mainly via the angiotensin type 1 (AT1) receptor (de 
Gasparo et al., 2000), mediating  numerous physiological actions including 
vasoconstriction and increased sodium and water retention both directly via the 
renal tubule cells and via aldosterone. These actions are described in Figure 1-2. 
The AT2 receptor is thought to antagonise some of these effects of the AT1 
receptor and appears to have a mainly hypotensive action although the precise 
nature of this is still a subject of debate (de Gasparo et al., 2000). 
 
Figure 1-2 Schematic representation of the classical renin-angiotensin-aldosterone system.  
 
 Angiotensin II was until relatively recently thought to be the critical and central 
product of the RAAS, but current evidence suggests an important role of a 
number of other biologically active peptide products of the RAAS. Angiotensin II 
is swiftly degraded via the enzymatic action of aminopeptidase A, giving rise to 
angiotensin III (AngIII or Ang 2-8) and this can be further cleaved to form 
Angiotensin  IV (AngIV or Ang 3-8), via aminopepdidase N. Ang III can bind to the 
AT1 receptor and there is evidence that this peptide has a centrally acting 
pressor effect; intracerebroventricular injections cause blood pressure to rise 
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(Wright et al., 1985), and aminopeptidase A inhibitors that can cross the blood 
brain barrier have been shown to reduce blood pressure in experimental animals 
(Fournie-Zaluski et al., 2004).  
 Angiotensin I can also be converted to angiotensin 1-7 by neutral 
endopeptidase, and it can also be generated from angiotensin II by angiotensin 
converting enzyme 2 (ACE2) (Donoghue et al., 2000). Angiotensin 1-7 appears to 
act as a vasodilator and the discovery of the ACE2 enzyme and its product has 
refocused investigation of the RAAS. Much interest has been shown in 
understanding its mechanism of action as well as potentiating its effects 
(Ferrario et al., 2005) but the physiological implications of these novel peptides 
remain unclear, particularly given their very short half lives in vivo.  
Bradykinin is a peptide with vasodilating properties and is part of the kallikrein-
kinin cascade, an important system of modulation of the cardiovascular system 
in its own right. It is known to be an alternative substrate for angiotensin 
converting enzyme (ACE). Pharmacological inhibition of ACE leads to increased 
bradykinin (in clinical practice this manifests as the most common side effect of 
cough) and is has been proposed that this may contribute to the beneficial 
effects of these agents (Sharma, 2006). A summary of these novel products of 
the RAAS are demonstrated in Figure 1-3. 
 
Figure 1-3 Schematic representation expanded renin angiotensin system.  
Enzymes are shown in shaded boxes and their role in enzymatic reactions by dotted arrows. 
Peptides with vasodilating properties are in italics.  
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 Thus, it is now apparent that the traditional concept of a simple, sequential 
pathway underestimates the complexity and sophistication of the RAAS. Further, 
it is clear that manipulation of the system as in the pharmacological treatment 
of hypertension can have multiple feedback consequences that were previously 
unrecognised. Of course, aldosterone is the end product of the RAAS and further 
discussion of its regulation and mechanism of action can be found in section 1.2 
and 1.3.  
Sympathetic nervous system 
The sympathetic nervous system influences the control of blood pressure both by 
regulating heart rate directly by innervations of the cardiac muscle to increase 
heart rate (positive chronotropy), inotropy and conduction velocity (positive 
dromotropy), via  beta-adrenoceptors, as well as activation of alpha 
adrenoreceptors in the adventitia, leading to vasoconstriction of the peripheral 
vasculature and increased peripheral resistance. In addition, it contributes in a 
more indirect manner via release of humoral factors into the blood stream. 
Renin release from the juxtaglomerular cells in the kidney is stimulated by 
sympathetic nerve activation, triggering the RAAS system discussed above 
(Gordon et al., 1967). Angiotensin II enhances the release of norepinephrine 
from sympathetic nerve endings and inhibits re-uptake, leading to enhanced 
sympathetic adrenergic function and producing a feedback loop (Wang et al., 
1997). Catecholamine release from the adrenal medulla contributes to the 
maintenance of blood pressure. Indeed, as the medulla originates from 
neuroectoderm tissue, it can be viewed as a modified sympathetic ganglion.  
The crucial role of the sympathetic nervous system (and the kidney as a key 
modulator of a number of pathophysiological mechanisms) has recently been 
highlighted in a study demonstrating the efficacy of selective renal denervation 
in the management of treatment-resistant hypertension (The Simplicity HTN-2 
Trial, 2010). The authors propose that selective denervation of the kidneys 
reduces renin release, renal blood flow and central sympathetic outflow and 
provide evidence that, in patients with hypertension resistant to pharmaceutical 
intervention, this technique is effective in lowering blood pressure by 
32/12mmHg (St Dev 23/11). Although the role of the sympathetic nervous 
system in both the aetiology and treatment of hypertension is the subject of 
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ongoing investigation, it is beyond the scope of this current work and will not be 
discussed further. 
Oxidative stress 
 The concept of oxidative stress as a key mechanism in the control of blood 
pressure and the development of hypertension has been the focus of much 
research. Increased generation or reduced clearance of reactive oxygen species 
leads to increased oxidative stress and this, it is suggested, leads to a myriad of 
alterations in cell signaling, ultimately leading to vascular injury, remodeling 
and hypertension (Briones and Touyz, 2010). While perturbations in oxidative 
stress have been shown to be associated with cardiovascular disease, it remains 
to be established whether this is a cause or a result of the underlying 
pathological mechanisms. For example, both animal models (Rocha et al., 1999) 
and human examples of aldosterone excess (Farquharson and Struthers, 2002) 
are associated with increased markers of oxidative stress.  
Given these various factors, it is apparent that the mechanisms of maintaining 
blood pressure homeostasis are interdependent and interconnected, involving 
numerous humoral factors and organ systems but ultimately culminating in their 
major effect on salt and water homeostasis mediated via the kidneys. Data from 
both animal (Rettig et al., 1990) and human (Curtis et al., 1983) studies 
underline this, with the observation that renal transplantation can normalise 
blood pressure in previously hypertensive subjects. With this in mind, there will 
now follow a discussion of investigations of genetic factors that may contribute 
to perturbations of blood pressure regulation.  
1.1.5 Genetic basis of hypertension 
 Hypertension has a strong genetic component, as clearly demonstrated by 
family and twin studies (Williams et al., 1991; Hunt et al., 1989; Havlik et al., 
1979; Rose et al., 1979). While there are lifestyle factors, as discussed above 
(1.1.3), that influence blood pressure, it is a highly heritable trait and family 
history remains one of the strongest predictors of future risk of developing high 
blood pressure. It seems likely that these genetic factors will lie in genes 
involved in systems which are known to contribute to the control of blood 
pressure (as described above). However, despite much investigation focused on 
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these systems, a comprehensive understanding of the causative genetic factors 
has not yet been achieved. 
 In recent years, two separate strategies have been proposed to investigate the 
genetic aetiology of hypertension. One focuses on comparing the prevalence of a 
specific candidate gene or genes identified from the systems previously 
described in groups of hypertensive or control subjects. The other is to seek to 
identify causative genetic regions by comparing the entire genome in groups of 
normotensive and hypertensive individuals. The following section will discuss 
some aspects of the progress made to date using these two approaches. 
1.1.6 Candidate gene studies 
 This approach depends on a detailed knowledge of the disease, and of the 
systems that might be responsible, in order to make a “best guess” at genes that 
have a high probability of being involved. Many of the studies using this 
approach have examined genes known or suspected to be involved in monogenic 
disorders of blood pressure regulation, and postulating that “essential” 
hypertension is a forme fruste of these conditions. After selecting the candidate 
gene of interest, the hypothesis is that if variation in a particular gene is 
responsible for elevated blood pressure it will be over represented in a group of 
patients with hypertension compared with a matched group of controls. There 
are numerous examples of monogenic conditions causing blood pressure 
disturbance and subsequent investigations into the mechanisms underlying them 
has informed the study of population variation in blood pressure. The specific 
examples regarding monogenic disorders of sodium chloride transport in the 
renal tubule are given below. However, a fuller list of monogenic disorders of 
blood pressure regulation incorporating other mechanisms including adrenal 
steroidogenesis and action is given in Appendix 7.1. 
Monogenic disorders of the distal convoluted tubule and the thick ascending 
limb 
 Monogenic disorders causing defects in the sodium chloride co-transporter of 
the apical (luminal) membrane in the distal convoluted tubule and thick 
ascending loop of Henle΄ can lead to dysregulation of blood pressure and 
electrolytes- Gitelman, Bartter and Gordon syndromes are all examples of this. 
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Greater understanding of these disorders has resulted in the identification of a 
number of candidate genes for hypertension. 
 Gitelman’s syndrome is characterised by renal salt wasting, resulting in 
hypokalaemia, hypomagnasaemia, hypocalciurea, metabolic alkalosis and low 
blood pressure. In addition, patients compensate for their salt wasting by 
activating the RAAS i.e. increasing serum renin and aldosterone levels. The 
molecular defect is known to be in the thiazide-sensitive sodium chloride 
cotransporter of the distal convoluted tubule (Figure 1-4). Mutations on solute 
carrier family 12 (sodium/chloride transporters), member 3 (SLC12A3) gene on 
chromosome 16, causes this condition (Simon et al., 1996) which is inherited in 
an autosomal recessive manner. This clinical syndrome resembles that seen in 
patients abusing thiazide diuretics.  
 
Figure 1-4 Schematic representation of salt losing tubulopathy Gitelman’s syndrome. 
 In the distal convoluted tubule Na+Cl- moves from the tubular lumen into the cell along a 
concentration and electrical gradient. A Na+-K+ ATPase pump allows Na+ to be reabsorbed at 
the basolateral membrane back into the circulation. Cl- is reabsorbed via a Cl- channel in the 
basolateral membrane. Calcium passes across the luminal membrane via a Ca2+ Channel 
and binds to vitamin D-induced binding protein (Ca-BP). It is then exchanged for Na+ which 
follows the concentration and electrical gradient. The site of disruption of these processes 
in Gitelman’s syndrome is shown in the apical membrane of the distal convoluted tubule. 
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 The thiazide-sensitive sodium chloride transporter in the distal convoluted 
tubule can also be affected by a gain of function mutation causing high blood 
pressure. This causes a phenotype precisely opposite to Gitelman syndrome and 
is known as pseudohypoaldosteronism type 2 (PHAII) or Gordon syndrome. The 
clinical features of hypertension, hyperkalemia, metabolic acidosis, normal renal 
function, low or low-normal plasma renin activity and normal or elevated 
aldosterone concentrations are inherited in an autosomal dominant fashion. The 
primary physiological defect in PHAII is enhanced distal chloride reabsorption 
and it is interesting to note that the abnormalities can be corrected by a 
thiazide diuretic, which these patients are exquisitely sensitive to. However, in 
contrast to Gitelman’s syndrome, there is no defect in the gene encoding the 
sodium chloride transporter in the DCT (SLC12A3) but rather mutations in genes 
located on chromosomes 12 and 17. These encode With No Lysine (WNK) 
serene/threonine kinases 1 and 4 respectively (Wilson et al., 2001). WNK1 and 4 
localise to the DCT and cortical collecting duct and are involved in the 
regulation of the NaCl transporter. In the presence of WNK4, the transporter is 
down regulated and in the presence of some isoforms of WNK1, WNK4 itself is 
down regulated (Yang et al., 2003) The WNK enzymes act via a kinase cascade, 
phosphorylating the effector kinases SPAK (Ste20-related proline-alanine−rich 
kinase)  and OSR1 (odd-skipped-related 1) shown in Figure 1-5.  
 
Figure 1-5 Kinase cascade regulating sodium/chloride transport.  
 In PHAII mutant WNK4 leads to loss of inhibition of sodium chloride cotransporter and 
increased expression at the apical surface 
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 With increased understanding of these monogenic disorders of blood pressure 
regulation, attempts have been made to implicate these in population blood 
pressure variation. Ji et al studied variation in the genes SLC12A3 (Gitleman’s 
syndrome), KCNJ1 and SLC12A1 (mutations here are known to be associated with 
Bartter’s syndrome), in the Framingham Heart Study offspring cohort (Ji et al., 
2008). 3125 individuals from this cohort had DNA available for analysis. They 
found that the carrier state for rare functional mutations in SLC12A1, SLC12A3 
and KCNJ1 reduced blood pressure by on average 6.3mmHg systolic 
measurements and -3.4mmHg diastolic. 
 A further examination of polymorphic variants in these genes and association 
with hypertension was undertaken in the GRAPHIC (Genetic Regulation of 
Arterial pressure of Humans in the Community) cohort (Tobin et al., 2008). This 
family study recruited 2037 individuals from around 500 families. The 
investigators looked at variants with a frequency of >0.1 in genes known to be 
involved in monogenic forms of altered blood pressure regulation. The study 
demonstrated a significant association between 5 single nucleotide 
polymorphisms (SNP) in KCNJ1 and mean 24 hour SBP and DBP. The effect size of 
the variants in this study was modest and in the order of -1.58mmHg for mean 
SBP and -0.95 for mean DBP. In this study, which was limited to examining 
common variants, no association was found in other genes involved in monogenic 
disorders, specifically those involved in other forms of Bartter’s syndrome, 
Gitelman’s syndrome, apparent mineralocorticoid excess, Liddle’s syndrome and 
autosomal recessive pseudohypoaldosteronism.  
 The same investigators had previously interrogated this cohort to examine the 
effect of SNPs in the WNK1 (9 SNPs) and WNK4 genes (1 SNP) and hypertension 
(Tobin et al., 2005). 996 individuals from 250 families were studied and an 
association was found between 4 polymorphisms in the WNK1 gene and mean 24 
hr SBP and 5 SNPs in WNK1 with mean DBP. The effect size was small, affecting 
both SBP and DBP by less than 1.5mmHg. There is little variability in the WNK4 
gene in Caucasian population and in this study, there were no associations with 
variation in WNK4 (one polymorphism) and blood pressure. The British Genetics 
of Hypertension study (BRIGHT) (Newhouse et al., 2005) also confirmed an 
association between variations in the WNK1 gene and extremely hypertensive 
subjects. Importantly, the BRIGHT investigators extended and replicated these 
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findings in a large case control cohort composed of 6 sub-studies (Newhouse et 
al., 2009). Although the effect of WNK1 variation did not always reach statistical 
significance in the replication groups, there was consistency in the direction of 
effect, and in combination the statistical association was strong in the 
replication groups. These findings in a large study cohort, with replication in an 
independent sample, using careful and comprehensive genotyping and 
appropriate statistical analysis, provided convincing evidence of the involvement 
of WNK1 in the pathogenesis of hypertension. It is also interesting to note that 
the BRIGHT investigators also found a significant blood pressure effect of rare 
haplotypes, in line with the findings of Ji et al (Ji et al., 2008) and Tobin et al 
(Tobin et al., 2008) as discussed above.  
1.1.7 Candidate Gene studies: Conclusions 
Major advances in the understanding of pathways involved in blood pressure 
regulation, renal salt handling and monogenic disorders of blood pressure have 
increased dramatically and this has led to focused exploration of candidate 
genes. However, despite this expansion in knowledge, there has been limited 
success in extending this to our understanding of genetic causes of essential 
hypertension. There are significant limitations of the candidate gene approach 
as there remain areas of incomplete understanding and possible pathways as yet 
undiscovered. The candidate gene approach is distinctly biased towards known 
pathways and previously explored hypotheses and unexpected genes involved in 
novel pathways could be missed. In addition, as most candidate gene studies 
investigate only one gene or one pathway at a time, the impact of gene-gene 
interactions and pathway-pathway interactions is not taken into account. This 
may lead to false positive or false negative studies. 
 In addition, given current knowledge of the likely small effect size of each 
mutation, most candidate gene association studies were too small and, as a 
result, underpowered to detect an effect. Perhaps as a consequence, there have 
often been conflicting reports regarding whether the variant of interest is 
associated with disease, and there have often been as many negative studies 
associated with a gene of interest as positive. Many examples of these are 
described above. Further explanation for this is likely to lie in the different 
ethnicities of study populations; there is significant variation in the haplotypes 
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structures of different ethnic groups, as well as often widely varying allele 
frequencies. These population differences have a substantial influence on the 
outcome of case-control studies, particularly bearing in mind that positive 
studies only confirm association and not causation. Thus, given the well 
recognised phenomenon of linkage disequilibrium, the genotyped polymorphism 
may not be functional, but merely co-inherited with the functional variation. 
Further, differences in study population sizes, definitions of disease as well as 
altered and unquantified changes in environmental factors are all likely to 
contribute to the heterogeneity of the results of many candidate gene studies. 
In response to some of the inherent flaws in the design of candidate gene 
studies, the alternative “genome wide” approach was proposed. This is discussed 
in the following section.  
1.1.8 Linkage analysis and GWAS 
Given that the inherent drawback of the candidate gene approach is the 
restrictive nature of the investigations in which results are limited to known 
pathways, alternatives have been proposed which do not suffer from this bias.  
Linkage analysis 
Linkage studies are a method whereby regions of a genome that contain genes 
which may be responsible for a trait can be identified. In order to understand 
linkage studies, two simple terms must be comprehended: linkage, and linkage 
disequilibrium. These terms have been used above but an understanding of the 
distinction between them is important. Two loci are linked if they are inherited 
together more often than expected if inheritance is random. Therefore, during 
meiosis, recombination occurs between the loci with a probability of less than 
50%. However, linkage disequilibrium (LD) refers to the phenomenon observed in 
a population when the two loci are found together on the same haplotype more 
often than expected. When recombination events occur between the two loci, 
linkage disequilibrium is weakened. LD is preserved the closer the loci are to 
each other.  
Linkage studies utilise family based cohorts and DNA is examined for areas that 
are shared by affected relatives but not by unaffected family members. Non-
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identical siblings should share 50% of the genome, so for any individual marker, 
the chance of sib pairs carrying the same marker is 1:2. In sib pairs that are both 
affected by hypertension, the allele close to the locus causing hypertension 
should be should shared more often. This allows the identification of 
quantitative trait loci (QTL) within which the causative gene may be located but 
depends on the phenomenon of linkage disequilibrium between the marker used 
(either a SNP or microsatellite) and the causative gene. Linkage is assigned a 
logarithm of the odds (LOD) score; large positive scores are evidence for linkage, 
and negative scores are evidence against. A LOD score of 3 is regarded as 
significant evidence of linkage with genome wide significance and this is 
equivalent to a p value of 00001. The QTL may encompass a significant area of 
the genome and does not identify the gene responsible for the phenotype.  
Numerous linkage studies for hypertension have been undertaken over the last 
10 years. Many linkage peaks have been identified but few have achieved LOD 
scores that suggest genome wide significance and fewer still have been 
replicated. Studies that have successfully isolated statistically significant 
associations suggesting association with chromosome 17q (60-76cM) (Levy et al., 
2000) from the Framingham cohort, 18q (80-94cM) in a genetically homogenous 
Icelandic cohort (Kristjansson et al., 2002), 4p (13-43cM) in a study of 18 Dutch 
families (Allayee et al., 2001) and 2p (26.5-27.1cM) in probands with severe 
hypertension from an isolated Sardinian village (Angius et al., 2002). In addition, 
the BRIGHT investigators identified a susceptibility locus on chromosome 6q in 
their cohort of severely hypertensive sib pairs (Caulfield et al., 2003). It is 
interesting that none of these results have been replicated within this group of 
studies, nor has there been any publication of replication with the same degree 
of statistical significance in the rest of the literature. The reason may be in the 
genetic heterogeneity of the different study populations with different genetic 
aetiologies underlying the causes of hypertension, altered effect size of the loci 
in different populations, and varying degrees of linkage disequilibrium in 
discrete ethic groups.  
Genome wide association studies 
With the advent of the Human Genome Project and the International HapMap 
project, a more complete knowledge of the reference sequence and the 
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common variations from this within the human genome, as well as a better 
understanding of the pattern of linkage disequilibrium was available. As a result, 
the linkage strategy was expanded and “tag SNPs” could be nominated to 
represent portions of the genome and give comprehensive coverage and the 
genome of cases and controls compared. High throughput genotyping using 
microarray chips enabled the practical application of this detailed understanding 
of the human genome to be interrogated further. This has allowed the 
genotyping of up to a million SNPs in thousands of cases and controls, and the 
conclusions of these studies were eagerly awaited and published in 2007. Initial 
results did not provide major insights into the origins of hypertension; the 
Wellcome Trust Case Control Consortium failed to identify any SNPs that were 
significant at a genome wide level (Wellcome Trust Case Control Consortium, 
2007). However, proof of concept was achieved in the identification of 
association signals in bipolar disorder, coronary artery disease, Crohn’s disease, 
rheumatoid arthritis, Type 1 diabetes and Type 2 diabetes. It was suggested that 
the reason for a lack of association with any SNPs for hypertension may have 
been that the effect size for each SNP was too small and as such the study was 
underpowered to detect them. A potential confounding factor was the validity of 
controls in this study as there was a significant discrepancy in age (cases mean 
age 68, controls mean age 48). This may have led to misclassification of controls 
that may go on to develop hypertension over the next 10-20 years. In addition, it 
was suggested that greater coverage across the genome could be achieved and 
this was undertaken in subsequent studies using 1000K chips.  
 In recognition that larger populations were needed, researchers collaborated to 
pool resources internationally. Two “mega-analyses” were constructed by 
collecting numerous biobanks of data. This resulted in the publication in 2009 of 
the Global BP-Gen consortium (Newton-Cheh et al., 2009) and the Cohorts for 
Heart and Ageing Research in Genome Epidemiology (CHARGE) BP consortium 
(Levy et al., 2009). These studies included 34,433 individuals from 17 studies in 
the Global BP-Gen and 29,136 individuals from 6 cohorts in the CHARGE study. 
Both undertook a comparison with data from the other study and were published 
simultaneously in Nature Genetics in 2009. The CHARGE study identified 13 SNPs 
for SBP, 20 for DBP and 10 for hypertension at P < 4 10-7 while the Global BP-
Gen study identified 3 SNPs for SBP and 5 for DPB. However, due to differences 
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in analysis, the results from each investigator were not identical and only 
CYP17A1 and SH2B2 achieved genome wide significance in both analyses for 
phenotypes of blood pressure (See Table 1-3). The magnitude of the effect on 
blood pressure varied between 0.5-1.5mmHg.  
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Chromosome Gene 
 
Possible 
Pathway  
 
Phenotype Study 
Ch10 CYP17A1 Steroidogenesis SBP 
HTN 
CHARGE 
BP-Gen 
Ch12 SH2B3 Negative regulator 
of cytokine 
signalling 
 
DBP CHARGE 
BP-Gen 
Ch 1 MTHFR Homocystine 
metabolism 
 
SBP 
DBP 
BP-Gen 
Ch 17 PLCD3 Phospholipase C, 
catalyses formation 
of second 
messengers (DAG, 
IP3) 
 
SBP BP-Gen 
Ch 4 PRDM8/ 
FGF5 
Fibroblast growth 
factor family 
 
DBP 
HTN 
BP-Gen 
Ch 15 CYP1A2 Drug metabolism 
 
DBP BP-Gen 
Ch 10 c10orf107 Uncharacterised 
protein 
 
DBP BP-Gen 
Ch 17 ZNF652 Zinc finger protein, 
transcriptional 
repressor 
 
DBP BP-Gen 
Ch 11 PLEKHA7 Cellular structural 
protein 
 
SBP CHARGE 
Ch 12 ATP2B1 Plasma membrane 
calcium pump 
SBP 
DBP 
HTN 
CHARGE 
Ch 10 CACNB2 Voltage dependant 
calcium channel 
protein 
 
DBP CHARGE 
Ch 15 CSK-ULK3 Sereine/threonine 
protein kinase 
 
DBP CHARGE 
Ch 12 TBX3-TBX5 Transcriptions 
factors involved in 
embryological 
development 
 
DBP CHARGE 
Ch 3 ULK4 Sereine/threonine 
protein kinase 
 
DBP CHARGE 
Table 1-3 Results from the Global BP-Gen and CHARGE meta-analyses 
 SNPs which achieved genome wide significance p<5x10-7. Possible pathways (summarised 
from NCBI Gene http://www.ncbi.nlm.nih.gov/gene) are given but it should be borne in mind 
that the SNPs examined are associated with hypertension but there is currently no proof of 
causation. The phenotype associated with SNP and the study which contributed evidence is 
displayed.  
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 Attempts have been made to replicate these findings in other, independent 
populations. The Women’s Genome Health Study (WGHS) was examined in which 
28 345 female health professionals from North America were genotyped for 
nominated SNPs (Ho et al., 2011). Many of the findings of the Global BP-
Gen/CHARGE studies were reproduced. SH2B3, ATP2B1, MTHFR, CYP17A1 and 
PLEKHA7 were significantly associated with SBP. Eight SNPs were associated with 
DBP in the WGHS: CACNB2, ATP2B1, CYP1A2, c10orf107, SH2B3, ZNF652, were 
significant. The significance level was set at P < 1.2 × 10-3 (this was arrived at 
after correction for multiple testing and is less stringent than required for 
genome wide significance). In addition, a new locus was identified, CASZ1,   
which did not reach significance in the Global BP-Gen or CHARGE studies. 
Reanalysis of the GRAPHIC study in a “pathway-omic” manner (Tomaszewski et 
al., 2010) (ie high throughput analysis of common variant in genes involved in 
nominated candidate pathways) concurred with the finding that SNPs in MTHFR 
(encompassing the CLCN6 gene) are implicated.  
 Two further studies have successfully identified SNPs that are significant at a 
genome wide level. First, Wang et al examined a group of Amish subjects and 
identified STK39 as independently associated with blood pressure increase of 
increases of 3.3/1.3 mm Hg in SBP/DBP (Wang et al., 2009). The investigators 
replicated their findings in 4 other Caucasian populations and found a consistent, 
albeit weaker BP effect. The STK39 gene encodes the SPAK protein, which 
interacts with WNK kinases (discussed in section 1.1.6) and thus a possible 
functional explanation exists as to why variation in this gene may influence 
blood pressure. Further work has supported this hypothesis and a polymorphism 
in STK39 has been associated with hypertension in a large group of middle aged 
Swedes (Fava et al., 2011) but not in a cohort of British subjects (Cunnington et 
al., 2009) and the STK39 gene has not been found to associate with hypertension 
in either of the two larges genome wide studies described above. Second, Org et 
al identified variation in CDH13 gene as being associated with blood pressure and 
hypertension (Org et al., 2009) although the association was not consistent in all 
cohorts examined. CDH13 encodes for a calcium-dependent cell–cell adhesion 
glycoprotein T-cadherin and is also an attractive susceptibility gene as it 
interacts in vascular endothelial and smooth muscle cells and may regulate 
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vascular wall functions. However, to date, there have been no further studies 
directly linking this gene to hypertension. 
GWAS from other ethnic populations have also been published within the last 
year. A large (25 826 subjects) Japanese study (Takeuchi et al., 2010), 
concluded that MTHFR, FGF5, CYP17A1, ATP2B1, and CSK-ULK3 were important 
loci in a non-European cohort as well as the Caucasian populations studied in 
CHARGE and Global BP-Gen. In addition, two further loci (CASZ1, ITGA9) which 
had been implicated but not confirmed in CHARGE and Global BP-Gen achieved 
statistically significant associations in this Asian cohort. A study of African-
American participants identified variation in PMS1, SLC24A4, YWHA7, IPO7, and 
CACANA1H as associated with hypertension (Adeyemo et al., 2009). Genes that 
were identified by CHARGE and Global BP-gen were associated with hypertension 
in this cohort but with less statistical significance. These results suggest that, 
while there may be similarities between ethnic groups, there are likely to be 
different genes involved in blood pressure disturbance and this should provoke 
caution when investigators are attempting to replicate their results in other 
populations.  
1.1.9 Linkage analysis and GWAS: Conclusions 
 The advent of techniques to analyse the genome in its entirety gave great 
promise for the understanding of heritable disease. However, disappointingly, 
despite the very large numbers of subjects studied and significant economic 
cost, results have not provided clear and incontrovertible candidate genes, nor 
have they yet suggested novel treatable pathways.  
 Although there is disparity between results in different replication studies and 
different ethnic populations, there have been some consistent messages from 
GWAS. However, it is important to remember that SNPs identified within these 
genes are “Tag SNPs” (as listed in Table 1-3) and that these represent many 
other SNPs that they are in linkage disequilibrium with, sometimes spanning 
significant portions of the genome. The causative SNP could lie a large distance 
away or even within another gene.  
However, the major message from the GWAS era has been the small effect size 
of many of the identified genes which leaves a large proportion of the heritable 
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component of blood pressure unexplained. This “missing heritability” has been 
the subject of much controversy. It has been proposed that hypertension is even 
more polygenic than previously thought, with many genes each having a very 
small effect, and consequently that studies have been underpowered to detect 
them. “Mega-analyses” sought to address this problem of loss of power but there 
remain significant missing data to account for the heritable nature of blood 
pressure variation. It has been proposed that another possible source of the 
“missing heritability” is in rare alleles. GWAS studies were set up to capture 
allele frequencies of greater than or equal to 5%. However it has been suggested 
that multiple rare alleles (rather than a few common alleles) may be the 
explanation for blood pressure heritability. Even the combined resources of the 
“mega-analysis” GWAS trials were not adequately powered to detect these rare 
variations. Further, the hypothesis-free approach of these studies results in 
multiple comparisons and consequently, there is a need to increase the 
stringency required to achieve statistical significance. This may have resulted in 
true positive findings being rejected. 
 As with previous methods of investigation, including candidate gene and linkage 
analysis, results have been difficult to replicate and population heterogeneity is 
again likely to be a factor in this. The small effect size of the variation in genes 
that have been implicated must make their effects more easily obscured in the 
different genetic and environmental milieu of a replicate study population. 
Gene-environment interactions are difficult if not impossible to study using 
GWAS approaches, due to the unmanageable number of subjects required. Given 
that environmental factors play such a crucial role in determining blood pressure 
phenotype (see section 1.1.3) on the background of genetic susceptibility, this 
may have reduced the power of these studies to identify culprit genes. Further, 
given that the accuracy and success of GWA studies depends heavily on the 
linkage disequilibrium in the population (this allows investigators to choose 
appropriate “tag” SNPs and impute and interpret results), accurate and precise 
knowledge of this is essential. The international HapMap project was a 
significant advance in our understanding of this. However, the 1000 Genome 
Project (Durbin et al., 2010) aims to detail this in a more complete manner and 
new sequencing technologies will allow this to be completed more 
comprehensively and economically. The 1000 Genomes project, using next-
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generation sequencing (NGS) or massively parallel sequencing technologies has 
allowed millions of sequence reads of short lengths (35–250bp) at a time. 
However, although cost has reduced substantially over the last 5-10 years, 
sequencing remains expensive. Innovative measures have been suggested e.g. 
pooling of DNA samples (Lee et al., 2011), to overcome some of these 
difficulties. These emerging technologies will undoubtedly increase the volume 
of data that can be gleaned from large scale GWA studies but there remain many 
other difficulties to be overcome before this approach is likely to produce 
clinically meaningful results.  
Therefore, while GWAS have provided important insights into the genetic 
architecture of human hypertension, the quest for causative genes and pathways 
continues and the debate surrounding how best to proceed persists. It seems 
clear that hypothesis driven research remains fundamental to progress in this 
area, given the complex nature of gene- environment interactions. While the 
limitations of candidate gene studies should be borne in mind, focused 
genotype- phenotype studies and continued use of sub-phenotypes of 
hypertension, are crucial to improving understanding of hypertension. Loci 
containing CYP17A1, MTHFR and SH2B3, as well as many other genes mentioned 
above, are likely to contribute to susceptibility to hypertension. However, there 
is strong evidence that many other genes and gene regulatory areas are 
involved; particularly those involved in renal sodium handling, prominent among 
these are those affecting aldosterone synthesis and action.  
1.2 Relative aldosterone excess: a sub-phenotype 
of hypertension 
 The multi-factorial mechanisms underlying the pathogenesis of hypertension 
have led to descriptions of sub-phenotypes, i.e. building a profile of clinical 
features of sub-groups which might share similar common pathogenic 
mechanisms. In terms of clinical research, a potential advantage of this 
approach is that, by enriching study cohorts with patients who share common 
aetiologies, the causes (particularly genetic) are more likely to be discovered. In 
addition, identifying homogeneous groups of patient may allow better targeting 
of therapies to control blood pressure and prevent complications. (A practical 
example of this is the advice regarding treatment for hypertension issued by the 
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British Hypertension Society which suggests the use of diuretics as first line 
therapy in older adults and those of African decent, and ACE inhibition in 
younger patients (Williams et al., 2004)) 
The sub-phenotype under further investigation in this work is that of relative 
aldosterone excess. In order to investigate this further, an understanding of the 
role of aldosterone in health and disease is necessary and this will be discussed 
in the following sections. 
1.2.1 Discovery of aldosterone 
Aldosterone was first identified by Silvia (nee Simpson) and James Tait in 1952 
and crystallised in 1953 in collaboration with the pharmaceutical company Ciba 
and the Reichstein group in Basel (Tait et al., 2004). This was achieved by 
extracting 60-70mg of pure aldosterone from a colossal 1500kg of pig adrenal 
glands (Heusler and Kalvoda, 1996). Initially named electrocortin, prior to its 
structure being known, this substance has long been recognised to be involved in 
the retention of sodium and water and is the most potent (although not the most 
abundant) mineralocorticoid in humans. We now know that aldosterone acts on 
the classic mineralocorticoid receptor in the cortical collecting duct of the 
kidney to increase activity of the epithelial sodium channel (ENaC), resulting in 
net reabsorption of sodium and water; electrical neutrality is maintained by loss 
of potassium and hydrogen ions from the renal cell to the tubular fluid. 
1.2.2  The mineralocorticoid receptor 
 The classical actions of aldosterone are mediated by the mineralocorticoid 
receptor (MR) which, like the glucocorticorticoid receptor (GR), belongs to the 
nuclear hormone receptor (NHR) family, a group of ligand- activated 
transcription factors. When unoccupied, these receptors are present in the 
cytosol but when bound by their ligand, translocate to the nucleus, interact with 
their respective response elements and induce a change in transcriptional 
activity leading to an increase in activity of the ENaC.  
The structure of both the MR and GR receptors are typical of this group of 
receptors, possessing an N-terminal domain, a central DNA-binding domain, and 
a hinge region that links to a ligand-binding domain (LBD) within the C-terminal 
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half of the receptor. The DNA-binding domain, which comprises two zinc finger 
structures, binds to specific DNA sequences on its target gene. The MR DNA-
binding domain is 94% identical to that of the glucocorticoid receptor (GR) and 
90% identical to that of the progesterone receptor (Lombes et al., 2000). Subtle 
differences in the structure of aldosterone and cortisol (discussed in greater 
detail in section 1.2.4) lead to greater affinity for their relative receptors; 
nevertheless, there is considerable overlap in the types of steroid that can be 
bound by MR and GR. Thus, in spite of its name, the MR is able to bind cortisol, 
which circulates in plasma at levels a thousand fold higher than 
mineralocorticoids, with equal affinity to aldosterone. Therefore an alternative 
mechanism is required to maintain the tissue specificity of aldosterone. The 
enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), acts to convert 
cortisol to cortisone; without this activity, cortisol, which binds with high 
affinity to the mineralocorticoid receptor, will activate the receptor and prevent 
its regulation by aldosterone (White et al., 1997)(Figure 1-6).  
 
Figure 1-6. Schematic representation of kidney cortical collecting duct.  
Cortisol (blue open circle) is inactivated to cortisone (blue lined circle) by the NAD+ 
dependant “chaperone” enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). 
This prevents promiscuous occupation and activation of the MR by cortisol and allows 
regulation by aldosterone (pink open circle).  
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11β-HSD is a bidirectional enzyme, and it has been proposed that the redox state 
of the cell determines whether it functions as a dehydrogenase (cortisol to 
cortisone) or reductase (cortisone to cortisol) (White et al., 1997). 
1.2.3 Mechanism of action of aldosterone 
Epithelial sodium channel 
In epithelial tissues, aldosterone primarily acts via the epithelial sodium channel 
(ENaC) to excrete potassium and retain sodium and water. Activation of the 
mineralocorticoid receptor by aldosterone results in increased expression of 
ENaCα subunit, which combines with ENaCβ and γ (which are constitutatively 
expressed) and this complex moves to the apical cell surface. The molecular 
mechanism of regulation of ENaC is now better understood as a result of the 
study of the monogenic disorder, Liddle’s syndrome. This is a rare autosomal 
dominant condition resulting in a gain of function of ENaC, and is clinically 
associated with moderate to severe hypertension presenting in childhood (see 
Appendix 1). The genetic abnormality causing Liddle’s syndrome lies on 
chromosome 16 and mutations identified to date affect the cytoplasmic C-
terminal tails of the β- and γ-subunits of ENaC (Hansson et al., 1995). These 
result in loss of an adaptor motif that interacts with Nedd4-2 (neural precursor 
cell-expressed, developmentally down-regulated 4-2). Nedd4-2 ligates a 
ubiquitin “tag” to the ENaC which targets it for internalisation and subsequent 
destruction (Soundararajan et al., 2010)(Figure 1-7). This induces constitutative 
activity of the epithelial sodium channel (ENaC) in the cortical collecting duct 
(Shimkets et al., 1994), as if activated by aldosterone (see Figure 1-7). 
Importantly, in this condition, spironolactone (a mineralocorticoid receptor 
antagonist) is not effective because activation of ENaC is not due to excessive 
aldosterone levels and is independent of the mineralocorticoid receptor. 
However, the ENaC is amiloride-sensitive making this the treatment of choice in 
these patients.  
 Other components of the ENaC regulatory complex (as shown in Figure 1-7 and 
discussed in the figure legend) are clearly also of physiological importance. 
Although no monogenic disorders of SGK1 affecting blood pressure have yet been 
identified, an SGK1 knock out mouse model demonstrated higher levels of 
aldosterone under normal conditions compared to wild type animals under 
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normal salt intake. When examined under reduced salt intake, the SGK1 knock 
out animals demonstrate a salt losing, aldosterone resistant phenotype, with 
lower blood pressure and reduced glomerular filtration (Wulff et al., 2002).  
While polymorphisms of SGK1 have been associated with hypertension in a 
candidate gene study (Busjahn et al., 2002), this has not been replicated in 
genome wide association studies (as discussed in section 1.1.7 and 1.1.9). 
 
Figure 1-7 The ENaC regulatory complex under the control of aldosterone.  
In the absence of aldosterone (top panel) the ENaC regulatory complex composed of NED4-
2, ERK, MEK and Raf-1 results in ubiquitination (U) and phosphorylation (P) of ENaC. This 
means the channel is degraded and endocytosed. In the presence of aldosterone (bottom 
panel) increased expression of SGK1 and GILZ1 is seen and these compounds prevent the 
inhibition of ENaC via NED4-2 and the ERK/MEK/Raf-1 complex, resulting in increased 
surface expression and increased sodium flux through the channel. Adapted from 
Soundararajan et al (Soundararajan et al., 2010) 
 
Aldosterone has other actions that increase ENaC expression or action. For 
example, aldosterone induces the expression of small, monomeric Kirsten Ras 
GTP-binding protein (Ki-Ras). The mechanism of action is not clear but Ki-Ras 
appears to both keep ENaC open and decrease the number of channels in the 
plasma membrane (Stockand, 2002). In addition, PI3K is a possible point of 
“cross talk” between ADH, insulin and aldosterone signalling (Stockand, 2002) as 
aldosterone increases PI3K activity and reduction in PI3K reduces the effects of 
aldosterone.  
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Other actions in the distal nephron 
While the main effect of aldosterone induced proteins in the distal nephron is to 
stimulate ENaC subunits or proteins that modify ENaC (as described above), 
aldosterone also regulates the Na-K-ATPase pump on the basolateral membrane 
via increased transcription of the pump subunits and activation of signalling 
cascades, including upregulation of SGK-1 (Thomas et al., 2008). The Renal 
Outer Medullary Potassium (ROMK) channel is also modulated by aldosterone, 
providing a mechanism for the secretion of potassium ions. These combined 
actions are known as the “aldosterone paradox”; that is, that the distal nephron 
has the ability to independently regulate salt reabsorption in a state of 
hypovolaemia versus potassium secretion in a state hyperkalaemia, given the 
same stimulus (increased aldosterone). The answer to how these two processes 
are differentially regulated despite the same initial stimulus arose from further 
study of pseudohypoaldosteronism type 2 (PHAII, see section 1.1.6). In PHAII, an 
inactivating mutation of WNK4 results in increased reabsorption of sodium 
without increased potassium secretion. It has also been demonstrated that 
phosphorylation of WNK kinases in response to hypertonic stress and possibly 
decreased chloride concentration, increases WNK4 activity and suppressing 
ROMK, providing a mechanism for uncoupling of this system in normal physiology 
(Kahle et al., 2010).   
Non-epithelial tissues 
Mimeralocorticoid receptors are present in a number of non-epithelial sites. 
However, it is not clear whether activation of these receptors can be attributed 
to aldosterone rather than cortisol in vivo, given the absence of co-localising 
11βHSD at these sites. Nevertheless, in experimental models of aldosterone 
excess, clear detrimental actions have been demonstrated. Cardiac fibrosis is 
seen in animals exposed to excess aldosterone, independent of blood pressure 
(Brilla and Weber, 1992). Histological features of aldosterone-induced cardiac 
fibrosis include proliferation of cardiac myocytes and fibroblasts and although 
the mechanism is unclear, an increase in collagen I and III synthesis is seen in 
response to aldosterone in cardiac fibroblasts (Robert et al., 1994). Excess 
aldosterone is also associated with evidence of increased myocardial 
inflammation (Brilla and Weber, 1992) and early increases in inflammatory 
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markers for example, tumour necrosis factor α and ED-1 positive macrophages 
has been observed in a rat model of mineralocorticoid hypertension (Young et 
al., 2003).  
Aldosterone excess is associated with reduced vascular reactivity (Farquharson 
and Struthers, 2002) and increased markers of oxidative stress; aldosterone 
regulates NADHP subunit expression and this can be ameliorated by blockade of 
the mineralocorticoid receptor (Young and Rickard, 2011). Further, aldosterone 
excess (in combination with salt loading) causes an increase in redox sensitive 
NFκB (Sun et al., 2002) as well as reduced glucose-6-phosphate dehydrogenase 
(G6DP) (Leopold et al., 2007), which plays an important part in determining the 
redox state of the cell.  
Mineralocorticoid receptors in the central nervous system (CNS) are unprotected 
by 11βHSD but aldosterone specific effects have been demonstrated (Gomez-
Sanchez, 1997). In addition, blockade of CNS receptors by RU28318 attenuates 
the hypertensive effects of systemic administration of aldosterone (Gomez-
Sanchez et al., 1990) but not the cardiac fibrosis and hypertrophy (Young and 
Funder, 1996).  
Nongenomic actions 
It has been proposed that aldosterone can also triggers rapid, non-genomic 
effects in both traditional aldosterone target tissues (cortical collecting duct) as 
well as in non-epithelial tissues. In epithelial tissues it is evident that there is 
increased ENaC activity measured by sodium flux within a few minutes of 
exposure to aldosterone (Zhou and Bubien, 2001). The rapidity of this response 
suggests actions that are not mediated by “genomic” mechanisms i.e. do not 
provoke increased gene transcription. In non-epithelial tissues rapid non-
genomic effects have also been observed in heart rate (Schmidt et al., 1999) 
baroreflex sensitivity (Yee and Struthers, 1998) and central (Schmidt et al., 
1999) and peripheral (Romagni et al., 2003) vascular resistance.  These non-
genomic effects may not act entirely via the mineralocorticoid receptor. For 
example recent work by Gros et al (Gros et al., 2011) ascribes the rapid action 
of aldosterone in vascular smooth muscle cells to a G protein coupled receptor, 
GPR30. These rapid effects are diminished but not abolished by the classical 
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mineralocorticoid receptor antagonists, spironolactone and eplerenone. 
Although remaining controversial, this recent data raise the possibility of 
developing novel pharmaceutical agents to block the rapid, non-genomic actions 
of aldosterone. If such agents were available, it would allow a more precise 
analysis of the mechanism of action of aldosterone as well as an improved 
understanding of the benefits of aldosterone blockade (as described in section 
1.3.2 and 1.3.3).  
1.2.4 Aldosterone synthesis 
The production of steroid hormones within in the adrenal gland and the gonads 
involves a pathway of sequential enzymatic reactions beginning with cholesterol 
as substrate. Steroid hormones share a common basic configuration of four 
carbon rings known as a cyclopentanoperhydrophenanthrene structure, shown in 
Figure 1-8. The universally accepted numbering of the carbon atoms of the 
cholesterol molecule is shown in Figure 1-9.  
 
Figure 1-8 The cyclopentanoperhydrophenanthrene structure.  
This structure is present in all steroid hormones. The rings are identified by letter according 
to the universally recognised International Union of Pure and Applied Chemistry (IUPAC). 
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Figure 1-9 Site of action of steroidogenic enzymes on cholesterol molecule.  
Cholesterol is the basic molecule from which steroid hormones are derived. The numbering 
of the carbon atoms is according to the universally recognised International Union of Pure 
and Applied Chemistry (IUPAC). Enzymes which confer changes that induce 
mineralocorticoid activity are shown in red while enzymes which confer changes associated 
with glucocorticoid activity are shown in blue. 3 β HSD, 3β-hydroxysteroid dehydrogenase, 
17αOH, 17α-hydroxylase, 21αOH, 21α-hydroxylase,11βOB, 11β-hydroxylase, aldo synthase, 
aldosterone synthase.   
 
The first step is the transfer of hydrophobic cholesterol across the aqueous 
mitochondrial membrane, and this rate limiting process is regulated by 
steroidogenic acute regulatory protein (StAR) (Stocco, 2001). Cholesterol is then 
converted to pregnenolone by the action of a cytochrome P450 enzyme (Side 
chain cleavage or CYP-450scc, encoded by the gene CYP11A1) which cleaves the 6 
carbon unit form the original cholesterol molecule, leaving a 21 carbon 
compound, pregnenelone.  
The fate of the pregnenolone molecule then depends on which enzyme it is then 
exposed to. The enzymes involved in steroidogenesis perform either a 
hydroxylase reaction (the conversion of a -CH  group to a -COH group) or 
hydroxysteriod dehydrogenase (the conversion of a hydroxyl –OH to carboxyl C=O 
group) as can be seen from Figure 1-10. This is discussed further in section 1.2.5.  
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Figure 1-10 Corticosteroid biosynthesis. 
 Enzymes, substrates and products in human steroidogenesis.  
With reference to the production of the corticosteroids, cortisol and 
aldosterone, there are 5 further key enzymes involved and the next steps take 
place in the endoplasmic reticulum. 3β-hydroxysteroid dehydrogenase (encoded 
by 3βHSD) oxidises the hydroxyl group at the 3rd carbon atom to from 
progesterone. If then exposed to 17 α-hydroxylase (encoded by CYP17A1), 
pregnenolone is the substrate for a hydroxylation reaction at carbon 17 to form 
17 α-hydroxypregnenolone and this step is necessary for the production of both 
androgens (prior to the action of 17,20 lyase (also encoded by CYP17A1) and 
glucocorticoid compounds. The carbon at position 21 is hydroxylased by 21 α-
hydroxylase (encoded by CYP21B) converting progesterone to 
deoxycorticosterone and 17 α-hydroxyprogesterone to 11-deoxycortisol.  
Like the initial enzymatic reaction involving P-450scc, the final steps aldosterone 
productions are undertaken in the mitochondria by a cytochrome P450 enzyme. 
The conversion of deoxycorticosterone to aldosterone involves three consecutive 
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reactions catalysed by aldosterone synthase (CYP11B2). This enzyme is the focus 
of this work and will be discussed in depth in future sections. It catalyses the 
formation of a hydroxyl group at position 11 to produce corticosterone, followed 
by 18-hydroxylation to yield 18-hydroxycorticosterone and finally 18-
methyloxidation to aldosterone (Connell and Davies, 2005) (see Figure 1-11).  
 
Figure 1-11 Reactions undertaken by aldosterone synthase at C18 of deoxycorticosterone 
 
Aldosterone spontaneously converts to the hemiacetal form (shown in Figure 
1-12) and this change is not associated with any change in activity. However, 
this structure does protect aldosterone from the action of 11 β-hydroxysteroid 
dehydrogenase which converts cortisol to the inactive cortisone (as discussed in 
section 1.2.2).  
 
Figure 1-12 Structure of aldosterone and the (predominant) hemiacetal form.  
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The enzyme 11 β-hydroxylase (encoded by CYP11B1) can also undertake a 
hydroxylation reaction at position 11 and 18 (Freel et al., 2004). However, the 
18-methyloxidation reaction is an exclusive function of aldosterone synthase and 
this is the final rate limiting step in the synthesis of aldosterone. 
1.2.5 Regulation of aldosterone production 
In order to further investigate the mechanisms of control of aldosterone 
synthesis, both genetic and environmental, it is necessary to spend some time 
describing the normal stimuli to aldosterone production and the points at which 
production can be regulated.  
Structural and anatomical mechanisms 
The structure and anatomy of the adrenal gland plays a crucial role in the 
mechanisms of regulation of production of aldosterone as well as of the other 
corticosteroids. Processes which disrupt this elegant arrangement provide clear 
examples of the importance of the structural integrity of the gland in 
maintaining an ability to differentially produce the physiologically relevant 
steroids in response to their trophins. The following section will address the 
functional relevance of the anatomical structure of the adrenal gland. 
The adrenal glands consist of an inner adrenal medulla and an outer cortex. 
These distinct regions arise from separate embryological origins; mesenchymal 
cells which form the cortex originate from the coelomic cavity lining, adjacent 
to the urogenital ridge, while invasion of neuroectoderm cells into this region 
give rise to the adrenal medulla (Wilson J.D. and Foster D.W., 1992). The 
adrenal cortex is further subdivided onto histological distinct zones which have 
separate functional properties. The outermost glomerulosa cells produce 
aldosterone, the fasciculata produces cortisol and corticosterone and the 
reticularis is the main site of adrenal androgen production. It is suggested that 
development of the vascular system in crucial in developing the functional 
zonation of the adrenal gland with blood vessels from the outer cortex draining 
inwardly into venules of the adrenal medulla. Thus, glomerulosa cells 
differentiate on the arterial side and reticularis cells on the venous side. 
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However, the crucial functional difference in the adrenal gland zonation is the 
differential expression of steroidogenic enzymes, i.e. aldosterone synthase 
(encoded by CYP11B2 gene) in the glomerulosa and 17 α- hydroxylase (encoded 
by CYP17A1) and 11 β-hydroxylase (encoded by CYP11B1 gene) in the 
fasciculata.  
 However, it is now recognised that the distinct histological zones of the adrenal 
gland are not static; in utero, the foetal adrenal consists of a smaller outer zone 
but it is the larger, inner zone that appears to be the dominant source of 
steroids, mainly DHEA and DHEAS. There is also a so called “transitional zone” 
between these two areas that appears to produce cortisol near the end of the 
gestational period (Kempna and Fluck, 2008). After birth, the large inner zone 
involutes and the three zoned adult adrenal begins to develop, and it is not until 
adrenache (a specifically human phenomenon that occurs around the age of 6-8) 
that adrenal androgens again begin to rise. The processes which initiate and 
maintain this functional zonation are not clear. It has been proposed that 
common stem cells exist within the capsule and differentiate while migrating in 
a centripetal direction to form these layers but  this remains a matter of debate 
(Wood and Hammer, 2011). Recent advances in this area stemmed from the 
identification of the crucial role of steroidogenic factor 1 (SF-1) in the 
development of the adrenal gland (Luo et al., 1994). The importance of this 
molecule in humans was confirmed when the monogenic disorder resulting from 
a mutation in SF-1 in humans was described, giving rise to a phenotypic female 
with an XY genotype as a result of gonadal dysgenesis and primary adrenal 
failure (Achermann et al., 1999). However, the multitude of signalling pathways 
involved in the maintenance of adrenal stem cells as well as their differentiation 
to functioning steroidogenic cells is only beginning to be understood.  
 The importance of the structure of the adrenal gland in regulating steroid 
production can be observed in a further monogenic condition, Glucocorticoid 
Remedial hyperaldosteronism (GRA). This is an autosomal dominant monogenic 
disorder caused by a hybrid gene comprising the regulatory element of 11 β-
hydroxylase and the coding region of aldosterone synthase gives rise to a 
phenotype of  hypertension and mineralocorticoid excess (Lifton et al., 1992). 
Aldosterone is produced in response to ACTH rather than its usual trophins (as 
described later in this section), but importantly, the chimeric gene is expressed 
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ectopically in the fasciculata, which is a much higher output system that the 
glomerulosa. This allows the gene product inappropriate access to greater 
quantities of 11-deoxycorticosterone as a substrate for substantial aldosterone 
production. Importantly therefore, it is not only that the gene is under 
regulation by ACTH that produces a state of mineralocorticoid excess, but also 
the aberrant locus of enzyme expression and structure of the gland that causes 
dysregulated corticosteroid production, thus highlighting the necessity of strict 
anatomical and functional zonation.   
For many years, further study of zonation in the human adrenal has been limited 
by the high degree of homology between aldosterone synthase and 11 β-
hydroxylase, making the development of specific antibodies difficult and thus 
reliable separation of the of the zones challenging. But recent success in the 
development of specific antibodies has been successfully achieved by Nishimoto 
et al (Nishimoto et al., 2010), who have confirmed the pattern of conventional 
zonation with CYP11B1 expressed constitutively in the fasciculata and CYP11B2 
expressed sporadically in the glomerulosa. However, they also demonstrated a 
novel pattern of CYP11B2 expression with clusters of aldosterone producing cells 
expressing CYP11B2, 3BHSD and no CYP17A1, which appeared to be 
constitutively active in terms of aldosterone production, in that they were 
present even in tissue adjacent to aldosterone-producing adenomas. This is in 
contrast to the previously held belief that there would be suppression of 
CYP11B2 expression due to the negative feedback of the renin- angiotensin 
system. This novel pattern of CYP11B2 expression was confirmed by Boulkroun et 
al (Boulkroun et al., 2010) who examined the structure of the zona glomerulosa 
in normal adrenals and compared this to aldosterone producing adenoma as well 
as tissue from around the adenoma. They provided further evidence that the 
tissue from around the adenoma was hyperplastic with persistent expression of 
CYP11B2, in some cases encompassing the entirety of the zona glomerulosa. This 
work adds further to the body of evidence confirming both the non-static nature 
of the structure of the adrenal gland, and specifically that the zona glomerulosa 
can enlarge and steroidogenic enzymes be switched on and off, with consequent 
implications for regulation of aldosterone. 
There remain many unanswered questions regarding the development and 
maintenance of adrenal zonation. Is the fate of an adrenal stem cell 
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predetermined or can it be altered by environmental factors? What causes the 
hyperplasia seen in adjacent tissue in aldosterone producing adenomas and how 
can this be influenced? What causes CYP11B2 to be constitutively expressed in 
this context and become unshackled from the control of the renin- angiotensin 
system? It is clear that the structure of the adrenal gland as well as the 
processes which regulate it are crucial to its function. While advances have been 
made, further investigations into the regulation of geographical expression of 
steroidogenic enzymes, as well as how this relates to the regulation of steroid 
production, would be enlightening. 
Cytochrome P450 enzymes and electron transport 
 As previously discussed, the enzymes involved in steroid synthesis fall into 
either cytochrome P450 enzymes (encoded by CYP11A1, CYP17A1, CYP21A2, 
CYP11B1 and CYP11B2) or hydroxysteroid dehydrogenase enzymes (e.g. 3βHSD). 
The cytochrome P450 enzymes can be further classified according to their 
location in the mitochondria or endoplasmic reticulum. The distinction is 
important because these two classes of enzymes use different strategies for 
electron transfer and this may be an important method of regulating enzyme 
function, distinct from enzyme expression.  
Mitochondrial enzymes receive electrons from reduced nicotinamide adenine 
dinucleotide (NADPH) via an electron transfer chain. NADPH binds to adrenodoxin 
(ferredoxin) reductase, which then interacts with and transfers a pair of 
electrons to adrenodoxin (ferredoxin). Adrenodoxin accepts and also interacts 
with the redox partner binding site of the mitochondrial P450 enzyme to donate 
electrons to it (Miller, 2005). Adrenodoxin reductase is encoded by a single gene 
on chromosome 17q24-q25 but recent evidence suggests that there are two 
forms of adrenodoxin/ ferredoxin, encoded by FDX1 on chromosome 11q22 and 
FDX2 on chromosome 19p13.2, each with distinct functions. FDX1 appears to be 
specific for electron transfer in steroidogenesis while FDX2 is essential for Fe/S 
protein biogenesis and haem A formation (protein co-factors essential for a 
variety of cellular functions) but is unable to reduce cytochrome P450 enzymes 
(Sheftel et al., 2010) (Figure 1-13). Steroid synthesis may be limited by the 
availability of reducing agents (or the relative composition). However, the 
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relative quantities of adrenodoxin 1/ 2, adrenodoxin reductase and CYP P450 
enzymes in humans are not currently known.  
 
Figure 1-13 Electron transport of ferredoxin and ferredoxin reductase in the mitochondria. 
 FDX1, ferredoxin 1, is involved in electron transfer in steroidogenesis and FDX2, ferredoxin 
2, involved in electron transfer in Fe/S protein biogenesis and haem A formation. FeRed, 
ferredoxin reductase; CYP, Cytochrome P450 enzyme. 
 
 In contrast, CYP P450 enzymes located in the endoplasmic reticulum receive 
electrons from NADPH via the electron chain involving P450 oxidoreductase 
(POR), sometimes with the assistance of cytochrome b5 (Miller, 2005). This 
electron transfer system is a mechanism by which the lyase/ hydroxylase dual 
action of the product of CYP17A1 is regulated. Cytochrome b5 acts as an 
allosteric factor to promote the interaction of CYP17 with POR, selectively 
increasing 17,20 lyase activity (Lin et al., 1993). Further, increased POR 
increases 17, 20 lyase activity (Lin et al., 1993) and greater amounts of POR are 
observed in testicular tissue (where C19 steroids are produced) rather than 
adrenal tissue (where steroidogenesis is predominantly limited to C21 steroids).  
While POR knock out in mice is embryonically lethal, the first POR mutations in 
humans were described in 2004 (Fluck et al., 2004). These individuals had 
disordered sexually development and steroid production consistent with partial 
deficiencies of CYP17 and CYP21. In addition, in individuals carrying severe 
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mutations, a disorder of skeletal development is also observed, similar to 
Antley-Bixler syndrome (http://www.omim.org/entry/207410). The POR gene is 
highly polymorphic and there is much interest in examining whether less severe 
mutations may be associated with clinical syndromes associated with milder 
alterations in steroid profiles. In addition, it is worth remembering that as well 
as being involved in crucial reactions in steroidogenesis, POR is the system by 
which electron donation is achieved for cytochrome P450 drug metabolising 
enzymes. Thus, the possibility of a greater understanding of pharmacogenetics 
may be possible with deeper knowledge of the effects of variation in POR. To 
date, no defects of adrenodoxin or adrenodoxin reductase have been described 
in humans but clearly, given the example of POR, this is a potential area of 
regulation of aldosterone production as yet largely uninvestigated. 
Trophins of aldosterone production 
 As has been previously mentioned, increased aldosterone secretion is an 
outcome of activation of the renin-angiotensin system, and has the effect of 
restoring circulating volume as well as being a mechanism for excreting 
potassium ions. Increases in angiotensin II and serum potassium levels are thus 
the major physiological regulators of plasma aldosterone concentration. Both 
utilise changes in intracellular free calcium to increase transcription of the key 
steroidogenic enzymes, but it is clear that there are discrete and separate 
mechanisms involved in the responses to these two trophins, as the rise in 
intracellular free calcium invoked by potassium could be blocked with  calcium 
channel antagonists but this was not the case for angiotensin II (Capponi et al., 
1984). This difference in action was further exposed by Pezzi et al (Pezzi et al., 
1997) who demonstrated the essential role of calmodulin and calmodulin-
dependant protein kinases (CaMK) in potassium stimulated increase in 
intracellular calcium but inhibition of calmodulan and CaMK had little effect on 
angiotensin II stimulated increases in aldosterone synthase transcripts. This 
suggests that the role of angiotensin II is more complex than potassium and 
relies on several mechanisms to stimulate increased aldosterone synthase 
transcription. These factors as well as other trophins of aldosterone production 
will be discussed in the following sections.  
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Angiotensin II 
As discussed above, angiotensin II-stimulated aldosterone production via the AT1 
receptor rather than the AT2 receptor (Section 1.1.4). Activation of this G 
protein receptor leads to a cascade of intracellular signalling mechanisms which 
are incompletely understood. Activation of phospholipase C, which hydrolyzes 
phosphatidylinositol 4,5-bisphosphate  (PIP2) to inositol trisphosphate (IP3) is 
observed and this leads to release of intracellular calcium ions, 1,2 
diacylglycerol (1,2 DAG) and activation of protein kinase C (PKC) (Spat and 
Hunyady, 2004) (see Figure 1-14). PKC does not appear to directly increase 
CYP11B2 expression (Denner et al., 1996) but does appear to reduce expression 
of CYP17 (Bird et al., 1996), thus preventing substrate from entering the 
glucocorticoid/ androgen pathway. 
. 
Figure 1-14 Angiotensin II and potassium regulation of intracellular calcium leading to 
increased aldosterone production.  
 
A rise in intracellular free calcium activates CaMKI and possible CaMKIV (Condon 
et al., 2002), feeding into the same mechanism utilised by increased calcium via 
potassium-dependant channels but the effect of angiotensin II on transcription of 
CYP11B2 is not limited to this mechanism.  
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Potassium 
The role of potassium as a regulator of aldosterone secretion is crucial to 
physiological homeostasis, the mechanisms were considered to be well 
understood and straightforward. However, recent investigations have suggested 
a novel molecular system of potassium-mediated regulation of 
mineralocorticoids. TASK (TWIK-related acid sensitive K+) channels are two pore, 
four trans-membrane domain potassium channels, first characterised in the early 
1990s and are expressed predominantly in cells where modification of the cell 
membrane potential is essential to function such as neurotransmitters, hormone 
secretion and neuronal and muscular excitability (for a review see Lesage et al 
(Lesage and Lazdunski, 2000), Bayliss et al (Bayliss and Barrett, 2008)). The 
importance of these channels in aldosterone secretion was highlighted by the 
development of a TASK subunit knock out mouse which exhibited features of 
autonomous aldosterone production (Davies et al., 2008).  These animals had 
increased plasma aldosterone concentrations apparently not stimulated by 
plasma renin which was unchanged or lower than in control animals. Plasma 
aldosterone concentrations were not suppressed by salt or by blockade of the 
AT1 receptor with candesartan. Elimination of functional TASK channels caused 
the membrane potential of the glomerulosa cells to be significantly more 
depolarised, and it is proposed that this leads to continuous calcium channel 
activity and increased sensitivity to angiotensin II. It is particularly interesting to 
note that there appears to be sexual dimorphism in the physiological 
consequences of manipulation of the TASK channels. Heitzmann et al (Heitzmann 
et al., 2008) produced a TASK 1 knock out mouse model in which impaired 
mineralocorticoid homeostasis was restricted to female animals. Both male and 
female animals exhibited abnormal adrenal cortex zonation i.e. ectopic 
expression of aldosterone synthase in the high capacity fasciculata layer, but in 
male mice, this regressed following puberty. This finding highlights two key 
points, firstly the crucial importance of geographic expression of steroidogenic 
enzymes within the adrenal cortex (as discussed in more detail earlier in this 
section) and secondly the multiple influences, in this case presumably sex 
hormones, that can influence steroidogenesis.  
The discoveries regarding the role of potassium channels have been further 
extended by the recent publication of a study identifying an inherited mutation 
in the KCNJ5 (potassium inwardly-rectifying channel, subfamily J, member 5) 
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gene in a family with severe hyperaldosteronism and bilateral adrenal 
hyperplasia. In addition, 2 different somatic mutations in the potassium channel 
gene KCNJ5 were found in 8 out of 22 aldosterone producing adrenal adenomas 
examined (Choi et al., 2011). The authors suggest that the mutations identified 
lead to the channel to be more permeable to sodium, resulting in sodium entry 
to glomerulosa cells, chronic depolarisation, and consequent activation of 
calcium channels, thus leading to constitutive stimulation of aldosterone 
production. This is an exciting development in the understanding of the 
aetiology of aldosterone excess and aldosterone-producing adenomas in 
particular, although further work is required to ascertain the contribution of this 
pathway to patients with less severe phenotypes. 
Adrenocorticotrophin stimulating hormone 
 Conventionally recognised as the principle trophin of cortisol, 
adrenocorticotrophin (ACTH) is released from the pituitary as part of a classical 
endocrine feedback mechanism as shown in Figure 1-15. 
 
 
Figure 1-15 Hypothalamic pituitary axis.  
Hormones released from the hypothalamus (CRH, corticotrophin releasing hormone, AVP, 
Vasopressin) regulate the release of pituitary hormone production which in turn stimulates 
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release of active hormone from the adrenal gland. Hypothalamic inhibition is achieved by 
glucocorticoids as well as a direct effect of ACTH.  
 
It is clear that the acute effects of increased ACTH stimulate aldosterone 
production. This is predominantly achieved via increased intracellular cyclic 
adenosine monophosphate (cAMP), which occurs after ACTH binds to cell surface 
receptors and activates adenlyate cyclase. However, this effect also depends on 
the movement of calcium into the cell, as no effect of ACTH stimulation is 
observed in the absence of calcium (Spat and Hunyady, 2004). It is important to 
remember that the mechanism by which ACTH leads to increased aldosterone 
may not simply be via increasing activity of the final steps in steroidogenesis. By 
increasing the generation of precursors to aldosterone as a result of increased 
activity of steroidogenic enzymes further upstream, the production of 
aldosterone may be increased, as long as aldosterone synthase is not the rate 
limiting step. Indeed ACTH  stimulation leads to increased  activity of StAR 
(Stocco, 2001), an early, rate limiting step in steroidogenesis (as described in 
1.2.4). However, chronic administration of ACTH suppresses aldosterone 
secretion (Rayfield et al., 1973). The mechanism behind this does not appear to 
be by down regulation of the renin-angiotensin system but rather by some direct 
effect on the ACTH signal either via its receptor or second messenger pathway 
(Abayasekara et al., 1989). In clinical practice, patients with hypopituitarism do 
not demonstrate signs of mineralocorticoid insufficiency, nor do patients with 
ACTH excess (i.e. Cushing’s disease) have high aldosterone levels, which would 
lend support to the theory that ACTH does not play a major role in regulating 
aldosterone. 
Nevertheless, there remain unanswered questions regarding the role of ACTH in 
regulating aldosterone production. In particular, it is striking that there is a 
diurnal variation in aldosterone secretion in man (Richards et al., 1986; Freel et 
al., 2008) consistent with some degree of regulation by ACTH. Recently 
published data described abnormally elevated aldosterone production in 
circadian clock–deficient Cry-null mice (Doi et al., 2010), a mechanism that may 
be at least partly mediated by ACTH. Further, some individuals with salt losing 
adrenal hyperplasia and mineralocorticoid insufficiency have been shown to 
carry severe loss of function mutations of the adrenocorticotrophin receptor 
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(MCR2) (Lin et al., 2007), suggesting ACTH is important in the maintenance of 
normal levels of aldosterone.  
Other pituitary factors  
There is some evidence for the involvement of other pituitary factors in the 
regulation of aldosterone. Corticotrophin releasing hormone and other ACTH 
secretagogues e.g. vasopressin are released from the hypothalamus and 
stimulate ACTH release in the form of a precursor molecule pro-
opiomelanocortin (POMC). This 241-amino acid peptide is cleaved to form ACTH 
which is only 39 amino acids in length, by the enzyme pro-hormone convertase 1 
(PC1/3) (Nillni, 2007). This cleaves the peptide at lysine-arginine to form 
biologically active products as shown in Figure 1-16.  
 
Figure 1-16 Processing of POMC to form ACTH and other anterior pituitary factors. 
POMC is cleaved in the anterior pituitary to form β-lipotrophin and pro-ACTH by the actions 
of pro-hormone convertase 1 (PC1/3). Pro-ACTH is further cleaved to form ACTH, N-teminal 
proopiocortin (N-POC) and joining protein (JP). These are anterior lobe peptides and boxes 
are coloured grey. Further cleavage takes place in the intermediate lobe which is not active 
in normal humans. Intermediate lobe peptides are coloured blue. These are not present in 
significant amount in normal human plasma, but may be present in tumours as well as in 
the foetus and during pregnancy. ACTH 1-7 and corticotrophin- like- intermediate lobe-
peptide (CLIP) is generated from ACTH cleavage by pro-hormone convertase 2 (PC2), which 
also acts on β-lipotrophin (β-LPH) to produce γ-LPH and β-endorphin (β-EP). PC2 also 
cleaves γ-LPH to produce β-melanocyte stimulating hormnone (β-MSH). Carboxypepdidase 
E and peptidyl α-amidating monooxygenase (PAM) act to produce deascetyl MSH (da-MSH), 
prior to the action of N-acetyl transferase (NAT) which converts this to α-MSH. Adapted from 
(Pritchard and White, 2007) and (Wilson J.D. and Foster D.W., 1992). 
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McCaa et al demonstrated that patients with pituitary insufficiency exhibit 
altered response to ACTH and angiotensin II which was not corrected by 
administration of ACTH (McCaa et al., 1981). POMC knock out mice have been 
demonstrated to have absent or low levels of aldosterone by some (Coll et al., 
2004; Karpac et al., 2005; Yaswen et al., 1999) but not all (Linhart and Majzoub, 
2008) investigators, and this phenotype is not reversed by administration of 
ACTH. Some specific POMC products other than ACTH stimulate aldosterone 
production e.g. β-endorphin (β-EP) and, to a lesser extent, joining peptide (JP), 
have the capacity to stimulate aldosterone production in human adrenal cell 
suspensions (Molloy et al., 1998) and  the actions of ACTH are potentiated by α-
MSH in rats (Vinson et al., 1980; Szalay, 1993). However, as these factors are 
present in negligible amounts in humans, it seems unlikely that they will 
contribute significantly to the regulation of aldosterone. 
Other Factors 
There is in vitro evidence to suggest that numerous other factors may be 
involved in the stimulation or inhibition of aldosterone. However, there is little 
in vivo evidence to suggest that they play a major physiological role.  These will 
not be discussed further but a list can be found in Table 1-4(adapted from 
(Wilson J.D. and Foster D.W., 1992; 1992))  
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INHIBITING FACTORS STIMULATING FACTORS 
Atrial natriuretic hormone*   
Calcitonin gene-related peptide   
Dopamine  
Nitric oxide  
Platelet-derived growth factor   
Somatostatin 
Transforming growth factor-  
Unsaturated fatty acids 
 
Acetylcholine  
Angiotensin II*  
ATP  
Bradykinin  
Cholecystokinin 
Corticotrophin (ACTH)*  
-Endorphine  
Enkephalins 
Endothelin 
Epidermal growth factor  
12-Hydroxyeicosatetraenoic acid 
K+* 
Melanocyte stimulating hormone 
Neuropeptide Y 
Neurotensin   
Norepinephrine  
Parathormone 
Prolactin 
Prostaglandins 
Serotonin  
Substance P 
Vasoactive intestinal polypeptide 
Vasopressin 
Table 1-4 Inhibitory and stimulatory factors regulating plasma aldosterone in vitro.  
Starred factors are thought to be physiologically most relevant.  
 
1.2.6 Aldosterone in circulating plasma and its metabolism  
Once aldosterone synthase catalyses the final reaction in the production of 
aldosterone, the steroid is not stored but immediately released from the adrenal 
gland into the circulation. Thus, in addition to the rate of production, the 
amount of “free” hormone (i.e. not bound by plasma proteins) and the rate of 
metabolism and clearance also affect the concentration of the steroid. The half 
life of aldosterone is much shorter than that of cortisol; some possible reasons 
for this are described in the following section. 
In contrast to cortisol which is 90-97% protein bound, aldosterone is only weakly 
associated with corticosteroid binding globulin (20%) and albumin (40%) (Wilson 
J.D. and Foster D.W., 1992), with the remainder circulating freely in the plasma. 
It is proposed that this may make plasma concentrations of aldosterone more 
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susceptible to variation than cortisol as being bound to plasma proteins provides 
a “reservoir” of cortisol, preventing rapid swings in plasma concentrations.  
The metabolism of aldosterone is achieved via reactions that take place in the 
liver: aldosterone is reduced by 5β-reductase and 3α-dehydrogenase enzymes 
and conjugated with glucuronic acid to render it more water soluble. The major 
urinary metabolite of aldosterone is tetrahydroaldosterone (this comprises 
around 35%) but aldosterone-18-glucuronide is formed from direct conjugation of 
the unreduced aldosterone (making up around 20%). There are acquired 
conditions associated with altered aldosterone metabolism and clearance; as 
aldosterone metabolism takes place almost exclusively via hepatic enzymes, 
these are predominantly due to alteration in liver function. For example, 
patients with liver failure, or patients with cardiac failure have a degree of 
functional liver failure due to hypo perfusion. Both these patient groups can 
have increased levels of aldosterone.  
 There are no reported cases in the literature to date of genetic abnormalities of 
metabolism of aldosterone. However, in the case of androgen metabolism, an 
exciting advance in understanding has highlighted how this aspect of control of 
steroid regulation may be important. Dehydroepiandrosterone (DHEA) is the 
principle precursor of adrenal androgens. Rather than being conjugated with 
glucuronic acid as is the case with aldosterone, DHEA is sulphated to form 
DHEAS. As DHEAS, it can be excreted in the urine and in humans this is the most 
abundant steroid. However, only DHEA can be converted to active androgens. 
Therefore, the control of DHEA sulfation is a mechanism by which androgen 
production can be regulated. Noordam et al (Noordam et al., 2009) described a 
patient with low levels of DHEAS and a phenotype of precocious puberty in 
childhood and features consistent with polycystic ovary syndrome in adulthood. 
They demonstrated that this was associated with a mutation in a key enzyme 
involved in the DHEA-DHEAS sulfation system. This enzyme, 3'-phosphoadenosine 
5'-phosphosulfate synthase 2 (PAPSS2) is an activated sulphate donor used by the 
sulfotransferase SULT2A1. Functional assays of these mutations in the PAPSS2 
gene reconstructed the DHEA-DHEAS sulfation system and confirmed inactivation 
of the PAPSS2 enzyme. This important discovery of a functional mutation in 
metabolism of adrenal androgens leading to a clinical syndrome of androgen 
excess highlights the potential role at this level of regulation. While these 
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mechanisms are clearly important in the regulation of androgens, little is known 
about the regulation of metabolism of aldosterone.  
1.2.7 CYP11B1 and CYP11B2 
As discussed above, the final steps of aldosterone and cortisol synthesis are 
catalysed by the enzymes aldosterone synthase encoded by CYP11B2 and 11β 
hydroxylase encoded by CYP11B1. Transcriptional regulations of these two rate 
limiting enzymes are crucial regulating mechanisms in the control of aldosterone 
and cortisol production. This thesis, in particular the experimental work, will 
focus on the effect of variation in CYP11B2 on regulation of transcription of 
aldosterone synthase. Current evidence regarding the regulation of CYP11B2 will 
be discussed in section 1.2.8 but in order to put this into context, a short section 
will follow on the general considerations to be taken into account when studying 
these two genes, including their origins, as well as a brief overview of general 
principles of transcriptional regulation. 
Evolution of CYP11B1 and CYP11B2 
Thought to arise from a gene duplication event around 400 million years ago 
around the time of colonisation of land (Colombo et al., 2006), CYP11B1 and 
CYP11B2 lie in tandem on chromosome 8 have 9 exons and share around 95% 
homology in their coding regions (Mornet et al., 1989) and this homology 
contributes to significant technical difficulties in laboratory experiment. Their 
structures diverge in the 5’ untranslated region of the genes as can be observed 
in Appendix 7.3. For some years there was controversy over whether one 
multifunctional gene was responsible for 11-hydroxylation, 18-hydroxylation and 
18-oxidation step in man (Globerman et al., 1988), as in the bovine adrenal 
(Hashimoto et al., 1989), or whether two separate genes were responsible 
(Mornet et al., 1989; Kawamoto et al., 1992). We now the second option is 
correct. The different biochemical reactions undertaken by these two enzymes 
are discussed above (section 1.2.4); however some consideration must also be 
given to the different mechanisms of regulation of gene transcription as 
maintaining independent function clearly depends on the ability to discriminate 
between signals to produce more cortisol without necessarily increasing 
aldosterone synthesis, and vice versa. 
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Gene transcription 
The principles of gene transcription are integral to the central dogma of 
molecular biology; that is the concept of DNA transcribed to RNA, and this then 
translated to protein. The control of these processes involves numerous 
mechanisms that ensure tight regulation of gene expression. RNA transcription 
must be controlled and regulated, and in contrast to DNA replication, processes 
must be present which allow selective transcription of certain genes and not 
others in order to maintain distinct cellular properties and functions. In order for 
transcription to take place, a pre-initiation complex is formed comprising of 
transcription factors including TATA box binding protein and RNA polymerase II 
(Pol II). The hydrogen bonds between complementary nucleotides of DNA are 
broken and Pol II moves along the DNA strand pairing RNA nucleotides with 
complementary DNA bases with the exception that thymines are replaced with 
uracils and the nucleotides are composed of a ribose (5-carbon) sugar where DNA 
has deoxyribose in its sugar-phosphate backbone. Finally, the hydrogen bonds of 
the untwisted RNA+DNA helix break, freeing the newly synthesized RNA strand.  
 The simplest transcriptional unit contains a core promoter element (usually a 
TATA sequence) around 20-30bp from the transcriptional start site, an upstream 
activator sequence, and silencer element both within 100-200 bp of the TATA 
box. However, a typical eukaryotic gene has more complex regulatory 
mechanisms, with a transcription factor complex containing numerous 
transcription factors which can be tissue specific. In addition, eukaryotic genes 
can possess several enhancer regions which can be located within introns, 3’ or 
5’ regulatory regions. Further, many genes contain binding sites for proximal 
regulatory factors which may not function as classical activators but rather 
tethering elements that act as anchors for other transcription factors to bind 
and act in a enhancing or repressive manner (Levine and Tjian, 2003). It is also 
now understood that distal regulatory elements (up to 1Mb away) can control 
gene transcription and this may be achieved through physical proximity if the 
DNA loops round to lie close to the transcriptional start site (Maston et al., 
2006).  
The chromatin structure of DNA is known to influence transcription as chromatin 
can prevent the transcriptional machinery from accessing the DNA. Chromatin-
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modifying activities and histone-modifying complexes, which add or remove 
covalent groups (e.g., acetyl groups, methyl groups, and phosphates) from 
histone tails can alter gene transcription and provide an alternative mechanism 
of control (Maston et al., 2006).  
DNA methylation is another mechanism by which transcription is regulated and is 
associated with transcriptional silencing. This can be achieved in two ways. 
Firstly, methylation at CpG dinucleotides (GC rich areas of the genome) can 
repress transcription by blocking the ability of transcription factors to bind their 
recognition sequences. Secondly, methylation-specific binding proteins can 
specifically bind methylated CpG dinucleotides and recruit histone 
deacetyltransferases which can alter the chromatin structure to make it 
available to transcriptional binding complexes (Clouaire and Stancheva, 2008).  
1.2.8 Transcriptional regulation of CYP11B2 
 The first observations regarding the transcriptional regulation of CYP11B2 via 
protein: DNA interactions in a human cell line were made by Clyne et al, using 
reporter constructs for promoter deletion assays, DNAse foot printing 
experiments and electromobility shift assays (Clyne et al., 1997). Functionally 
important regions of the human CYP11B2 promoter were identified by this group 
as -776/756 (NBRE-1), -129/144 (Ad5) and -71/64 (CRE).  
 This last site, CRE, is also present in the CYP11B1 promoter (Bassett et al., 
2004b) and therefore it is likely that the NBRE-1 and Ad5 sites are more 
important for differential regulation of CYP11B1 and CYP11B2. It was observed 
that the CRE site was similar to other sites that bound CREB, ATF-1 (activating 
transcription factor 1) and ATF-2 (activating transcription factor 2) and 
therefore, DNA- protein complexes were interrogated for the presence of these 
transcription factors using electromobility shift assays and a  “super-shift” 
approach with antibodies to these proteins (Bassett et al., 2000). More recently, 
their role was further confirmed by siRNA knock down as well as transfection 
with constitutively active vectors for of ATF1, ATF2 and CREM and CREB 
(Nogueira and Rainey, 2010).  
 Transcription factors belonging to the NGFIB family were previously known to be 
expressed in the human adrenal gland and implicated in the transcriptional 
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control of other steroidogenic enzymes e.g. CYP21 (Davis and Lau, 1994). The 
presence of a consensus sequence for NGFIB (AAAGGTA) within one of the 
functionally important regions supports the hypothesis that they are likely to be 
involved in the transcriptional regulation of CYP11B2. Indeed, NGFIB (Nerve 
Growth factor 1B, also known as NURR77 and NR4A1) and NURR1 were shown to 
form complexes with oligonuctiotides spanning the sequences for the NBRE-1 and 
Ad5 sites (Wilson et al., 1993).  
The Ad5 element has also been shown to bind COUP-TF (chicken ovalbumin 
upstream promoter transcription factor), a transcription factor that is thought to 
inhibit transcription of CYP17 but to promote that of CYP11B2. It has been 
suggested that this tissue specific regulation is mediated by co-regulator 
proteins, for example, Ubc9, small ubiquitin-related modifier-1 (SUMO-1)-
conjugating enzyme and PIAS1 (protein inhibitor of activated STAT 1) SUMO-1-
conjugating ligase (Shibata et al., 2004; Kurihara et al., 2005).  
 A summary of these transcription factors and binding sites within the CYP11B2 
promoter are shown in Figure 1-17. It is worth noting that these discoveries have 
arisen as a result of focused, hypothesis-driven experiments. However, they do 
not exclude the possible role of other factors in controlling CYP11B2 
transcription. Recent advances in molecular biology techniques allow a more 
biologically agnostic approach, without a priori assumptions which may limit the 
discovery of novel mechanisms. In addition, to date, there has been no research 
published regarding the influence of mechanisms such as chromatin modification 
or methylation (as described above) on the transcriptional regulation of 
CYP11B2. In short, there remain many unanswered questions around the control 
of this important process. 
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Figure 1-17 Transcription factor binding sites characterised in the CYP11B2 promoter 
region.  
DNA binding sites denoted by grey rectangles, position relative to transcriptional start site 
given in italics. Transcription factor proteins denoted by blue shapes below. NGFIB, Nerve 
Growth factor 1B; NURR1, Nuclear receptor related protein 1; COUP-TF, chicken ovalbumin 
upstream promoter transcription factor; ATF1, activating transcription factor 1; ATF2, 
activating transcription factor 2; CREB, cAMP response element-binding protein.  
 
1.2.9 Angiotensin II and CYP11B2 gene transcription 
In order to further investigate the effect of angiotensin II on aldosterone 
producing cells, both Rainey (Nogueira et al., 2007) and Gomez-Sanchez (Romero 
et al., 2007) et al have carried out microarray analyses of RNA from H295R cells 
(an adrenal cortical carcinoma cell line) exposed acutely to angiotensin II and 
compared the response to cells under basal conditions. This technique allows 
quantitative changes in expression of thousands of gene to be measured across 
the human genome. Despite experimental differences (angiotensin II 
concentrations were not the same, nor was the time incubated with the 
trophin), these two groups identified a core of 6 transcription factors in 
common. Included in these were transcription factors from the NGFIB family 
(Nurr1 and Nor1). In addition, members of the AP1 (activator protein 1, i.e. FOS 
and JUNB) family of transcription factors, which are known to be induced in the 
adrenal gland by angiotensin II (Viard et al., 1992): Egr (early growth response), 
BTG2 and ATF3 (activating transcription factor 3). It is interesting that 
mechanisms previously suspected to be involved in regulation of aldosterone 
synthase transcription have now been confirmed using this unbiased approach. 
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However, there are problems with this experimental method. Only a fraction of 
the volume of data produced in these experiments is published and although 
some investigators use publicly available repositories for depositing their data, 
methodological details are not always available or not similar enough to allow 
valid comparisons with other experiments. In addition, given the pleotrophic 
effects of angiotensin II, including its effects on other steroidogenic enzymes, it 
is not possible from microarray data alone to identify transcription factors which 
directly influence aldosterone synthase transcription and further experiments 
are required to confirm the role of transcription factors identified by this 
method. However, this does not always result in a clear answer. For example, 
both groups demonstrated up-regulation of FOS by angiotensin II, and the 
Gomez-Sanchez group indicated that up-regulation of FOS was associated with 
increased aldosterone synthase promoter activity (Romero et al., 2007). It would 
be tempting to speculate that increased angiotensin II leads to increased FOS 
causing increased aldosterone synthase promoter activity and increased 
production of aldosterone. However in the experimental model used by Nogueira 
et al this was not found to be the case in H295R cells (Nogueira et al., 2009a). It 
is worth noting that there is evidence that increased FOS leads to down-
regulation of CYP17 (possibly via an interaction with SF-1) (Sirianni et al., 2010). 
This effect may not be seen in H295R cells as they express all the characteristics 
of androgen, glucocorticoid and mineralocorticoid producing cells (Gazdar et al., 
1990); in fact their principle product is adrenal androgens, thus a relative excess 
of CYP17 compared to CYP11B2 may obscure this phenomenon in H295R cells. 
 Both groups have published subsequent work in order to further dissect these 
pathways (Nogueira et al., 2009b; Romero et al., 2010a). However, the relative 
contributions of these novel transcription factors in steroidogenesis in general 
and the regulation of aldosterone synthase in particular remains to be further 
elucidated.  
 The effects of potassium and ACTH on the transcription of human CYP11B2 are 
even less clear. This is predominantly due to limitations of the model system. 
H295R cells respond to potassium but only at supra-physiological concentrations 
and there is no effect of ACTH (although the effect of ACTH can be mimicked by 
the use of dibutyryl cyclic AMP or forskolin) due to low levels of expression of 
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the ACTH receptor. To date, there are limited data regarding the mechanisms of 
their actions on transcription of CYP11B2. 
1.3 Cardiovascular consequences of disruption of 
aldosterone production  
The main physiological role of aldosterone and the mechanisms by which its 
production is regulated have been discussed in the preceding sections. How 
disruption of these mechanisms may lead to adverse cardiovascular 
consequences will be discussed in the following sections. 
1.3.1 Blood pressure effects of mutations in steroidogenic 
genes: Congenital adrenal hyperplasia 
As discussed previously, the perturbation of normal mechanisms of homeostasis 
observed in monogenic disorders can provide useful insights into normal function 
and the steroidogenic pathway offers many such examples.  
 The commonest condition seen in clinical practice is 21 -hydroxylase deficiency, 
which is described as either classical, commonly presenting in the neonatal 
period with salt wasting +/- ambiguous genitalia (rare: incidence 1:14 000 (New, 
2004)), or non-classical, presenting in adulthood with symptoms of androgen 
excess and often asymptomatic in men (more common: incidence estimated 
1:100 in Caucasian population (New, 2004) and http://omim.org/entry/613815). 
The biochemical phenotype, while covering a wide spectrum, arises from a 
reduced ability to convert progesterone and 17 α-hydroxyprogesterone (17-OHP) 
to 11-deoxycorticosterone (DOC) and 11-deoxycortisol (Compound S) and thence 
to the end products, aldosterone and cortisol (Compound F) respectively. This 
leads to increased ACTH drive in an attempt to restore homeostasis; however, 
this results only in androgen excess. Indeed, the diagnosis is made on the basis 
of elevated 17- OHP levels in response to ACTH. Treatment with exogenous 
steroids to suppress ACTH ameliorates many of the metabolic manifestations.  
However, mutations in other genes in the steroidogenic pathway can lead to 
congenital adrenal hyperplasia (CAH), and provide clear examples of the 
influence of these genes on steroid, and cardiovascular phenotypes. These are 
described in Table 1-5.The syndrome of aldosterone synthase deficiency is 
associated with low blood pressure and salt loss but a condition associated with 
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a “gain of function” would be of interest in the development of hypertension 
and relative aldosterone excess. Of particular relevance to studies of the 
pathogenesis of hypertension, it is worth noting that 17α-hydroxylase deficiency 
can present with perturbations of blood pressure and it has already been 
observed that a SNP in the locus of this gene has been identified as associated 
with blood pressure phenotypes in genome wide association studies of essential 
hypertension (See section 1.1.8,). No further direct association studies have 
been carried out with variants in this gene in populations of hypertensive 
patients, nor has any functional work to identify “milder” mutations yet been 
published. This would be an area of much interest for future work. 
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ENZYME 
21 
hydroxylase  
11-beta-
hydroxylase  
Aldosterone 
synthase  
17-alpha-
hydroxylase  
3-beta 
hydroxysteroid 
dehydrogenase  
 
GENE 
AFFECTED 
 
CYP21A 
 
CYP11B1 
 
CYP11B2 
 
CYP17 
 
HSD3B2 
 
AMBIGUOUS 
GENETALIA 
 
Females 
 
Females 
 
No 
Males 
No pubertal 
development 
in females 
Males 
Mild in females 
 
INCIDENCE 
 
1: 14 000 
 
1:10 000 
 
Rare 
 
Rare 
 
Rare 
 
GLUCO-
CORTICOIDS 
 
↓ 
 
↓ 
 
Normal 
 
↓ 
 
↓ 
 
MINERALO-
CORTICOIDS 
 
↓ 
 
↑ 
 
↓ 
 
↑ 
 
↓ 
 
ANDROGENS 
 
↑ 
 
↑ 
 
Normal 
 
↓ 
 
↓Males 
↑Females 
 
BLOOD 
PRESSURE 
 
↓ 
 
↑ 
 
↓ 
 
↑ 
 
↓ 
 
NA BALANCE 
 
↓ 
 
↑ 
 
↓ 
 
↑ 
 
↓ 
 
K 
BALANCE 
 
↑ 
 
↓ 
 
↑ 
 
↓ 
 
↑ 
 
ACIDOSIS 
 
Yes 
 
+/- alkalosis 
 
Yes 
 
+/- alkalosis 
 
Yes 
 
 
ELEVATED 
STEROIDS 
 
17OHP 
 
DOC, 
11-
deoxycortisol 
 
Corticosterone 
+/- 18-
hydroxy-
corticosterone 
 
DOC, 
corticosterone 
 
DHEA, 17OHPreg 
Table 1-5 Characteristics of different forms of CAH. 
Adapted from(146). 17OHP, 17 α-hydroxyprogesterone, DOC, deoxycorticosterone, DHEA, 
dehydroepiandrosterone, 17OHpreg, 17α- hydroxypregnenelone.   
 
1.3.2 Aldosterone and Hypertension 
10-15% of patients with hypertension have an aldosterone level that is elevated 
in relation to the level of renin (Rossi et al., 2006; Lim et al., 1999; Lim et al., 
2000a; Fardella et al., 2000). A proportion of these patients will have 
autonomous aldosterone secretion. From a clinical perspective, classical Conn’s 
syndrome or an aldosterone-producing adenoma remains the most important 
diagnosis to make in this context, as patients who have no contraindications to 
surgery may be cured of their high blood pressure by adrenalectomy, as initially 
described by Jerome Conn in 1956 (Conn and LOUIS, 1956). Since this 
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phenomenon was first described by Conn, there has been significant controversy 
regarding the contribution of aldosterone excess to the incidence of 
hypertension. However, it quickly became apparent that relatively few patients 
with hypertension harboured a large, unilateral, surgically resectable adenoma. 
Difficulties interpreting biochemical analyses including difficulties establishing 
normal reference ranges, the confounding effects of antihypertensive 
medication and other environmental factors all contributed to the difficulty in 
arriving at a diagnosis of aldosterone excess and establishing the prevalence of 
aldosterone excess in hypertension. The greater use of the aldosterone to renin 
ratio (ARR) as a screening test meant that the diagnosis could be considered and 
excluded in a significant proportion of hypertensive patients (unlike serum 
potassium which may be normal). This lead to a number of investigators 
contributing data to suggest the prevalence of aldosterone excess was greater 
than previously recognised (Gordon et al., 1994; Fardella et al., 2000; Calhoun 
et al., 2002; Lim et al., 2000b; Lim et al., 1999; Loh et al., 2000; Rossi et al., 
2006). The largest and most comprehensive of these studies was the PAPY study 
(Rossi et al., 2006). This prospective study carefully established the biochemical 
features of aldosterone excess using suppression testing after an initial ARR 
screening test, and attempted to lateralise the source of aldosterone excess 
with adrenal vein sampling where available. The rates of aldosterone secreting 
adrenal adenoma in this study were 4.8% and the overall rate of aldosterone 
excess was 11%.  Similar rates have been described in Scottish primary (Lim et 
al., 1999) and secondary care (Lim et al., 2000a) settings.  
 In patients with aldosterone excess but no evidence of a unilateral adenoma, 
the underlying pathophysiology is less clear and the majority of cases are 
attributed to “idiopathic bilateral hyperplasia”. The spectrum of pathological 
change from a normal adrenal gland to an aldosterone-producing adenoma is not 
well understood and there remains much controversy as to whether the 
development of abnormal bilateral hyperplastic adrenals precedes the 
emergence of a single dominant nodule. Some aspects of this have been 
discussed in section 1.2.5. While this topic raises interesting and important 
points, it is clear that regardless of the precise process of pathological change, 
there is a relationship between plasma aldosterone concentration and risk of 
high blood pressure, even when levels are within the so-called normal range and 
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secretion does not exhibit automaticity as in primary aldosteronism. Evidence 
for this comes from the Framingham cohort where, in normotensive subjects, a 
plasma aldosterone level at the top end of the normal range was associated with 
a higher incidence of hypertension at 4 year follow up than a lower plasma 
aldosterone level (Vasan et al., 2004). Further, data from Reynolds et al 
(Reynolds et al., 2009) demonstrated in an elderly population a positive 
correlation between plasma aldosterone concentration after stimulation, and 
suppression and blood pressure. The efficacy of spironolactone as a blood 
pressure lowering agent in resistant hypertension (Chapman et al., 2007) has 
also contributed to the body of evidence which places aldosterone in a central 
role in the pathogenesis of hypertension. 
1.3.3  Cardiovascular damage independent of blood 
pressure 
 Animal models from Rocha et al (Rocha et al., 1998; Rocha et al., 2000; Rocha 
et al., 1999) and Weber et al (Brilla et al., 1990) elegantly demonstrated the 
detrimental effect of aldosterone on a range of cardiovascular tissues, including 
the heart, brain and the kidney in rat models of mineralocorticoid excess and 
hypertension. Vascular damage was prevented by mineralocorticoid blockade 
and was independent of blood pressure. It is of interest that the presence of 
aldosterone proved necessary but not sufficient for the development of vascular 
pathology as the detrimental effects required the presence of a high salt diet 
(Rocha et al., 1998; Rocha et al., 2000; Blasi et al., 2003). A murine model of 
aldosterone induced vascular damage did not develop the cardiovascular 
phenotype in the absence of high salt diet (Wang et al., 2004), confirming that 
this phenomenon is constant across species. In man, the crucial role of dietary 
sodium has been confirmed in a cohort of hypertensive patients, where the 
blood pressure lowering effect of a restricted sodium intake was considerable 
(Pimenta et al., 2009). These data from Pimenta et al suggests that elevated 
aldosterone (without confirmation of autonomous aldosterone production) in 
combination with a high salt intake, leads to increased urinary protein 
excretion, independent of blood pressure. Further evidence of end organ 
damage caused by the combination of high salt and high aldosterone can be 
found in work by Du Cailar et al, who demonstrate that in a group of patients 
with hypertension, left ventricular hypertrophy progressively increased across 
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sodium tertiles only in patients with high plasma aldosterone concentration (du 
Cailar G. et al., 2010).  
Further evidence for the adverse effects of aldosterone is provided by findings 
that patients with primary aldosteronism have higher rates of left ventricular 
hypertrophy (Rossi et al., 1996) and other adverse cardiovascular events 
including stroke, non-fatal myocardial infarction (MI), atrial fibrillation (Rossi et 
al., 1996; Milliez et al., 2005) and renal dysfunction (Sechi et al., 2006) than 
patients with similar levels of blood pressure where aldosterone is not increased. 
The increased proteinurea associated with primary aldosteronism is partly 
reversible following medical therapy with mineralocorticoid antagonist or 
surgical resection (Sechi et al., 2006). 
 Aldosterone excess has also been associated with poor outcomes in heart failure 
as well as adverse events post myocardial infarction (Beygui et al., 2006). It is 
known that the degree of neurohumoral activation and specifically, increased 
aldosterone concentrations in plasma, are associated with increased mortality; 
both the SAVE trial (Vantrimpont et al., 1998) (post MI) and CONSENSUS 
(Swedberg et al., 1990) (heart failure) demonstrated that high aldosterone levels 
predict poor cardiovascular outcome. In addition, further data have confirmed 
that this association of increased mortality is present in patients across all NYHA 
classifications of heart failure (Guder et al., 2007).  These adverse effects are 
likely to reflect specific actions of aldosterone on the heart, given that the 
hormone in excess provokes myocardial fibrosis and remodelling in the rat heart, 
independent of blood pressure and angiotensin II (Brilla et al., 1990). Blocking 
aldosterone using mineralocorticoid receptor antagonists is associated with less 
remodelling both in animal models (Fraccarollo et al., 2003) and in a human 
cohort post MI (Weir et al., 2009). 
 Finally, the importance of mineralocorticoid receptor activation on 
development of cardiovascular dysfunction is illustrated by studies in patients 
with cardiac failure and myocardial infarction. A large number of clinical trials 
have investigated the utility of inhibition of renin/angiotensin system the in 
cardiovascular conditions, but the focus was predominantly on inhibition of 
angiotensin converting enzyme (ACE) or blockade of the angiotensin II receptor. 
However, pilot data from the RESOLVD trial (McKelvie et al., 1999) 
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demonstrated that even the combination of an ACE inhibitor and angiotensin 
receptor blocker does not chronically suppress aldosterone secretion - a 
phenomenon described as “aldosterone escape” - prompting the evaluation of 
inhibition of aldosterone action as an alternative approach in cardiovascular 
therapy.  The Randomised Aldactone Evaluation Study (RALES) (Pitt et al., 1999) 
provided the first crucial evidence that blockade of aldosterone receptors 
decreased mortality in patients with left ventricular systolic function, leading to 
a re-evaluation of the perception of aldosterone antagonists and their clinical 
applications. This study had a major influence on clinical practice and indeed, 
prompted a degree of concern regarding the increased incidence of adverse 
events associated with spironolactone, specifically hyperkalaemia. The EPHESUS 
study used the selective mineralocorticoid-receptor antagonist eplerenone 
added to recommended medical therapy. This reduced the rates of death from 
any cause and hospitalization for cardiovascular reasons among patients with 
acute myocardial infarction complicated by left ventricular systolic dysfunction 
and heart failure (Pitt et al., 2003). Most recently, EMPHASIS-HF evaluated the 
effects of eplerenone in patients with systolic heart failure and mild symptoms 
(NYHA class II) and also confirmed a mortality benefit as well as a reduction in 
hospitalisation (Zannad et al., 2011). 
In summary, it is clear that inappropriate aldosterone for the level of renin and 
salt intake can be detrimental and that blocking the action of aldosterone via 
mineralocorticoid receptor antagonists ameliorates this effect.  The mechanisms 
behind inappropriate aldosterone production are not clear. However, 
aldosterone levels (Inglis et al., 1999) and the aldosterone to renin ratio 
(Alvarez-Madrazo et al., 2009; Newton-Cheh et al., 2007) (the most commonly 
used screening test for aldosterone excess) are heritable, consistent with an 
underlying genetic mechanism. The aldosterone synthase gene catalyses the 
final rate limiting steps in the production of aldosterone and is a logical 
candidate gene for hypertension and the sub-phenotype of relative aldosterone 
excess. Further discussion of the aldosterone synthase gene and the effect of 
variation within it, leading to altered regulation of plasma aldosterone 
concentration will now follow.  
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1.4 Structure of CYP11B2: Mutations and variations  
 CYP11B2 lies on chromosome 8 q24.3 and is a gene with 9 exons, all of which 
are transcribed. It is highly polymorphic with high linkage disequilibrium across 
the locus (White and Slutsker, 1995). However, this varies according to ethnicity 
with a greater degree of polymorphism and less strong LD in African populations, 
presumable due to greater frequency of recombination events (Alvarez-Madrazo 
S et al., 2009). CYP11B2 lies just 40kb from CYP11B1 (11 β-hydroxylase). These 
two enzymes are structurally very similar, with around 93% homology, reflecting 
their shared origin (they are thought to be as a result of a gene duplication 
event). However, there is less similarity between their 5’ untranslated regions, 
presumable reflecting their separate mechanisms of regulation. 
Mutations in aldosterone synthase which alter the protein code can result in 
decreased or absent aldosterone synthase activity. As aldosterone synthase 
catalyses both the 18-hydroxylation of corticosterone to 18-
hydroxycorticosterone (18-OHB) as well as the final biochemical step of 
aldosterone biosynthesis, the 18-hydroxylation of 18-OHB to aldosterone, an 
inability to undertake either or both of these reactions can occur. 
 To test the hypothesis that variation in aldosterone synthase could lead to a 
phenotype of hypertension and inappropriate aldosterone level for the level of 
renin, Smithies group (Makhanova et al., 2008) generated a mouse model with 
increased expression of the aldosterone synthase gene. This was achieved by 
inserting the more stable 3’ end of the human growth hormone gene instead of 
the endogenous 3’ end of aldosterone synthase gene. The group confirmed that 
the experimental mouse had greater levels of expression of aldosterone synthase 
and demonstrated that the experimental mouse had less activation of the RAAS 
under low salt conditions with less deactivation of the RAAS under high salt 
conditions than control animals. In addition, the experimental mice became 
hypertensive in response to high salt conditions and demonstrated greater 
cardiac hypertrophy in response to angiotensin II infusions, a phenomenon not 
exhibited by control mice. These important experiments are a proof of principle 
that increased expression of aldosterone synthase can lead to minor elevations 
in plasma aldosterone concentrations, but that phenotypic differences in the 
Chapter 1  85 
form of hypertension and other adverse cardiovascular phenotypes are only 
evident under specific environmental conditions.  
Polymorphic variations in CYP11B2 (i.e. variation that is more frequent than 5% 
of the population and do not affect protein coding) have been described. White 
et al first described a polymorphism at position -344 in the 5’untranslated region 
of the gene (White and Slutsker, 1995). This corresponds to a binding site for 
steroidogenic factor 1 (SF-1), a transcription factor implicated in the 
transcriptional regulation of many steroidogenic enzymes. The C allele at 
position -344 binds SF-1 four-five times more avidly than the T allele (White and 
Slutsker, 1995; Bassett et al., 2002) but, this site appears to have no functional 
effect in vitro as deletion has no effect on transcription (Clyne et al., 1997) and 
reporter constructs carrying to two contrasting alleles are expressed at the same 
level (Bassett et al., 2002). 
 In addition, a variation in the intron 2 was also first described by White et al 
(White and Slutsker, 1995), where part of the sequence in the CYP11B2 intron 2 
corresponds to that of the intron 2 in CYP11B1. It is though that this has arisen 
from a gene conversion event. However, its functional significance is unclear 
and has as yet not been assessed in vitro, or indeed, clearly delineated in vivo. 
As we are now recognising the possible functional roles of what was previously 
thought of as “junk DNA” it may be worth investigating the possibility that the 
intron conversion polymorphism may play a functional role resulting in altered 
regulation of the gene.  
1.5 CYP11B2 and hypertension phenotypes 
There has been much interest in the polymorphic variation in CYP11B2 in 
relation to hypertension and the sub-phenotype of inappropriately elevated 
aldosterone levels. The T allele at -344 has been associated with increased 
excretion of urinary metabolites of aldosterone (Davies et al., 1999) and plasma 
aldosterone (Paillard et al., 1999). There is also evidence that, amongst 
hypertensive subjects with an elevated ARR, the T allele is more frequent (Lim 
et al., 2002). However, there are conflicting reports in the literature as to 
whether the T or the C allele is more prevalent in patients with hypertension. 
The discrepancy between different populations (not an uncommon finding in 
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candidate gene studies as discussed above in section 1.1.6) may be as a result of 
variation in linkage disequilibrium in different populations, a phenomenon that 
we know varies with ethnicity. A meta-analysis conducted in 2007 concluded 
that, overall the -344 C allele was associated with around a 17% reduced relative 
risk of hypertension than the -344 T allele (Sookoian et al., 2007).  
 An interesting phenomenon associated with genetic variation at -344 is that of 
an alteration in index of 11β- hydroxylation. Elevated deoxycorticosterone and 
11-deoxycortisol in relation to corticosterone and cortisol has been consistently 
found in T allele carriers compared to C allele carriers (Davies et al., 1999; 
Davies et al., 2001). Why alteration in CYP11B2 is associated with a phenotype 
of reduced efficiency of the enzyme encoded by CYP11B1 is not clear. However, 
it has been demonstrated that the polymorphism at -344 in CYP11B2 is in strong 
LD with variation in the promoter region of CYP11B1 which is associated with 
reduced transcriptional activity in response to ACTH in in vitro studies (Barr et 
al., 2006). The mechanism may have some similarities to that observed in 
individuals with 11 β-hydroxylase deficiency i.e. that increased ACTH as a result 
of an absence of negative feedback from cortisol, leads to increased drive to the 
adrenal cortex. In the case of congenital adrenal hyperplasia caused by the 
monogenic disorder 11 β-hydroxylase deficiency, this increased ACTH drive is 
associated with increased deoxycorticosterone (see section 1.3.1, Table 1-5) 
which acts as a mineralocorticoid leading to increased sodium and water 
retention and thus suppression of renin. In contrast, in the case of the more 
minor reduction in 11 β-hydroxylation described here, in which cortisol levels 
are entirely normal, it has been suggested that increased ACTH drive (as 
evidenced by increased morning plasma ACTH concentrations (Freel et al., 2008) 
and increased adrenal androgens (Freel et al., 2007), leads to increased 
synthetic capacity for aldosterone production either by causing hyperplasia of 
the zona glomerulosa or by increasing expression of CYP11B2. Thus, according to 
this hypothesis, the phenotype may not be driven by variation in the CYP11B2 
gene but rather that the -344 polymorphism is merely a “passenger” SNP which 
is inherited along with the “driver” SNPs in the promoter region of CYP11B1. 
However, as described above (see section 1.2.5), the role of ACTH as a trophin 
of aldosterone production is controversial. Indeed, in the case of CAH due to 11 
β-hydroxylase deficiency hypertension is caused not by increased aldosterone 
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but rather by increased deoxycorticosterone secretion, and aldosterone levels 
are low. 
Another possible alternative hypothesis is that the entire CYP11B1/ CYP11B2 
locus is necessary for the development of the phenotype, with variation in the 
CYP11B1 promoter driving the elevated DOC: S, B: F ratio and that this is co 
inherited with variation within the CYP11B2 promoter which causes increased 
aldosterone. Recent data from within the Connell/ Davies group suggest that the 
haplotype containing the T allele at -344 along with A/G at -1881/ 1851 in 
CYP11B1 is associated with increased transcription of aldosterone synthase and 
reduced transcription of 11 β-hydroxylase in vitro and an increased risk of 
hypertension in vivo. 
Having described some of the current knowledge in the field relating to the 
regulation of aldosterone levels in general and the regulation of transcription of 
aldosterone synthase in particular, a programme of work has been undertaken to 
investigate the hypotheses discussed in the following section.  
1.6 Hypothesis: Aldosterone and essential 
hypertension 
1.6.1 Hypothesis  
The principle hypotheses to be explored in the following work is firstly, that 
there is a genotype-dependant increase in basal aldosterone production and/ or 
increased responsiveness of aldosterone production to its principle trophins and 
secondly, that this phenotype also displays evidence of inefficient 11β-
hydroxylase activity as evidenced by an increase in the ratio of 11-deoxycortisol 
to cortisol and an increase in the ratio of 11-deoxycorticosterone to 
corticosterone. Further, I propose that the molecular mechanisms that produce 
this phenotype are a result of polymorphisms that are inherited in a non-random 
fashion in the two genes controlling the final stages of corticosteroid 
metabolism. Specifically, I aim to test whether increased aldosterone production 
is a result of variation in the promoter region of CYP11B2 and corresponds to 
increased promoter activity and/ or increased sensitivity to trophins. Thus, a 
mechanism for increased aldosterone in some individuals may be independent of 
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relative inefficiency of 11β-hydroxylase which is co-inherited as a result of high 
linkage disequilibrium within the locus. 
1.6.2  Aims 
To identify the pattern of linkage disequilibrium across the promoter region of 
aldosterone synthase. 
To investigate and validate the H295R adrenocortical cell line as an appropriate 
model for the study of the regulation of steroidogenesis in general and 
aldosterone production in particular.  
To investigate the functional effects of candidate polymorphisms in the 
promoter region of aldosterone synthase in order to determine their likely 
effects on aldosterone production.  
To explore in detail the effect of variation in the promoter region of aldosterone 
synthase on corticosteroid production and regulation in normal adult volunteers 
studied under standardised salt conditions.  
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2. Methods 
2.1 Genotyping of polymorphisms in the CYP11B2 
and CYP11B1 locus 
2.1.1 Subjects 
Oxford cohort (HTO) has been previously described (Baker et al., 2005) and 
consists of 1773 individuals from 255 families where the proband was found to 
have essential hypertension. Subjects were recruited from 1993-1996 and 
families were ascertained from the hypertension clinic at the John Radcliffe 
Hospital, Oxford, or through general practices in the Oxford area. Hypertension 
was defined as mean SBP> 140mmHg and DBP>90mmHg on daytime ambulatory 
monitoring or more than three office BP readings of SBP>160mmHg 
DBP>95mmHg. All patients were 60 or younger at time of onset of hypertension. 
Subjects aged more than 30 years with a diastolic blood pressure <90 mmHg and 
a systolic blood pressure <140 mmHg were considered unaffected. Exclusion 
criteria were a BMI >30 kg/m2, use of oral contraception or a diagnosis of a 
secondary causes of hypertension. All probands and family members were UK 
residents of self reported Caucasian ethnicity. For the purposes of this work, 279 
individuals were selected at random from this cohort for genotyping across the 
CYP11B2 promoter region. 
2.1.2 PCR of CYP11B2 promoter region 
The 2kb region of the CYP11B2 promoter was amplified by polymerase chain 
reaction (PCR) followed by sequencing. A number of primers were designed 
based on published sequences of the CYP11B2 gene 
(http://www.ensembl.org/index.html) and were between 20 -24 bp in length. 
They had less than 60% Guanine/ Cytosine (G/C) content and were screened for 
their ability to form secondary structures and dimers. In addition, they were 
checked for specificity using the BLAST database, 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  The primers, which had been purified 
by the High Purity Salt Free (HPSF) purification method, were commercially 
obtained (Eurofins MWG Operon, Ebersberg, Germany). The optimum primer 
combination was selected and used for PCR amplification of the region. Primer 
sequences are shown in the following table.  
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PRIMER 
DIRECTION 
 
SEQUENCING/ 
PCR 
PRIMER 
NAME 
SEQUENCE BASE 
PAIRS 
TM 
(°C) 
Sense PCR B2_F2 GCC AAT AGA 
ACT GAC TTG CC 
20 57.3 
Antisense Sequencing B2_R1 AGG ATT T GG 
GCT GAA CA G 
GGT GGA 
24 64.4 
Antisense Sequencing SF1R AGG CGT GGG 
GTC TGG ACT 
18 60.5 
Antisense Sequencing B2Pro494 TTC AAG CAA 
TTC TCC CGC CT 
20 57.3 
Antisense PCR B2 5’ 
783 
AGA TCA TCC 
CAC TGC ACT 
CC 
20 59.3 
 
The Taq polymerase that was used was a mixture of Thermostable Taq DNA 
Polymerase and a polymerase with proof reading (3’-5’ exonuclease) activity, 
Expand High Fidelity PCR systems (Roche Diagnostics, Mannheim, Germany). The 
PCR conditions were optimized using a temperature gradient and the most 
successful annealing temperature was chosen. PCR reactions were set up in 96 
well plates and the PCR was performed on Tetrad PTC-225 Thermo Cycler (MJ 
Research Waltham, Massachusetts, USA). 5 µl DNA (5ng/ µl) was added to the 
following reaction mixture: 
Reagent Volume added per 
well  
Final concentration 
dNTPs 2 µl 80µM 
Forward Primer 0.75µl 400nM 
Reverse Primer 0.75µl 400nM 
Expand High Fidelity Taq DNA 
polymerase  
0.75µl 
Expand High Fidelity Buffer, 
10x conc. with MgCl2  
2.5 µl 
Nuclease free water  13.25 µl 
Total 20 µl 
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The PCR conditions were as follows: 
1. 94°C for 2 mins    Denaturing step 
2. 94°C for 15 secs    Denaturing step 
3. 61.4°C for 30 secs    Annealing step 
4. 68°C for 4 mins    Elongation step 
Repeat steps 2-4 for 9 cycles 
5. 94°C for 15 secs    Denaturing step 
6. 61.4°C for 30 secs     Annealing step 
7. 68°C for 4 mins (+ 5 secs per cycle) Elongation Step 
Repeat step 5-7 for 19 cycles 
8. 72°C for 7 mins    Final Elongation 
 
Selected samples, including a negative control, were resolved on a 1% agarose 
gel. Agarose (1g) was added to 100ml TBE buffer and heated to boiling point in a 
950W microwave oven for 50 seconds. 1 µl ethidium bromide was added and 
gently mixed. This was allowed to cool in gel moulds with Teflon combs until 
set. To confirm the presence of PCR product and the absence of contamination, 
10 µl of PCR product was loaded into the wells and run at 90 volts for 40 mins. 
DNA bands were visualised under UV light at 302nm and results were recorded 
using Multi-Analyst software v1.1 (Bio-Rad, Hertfordshire, UK) and a 2kb band 
was visualised. 
The PCR product was cleaned up prior to sequencing using the AMPure system 
(Agencourt, Beverly, MA, USA.) removes unincorporated primers, dNTPs, DNA 
polymerases and salts used during PCR amplification that can interfere with the 
sequencing reaction. AMPure was re-suspended by vortexing before adding to 
the PCR reaction products. The plate was spun down and incubated for 3 min 
before being placed on a magnetic block for 10 min. 200µl of 70% ethanol was 
added to each well and after 30 sec, the supernatant was discarded by inverting 
the plate, whilst still on the magnet, onto absorbent paper. The inverted plate 
and magnet were spun down at 76x g for 30 sec. The plate was removed form 
the magnet and left to air dry for 20 min before the addition of 40µl of NF 
water. The plate was returned to the magnet for 10 min and 2µl of this final 
solution was the substrate for the sequencing reaction.  
2.1.3 Sequencing reactions for CYP11B2 promoter region 
PCR products were sequenced using Applied Biosystems Big Dye v3.1 cycle 
sequencing chemistry (PE Applied Biosystems, Foster City, California, USA), a 
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modification of the chain terminator method. This process requires a primer 
which is complementary to the beginning of the sequence of DNA previously 
amplified by PCR. This is annealed to the DNA and then extended by DNA 
polymerase using modified substrate which includes labeled 2’-3’- 
dideoxynucleotides. Each base is labelled with a different colour; these ddNTPs 
are incorporated into the replicate DNA however, once incorporated further 
extension is not possible due to the lack of a 3’ hydroxyl group. PCR products of 
varying lengths are produced, which can be fractionated on a sequencing 
column. Fluorescent sensors detect the colour of each DNA strand, allowing the 
nucleotide sequence to be interpreted.  
Sequencing reactions were set up in 96 well plates with the following 
components:  
Reagent Volume added per well  
PCR product 2 µl 
Primer (3.2pmol/ µl) 1 µl 
Sequencing Buffer (5x) 3.5 µl 
ABI PRISM BigDye Termination v3.1 
Ready Reaction Mix 
0.5 µl 
Nuclease free water 13 µl  
Total 20 µl 
 
Sequencing primers are shown in the first table. The sequencing reaction was 
performed on 96 well PTC 225 Peltier Thermal Cycler (MJ Research, Waltham, 
MA, USA) and the conditions were as follows: 
1. 96°C for 45 seconds 
2. 50°C for 25 minutes 
3. 60°C for 4 minutes 
4. Repeat from step (1) x 24 
5. Incubate at 94°C for 15 minutes 
 
The CleanSEQ purification method (Agencourt, Beverly, MA, USA) was utilised to 
remove reagents of the sequencing reaction prior to automated sequencing. The 
CleanSEQ reagent was resuspended by vortexing before adding 10µl was added 
to the sequencing product. 62µl of 85% ethanol was also added to each well. The 
plate was placed on the magnet for 5 min before the solution was removed and 
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discarded. 150µl of 85% ethanol was added to each well and this was incubated 
at room temperature for 30 secs. The plate and magnet were inverted on 
absorbent paper and centrifuged at 210 x g for 30 secs. The plate was removed 
from the magnet and left to dry for 20 min before the addition of 40µl of NF 
water. The plate was vortexed, spun down at 210 x g for 30 sec before being 
placed back on the magnet when 20µl was transferred to a bar coded plate for 
automated sequencing.  
Automated sequencing was preformed on ABI 3730 DNA analyser (Applied 
Biosystems, Foster City, CA, USA) 
Results were analysed using SeqScape v2.2 genotyping software (Applied 
Biosystems, Foster City, CA, USA) and sequences were aligned to a reference 
sequence based on published sequences of the CYP11B2 gene (Entrez Gene 
database, NCBI  http://www.ncbi.nlm.nih.gov/gene). Sequence annotated with 
location of SNPs and primers used is given in Appendix 7.2. Samples of poor 
quality were excluded from further analysis.  
2.1.4 PCR and sequencing of CYP11B2 intron 2 region 
The intron 2 polymorphism was genotyped according to a protocol previously 
optimised in the laboratory. The PCR primers are shown in the following table. 
PRIMER 
DIRECTION 
SEQUENCING/
PCR 
PRIMER NAME SEQUENCE BASE 
PAIRS 
TM 
(°C) 
Sense PCR ICTAQMAN F GATGGCATGAAGCA
CAAAGCT 
21 57.9 
Antisense PCR ICTAQMAN R CCTTGGGCGACAG
CACA 
17 57.6 
Antisense Sequencing INTCONR 
(B1B2) 
GTGTTCGAGCTGC
AGCCTTTTC 
22 62.1 
 
 PCR reactions were set up in 96 well plates and the PCR was performed on 
Tetrad PTC-225 Thermo Cycler (MJ Research Waltham, Massachusetts, USA).10µl 
of DNA (5ng/µl) was added to the following master mix: 
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Reagent Volume added per 
well 
Final concentration 
dNTPs 5 µl 200µM 
Forward Primer 0.5µl 400nM 
Reverse Primer 0.5µl 400nM 
MgCl2(25mM) 2 2.0mM 
Thermostart Taq, Abgene  1.25µl 
Thermostart Buffer, 10x conc. 2.5 µl 
Nuclease free water  6.25 µl 
Total 15 µl 
 
 
The PCR conditions were as follows:  
1. 95°C for 15 mins 
2. 95°C for 15 secs 
3. 62°C for 30 secs 
4. 72°C for 2 mins 
Repeat steps 2-4 for 44 cycles 
5. 72°C for 7 mins 
 
Selected samples, including a negative control, were resolved on a 1% agarose 
gel as previously described and a 600bp band was visualised. The PCR products 
were cleaned up as previously described.  
2.1.5 PCR and sequencing of CYP11B1 promoter region 
The polymorphisms in the promoter region of CYP11B1 were genotyped 
according to a protocol previously optimised in the laboratory. The PCR primers 
are shown in the following table. 
PRIMER 
DIRECTION 
SEQUENCING/ 
PCR 
PRIMER 
NAME 
SEQUENCE BASE 
PAIRS 
TM 
(°C) 
Sense 1ST PCR B1 5’UTR TCCTTCGCATCCCTTG
TAAGTT 
22 58.4 
Antisense 1ST PCR B1 PROM-
260 
CTTGGATTATTCAT
CTCCTTGCAAGG 
26 61.6 
Sense 2ND PCR B1 5’  
732 
GCATCCCTTGTAAG
TTGGATTCCTAA 
26 61.6 
Antisense 2ND PCR B1 5’ 
369-393 
AAGCATTCCCTTTG
AAAACTGGTAC 
25 59.7 
Antisense Sequencing B1 PROM 
250-229 
AAGTCAAATTGTCT
CTGTTTG 
21 52 
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The first PCR reactions were set up in 96 well plates and the PCR was performed 
on Tetrad PTC-225 Thermo Cycler (MJ Research Waltham, Massachusetts, 
USA).5µl of DNA (5ng/µl) was added to the following master mix: 
Reagent Volume added per 
well 
Final concentration 
dNTPs 5 µl 200µM 
Forward Primer 1µl 400nM 
Reverse Primer 1µl 400nM 
MgCl2(25mM) 1.5 µl 2.0mM 
Thermostart Taq, Abgene  0.25µl 
Thermostart Buffer, 10x conc. 2.5 µl 
Nuclease free water  8.75 µl 
Total 20 µl 
 
 
The PCR conditions were as follows:  
1. 95°C for 15 min 
2. 95°C for 30 sec 
3. 60°C for 30 sec 
4. 72°C for 3 min 
Repeat steps 2-4 for 34 cycles 
5. 72°C for 7 min 
 
The PCR products were then diluted 1:10 in nuclease free water and 1µl used as 
a template for the second PCR reaction using the following master mix: 
Reagent Volume added per 
well 
Final concentration 
dNTPs 5 µl 200µM 
Forward Primer 1µl 400nM 
Reverse Primer 1µl 400nM 
MgCl2(25mM) 1.5 µl 2.0mM 
Thermostart Taq, Abgene  0.125µl 
Thermostart Buffer, 10x conc. 2.5 µl 
Nuclease free water  12.875 µl 
Total 24 µl 
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The PCR conditions were as follows:  
1. 95°C for 15 min 
2. 95°C for 30 sec 
3. 60°C for 30 sec 
4. 72°C for 3 min 
Repeat steps 2-4 for 34 cycles 
5. 72°C for 7 min 
 
Selected samples, including a negative control, were resolved on a 1% agarose 
gel as previously described and a 387bp band was visualised. The PCR products 
were cleaned up as previously described.  
2.1.6 Data analysis 
The data from the sequencing of the CYP11B1 and CYP11B2 region was analysed 
using Haploview V4.2 (http://www.broad.mit.edu/mpg/haploview)(Barrett et 
al., 2005). This package was used to determine Hardy- Weinberg equilibrium, 
percentage of genotyping, pattern of linkage disequilibrium and haplotype 
structure.  
2.2 Cell culture  
2.2.1  H295R cell maintenance and subculturing procedure 
H295R cells were a gift from Prof W Rainey (Medical College of Georgia). DNA 
was extracted according to standard techniques and Short Tandem Repeat (STR) 
profiling was performed by LGC standards (Teddington, Middlesex, UK). Short 
tandem repeat analysis is a commonly used forensic test and has been proposed 
for verifying the identity of cell lines (Masters et al., 2001). Shown below Figure 
2-1 is the profile of the Strain 2 H295R cells, cultured as described above. This 
profile matches the expected result from the commercially available H295R cells 
(H295R CRL-2128) and verifies that the cells have not been cross contaminated 
or misidentified. 
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Figure 2-1 Short Tandem Repeat analyisis of H295R DNA 
 
Cells were grown in a monolayer in medium consisting of DMEM/ F12 (Invitrogen, 
Paisley, Scotland) supplemented with 2% Ultroser G serum (Pall scientific, Cergy, 
France), 1% ITS Universal culture supplement (Insulin, Transferrin, Selenous acid. 
BD Bioscience, Oxfordshire, UK), 1% Penicillin/streptomycin (Invitrogen, Paisley, 
Scotland). Cells were cultured at 37°C with 5% CO2 until approximately 80% 
confluent.  The culture medium was removed and the cells rinsed with 
phosphate buffered saline (PBS) solution. Trypsin-EDTA 0.25% (Sigma, St Louis, 
Missoiuri, USA) was added to cover the cells and after incubation for 
approximately 3 minutes the cells detached from the flask. Complete growth 
medium was added to inactivate the trypsin and the solution was spun at 
1500rpm for 5 minutes. The cells formed a pellet and after removing the growth 
medium, were re-suspended in fresh complete growth medium and aliquoted to 
new flasks according to the desired sub cultivation ratio. Cells were fed with 
fresh media every 3 days and usually spit in a ratio of 1 in 2 to 1 in 3 once per 
week.  
 Cells that were frozen down were handled in the same way however, after 
being spun down to a pellet they were re suspended in growth medium 
supplemented by dimethyl sulphoxide (DMSO). Aloquots were transferred to 
cryovials and frozen gradually in a Nalgene cryo freezing container (Thermo 
Fisher Scientific, NY, USA) before being transferred to liquid nitrogen for long 
term storage. When cells were removed from liquid nitrogen, they were thawed 
in a water bath at 37°C, the cell were pelleted by centrifugation and after the 
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defrosted medium was removed, fresh growth medium was added and the 
solution was transferred to a 75cm3 flask and incubated at 37°C with 5% CO2. 
2.2.2 H295R Phenotyping: General 
H295R cells were sub-cultured into 100mm tissue culture dishes at a 
concentration of 5x106 per dish. After 24 hours, the cells were rinsed with 
phosphate buffered saline (PBS) (Invitrogen, Paisley, Scotland) and the medium 
replaced with serum-free medium (10 ml). After a further 24 hours, this was 
replaced, either with fresh serum-free medium alone or with medium containing 
Ang II (10 pM), potassium chloride (6 mM) or dibutyryl cAMP (Bu2cAMP) (1 mM) 
(Sigma, St Louis, Missouri). Each experiment was performed in triplicate.   
2.2.3 H295R phenotyping: RNA extraction and analysis 
Cells were trypsinised and pelleted as described above and the pellet was 
washed twice in DPBS. The cells were disrupted using Buffer RLT from RNeasy 
Mini Kit (QIAGEN, Crawley, U.K.) with the addition of 1% β-mercaptoethanol to 
inhibit RNAse activity. Lysates were transferred to 2ml lysing matrix tubes 
(Lysing matrix D 1.4mm ceramic spheres, MP Biomedical, Salon, Ohio, USA) and  
homogenised for 30 sec on a rotator stator homogeniser (MagNA Lyser Roche, 
Switzerland). One volume of 70% ethanol was added and mixed well by 
pippetting. This was passed through an RNeasy spin column, which selectively 
binds RNA molecules longer than 200 bases to its silica membrane, and 
centrifuged for 15 secs at > 8000x g. The membrane was washed with 700µl of 
buffer RW1 followed by 2 washes of 500µl Buffer RPE before being eluted with 
30µl of PCR grade water (x2).   
To eliminate genomic DNA contamination, the samples were DNased using the 
TURBO DNA-free kit (Applied Biosystems, Foster City, CA, USA). 0.1 volumes of 
10x Turbo DNase buffer and 1 µl TURBO DNase was added to the RNA. This was 
incubated at 37°C for 30 min before the addition of 0.1 volume of DNase 
inactivation reagent. This was left for 5 min at room temperature with 
occasional mixing before being spun down at 10 000 x g for 1.5 min. The 
supernatant containing the RNA was aspirated and the remaining pellet 
discarded.   
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RNA was diluted to a constant concentration using a spectrophotometer (ND-
1000 spectrophotometer, Nanodrop Technologies, Washington, USA) before 
being transcribed to cDNA using the ImProm-II Reverse Transcription System 
(Promega, Madison, Wisconsin, USA) on a 96 well plate according to the standard 
protocol. All samples were reverse transcribed alongside an equivalent reaction 
omitting reverse transcriptase (–RT control) and reactions substituting water for 
RNA were also performed (blank controls).   
Denature 
Reagent Volume per reaction 
 
RNA 2 µl 
Random primers(0.5 µg/reaction) 1 µl 
Nuclease free water 2 µl  
Total 5 µl 
 
This was heated to 70°C for 5 mins then chilled on ice to 5°C for 5 mins. 
Reverse transcription 
Reagent Volume per reaction Final concentration 
Nuclease free water 3.7 µl 
ImProm-II 5x reaction buffer 4.0 µl 
 
MgCl2  4.8 µl 6 mM 
dNTPs  1.0 µl 0.5 mM each dNTP 
Inhibitor 0.5 µl 20 U 
RT/Water 1.0 µl 
Total 15 µl 
 
 
The Reverse transcription conditions were as follows:  
 
1. 25°C for 5 mins     Annealing step 
2. 42°C for 1 hour    Elongation step 
3. 70°C for 15 mins    Inactivation 
 
Quantitative RT-PCR assays for CYP17 (17α-hydroxylase), CYP11B1 (11β-
hydroxylase) and CYP11B2 (aldosterone synthase) were performed with β-actin 
used as a housekeeping gene. All reactions were performed in a 384-well plate 
format on an ABI 7900 HT Prism Sequence Detection System (Applied Biosystems, 
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Foster City, California, USA). Primers were obtained from Eurofins MWG Operon, 
Ebersberg, Germany, ABsolute QPCR ROX Mix from ABgene,Epsom, UK and 
probes from Universal Human Probe Library, Roche Diagnostics, Burgess Hill, UK. 
GENE PRIMER SEQUENCE PROBE 
CYP11B2 (F) GCACCTGCACCTGGAGATG 
(R) CACACACCATGCGTGGTCC 
 
#57 
CYP11B1 (F) ACTAGGGCCCATTTTCAGGT 
(R) GGCAGCATCACACACACC 
 
#68 
CYP17 (F) CTATGCTCATCCCCCAC AG 
(R) TTGTCCACAGCAAACTCACC 
 
#67 
β-ACTIN (F) CCA ACC GCG AGA AGA TGA 
(R) CCA GAG GCG TAC AGG GAT AG 
 
#64 
 
Reagent 
 
Volume per reaction Final concentration 
Nuclease free water 2.1 µl 
ABsolute QPCR ROX Mix 5.0 µl 
 
Forward primer 0.4 µl 400nM 
Reverse primer 0.4 µl 400nM 
Probe 0.1 µl 100nM 
Total 8 µl  
 
  8 µl master mix was pippetted into a 384 well plate. This was spun down before 
the addition of 2 µl cDNA. Reactions were incubated at 95°C for 15 min followed 
by 40 cycles at 95°C for 15 s and 60°C for 1 min. Results were analysed using the 
comparative CT method (2
-∆∆Ct) (Livak and Schmittgen, 2001). 
2.2.4 H295R phenotyping: steroid and protein 
measurements 
Medium was removed at 24 hours and stored at -20°C. Steroid extraction and 
measurement was performed by Miss Mary Ingram. Steroids were extracted from 
medium (10 ml) using ChemElute cartridges (Varian, CA, USA) and eluted with 
dichloromethane. The eluates were evaporated to dryness under nitrogen and 
reconstituted in acetonitrile (60 µl). An aliquot (20µl) was chromatographed on a 
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reversed phase column (Polaris 5 µm, 150mm x 2mm C18-A) and the effluent 
analysed by tandem LC:MS (Varian 1200L, California, USA).  
2.2.5 Protein assay: Bicinchoninic acid (BCA) assay 
Cells were washed with DPBS, (Invitrogen, Paisley, Scotland), 1000µl of Reporter 
Lysis Buffer (Promega, Wisconsin, USA) was added and the cells left at room 
temperature for 15 mins with occasional rocking. Culture vessels were then 
stored at -70°C until analysis. Samples were thawed and protein assays were 
carried out to correct for cell number using a commercially available 
bicinchoninic acid (BCA) kit (Pierce Biotechnology, Rockford Illinois, USA). This 
assay relies on the principle that protein will reduce Cu 2+ to Cu 1+ in an alkaline 
environment. The Cu 1+ ion can be detected by the reaction of bicinchoninic acid  
with Cu 1+ which turns purple. The BCA/copper complex is water-soluble and 
exhibits a strong linear absorbance at 562 nm with increasing protein 
concentrations. 25µl of cell lysate was pippetted into a clear 96 well plate. 
200µl of BCA working reagent was added to the sample and after incubation at 
37°C for 30 mins the plate was read using a Wallac Victor 1420 Multilabel 
Counter (PerkinElmer Life Scciences, Boston, Massachusetts, USA). A standard 
curve was made up with bovine serum albumin (BSA) protein standards and 
Reporter Lysis Buffer, and this was used to determine protein concentration. 
2.3 Promoter in vitro functional studies 
2.3.1 Reporter gene system 
The effect of polymorphic variation on the promoter activity was investigated 
using a reporter gene assay system. The CYP11B2 5’ region (1880kb) was cloned 
into the pGL3 Basic vector (Promega, Wisconsin, USA) by Mrs Christine Holloway. 
The pGL3 Basic vector contains a modified coding region for firefly (Photinus 
pyralis) luciferase. The construct was sequenced to confirm the insert was 
present and orientated correctly. Site directed mutagenesis was carried out by a 
commercial company (Eurofins MWG Operon, Ebersberg, Germany). This resulted 
in one plasmid containing a T allele at position -1651 and one identical plasmid 
with the exception of a C allele at position -1651. In order to control for 
transfection efficiency, the plasmid pGL4.73 was co-transfected with the pGL3 
reporter construct at a ratio of 50:1. The pGL4.73 plasmid contains a coding 
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region for renilla (Renilla reniformis) luciferase. Both plasmids were prepared in 
the same way as described in the following sections.  
2.3.2 Transformation of competent cells 
The plasmid DNA was transformed into JM109 E.Coli competent cells (Promega, 
Wisconsin, USA). Each construct was transformed alongside a positive control 
and a no DNA control. 1ml eppendorf tubes were pre chilled on ice and JM109 
cells were thawed to 4°C.  50µl of competent cells were dispensed to the pre 
chilled eppendorfs before adding 50ng of plasmid DNA. This was left on ice for 
10 minutes before being subjected to heat-shock treatment at 42°C for 50 
seconds. The cells were returned to ice for a further 2 minutes before 900µl cold 
Super Optimal broth with Catabolite repression medium (SOC) was added. This 
was incubated for 1 hour at 37°C while shaking. 100µl of cells were plated on 
Luria broth with ampicillin and incubated overnight at 37°C. Single transformed 
colonies were used to inoculate incubations which were then shaken overnight at 
37°C in 5ml Luria broth with ampicillin. 
2.3.3 DNA purification 
Plasmid DNA was extracted using the QIAprep Mini Prep kit (QIAGEN Ltd, West 
Sussex, UK). The cultured Luria broth was transferred to a 1.5ml eppendorf tube 
and centrifuged at maximum speed for 2 min. The resultant cell pellets were 
resuspended in 250µl of Buffer P1 (50mM 2-amino-2-hydroxymethyl-1,3-
propanediol, pH8; 10mM EDTA, 100µg/ml RNAase A). To lyse the cells 250µl 
buffer P2 (200mM NaOH; 1% sodium dodecyl sulphate) was added and mixed 
gently by inverting. 350µl buffer P3 (3 M potassium acetate at pH5.5) was added 
and mixed by gently inverting the tube. The samples were centrifuged at 
maximum speed for 10 min using a table top centrifuge. The supernatants were 
transferred to a QIAprep Spin Column and centrifuged at maximum speed for 1 
min. The flow through was discarded and the column washed by adding 0.5 ml 
buffer PE before being centrifuged at maximum speed for 1 min. This step was 
repeated with 0.75ml buffer PE before further centrifugation at maximum speed 
for 1 min. The column was then placed in a clean 1.5 ml eppendorf and the DNA 
eluted by adding 50µl of nuclease free water to the spin column. This was 
allowed to stand for 1 min prior to being centrifuged at maximum speed for 1 
min. The mini preps were stored at 4°C for further use.  
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2.3.4 Restriction digestion 
To ensure the construct was of the correct size and contained the appropriate 
insert, restriction analysis was performed. Plasmid DNA was digested with HinDIII 
restriction enzyme, which linearized the cDNA, producing a single fragment of 
6740 bp and BamHI which produced 3 fragment of 2863 bp, 2594 bp and 1283 bp. 
2 µl of plasmid DNA was incubated with 0.5 µl of enzyme, 2 µl of buffer, 0.2 µl 
of BSA and 15.3 µl of nuclease free water. The reaction mixture was incubated 
for 2 hours at 37°C. The construct was resolved on a 1% agarose gel. Agarose 
(1g) was added to 100ml TBE buffer and heated to boiling point in a 950W 
microwave oven for 50 seconds. 1 µl ethidium bromide was added and gently 
mixed. This was allowed to cool in gel moulds with Teflon combs until set. The 
gel and digestion products were subjected to electophoresis at 100V for 40 min.  
 
Figure 2-2 Agarose gel electrophoresis of plasmid construct and plasmid control.  
Lane 1 ladder, lane 2 pGL3 basic vector following restriction enzyme digestion, lane 3 basic 
vector incubated with no enzyme, lane 4 pGL3 control vector following restriction enzyme 
digestion, lane 5 pGL3 control vector incubated with no enzyme, lane 6 pGL3 construct 
(CYP11B2 5’ region) following restriction enzyme digestion, lane 7 pGL3 construct 
(CYP11B2 5’ region) incubated with no enzyme, lane 8 reaction mix, no DNA, lane 9 ladder. 
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2.3.5 Large scale plasmid preparations 
Large scale plasmid preparations were performed using a QIAgen plasmid Maxi 
kit. A single colony from a freshly streaked ampicillin Luria plate which had been 
gown overnight was picked and used to inoculate a starter culture. This was 
grown in 5ml Luria broth containing 100µg/ml ampicillin and shaken in an 
incubator at 37°C for 8hrs. 1ml of this was diluted in 100ml of Luria broth with 
ampicillin and incubated overnight in a shaking incubator at 37°C.  
The bacterial cells were harvested by centrifugation at 6000 x g for 15 min at 
4°C. Culture media was removed and pellets were resuspended in 10ml of buffer 
P1 (50mM 2-amino-2-hydroxymethyl-1,3-propanediol, pH8; 10 mM EDTA, 100 
µg/ml). 10 ml of buffer P2 was added (200 mM NaOH; 1% SDS) to initiate the lysis 
reaction and this was inverted 4-6 times and kept at room temperature for 5 
min. 4ml of chilled buffer P3 (3 M potassium acetate at pH5.5) was added to 
neutralise the lysate and the mixture was inverted again 4-6 times and 
incubated on ice for 20 min. The solution was centrifuged at 16000 x g for 40 
min at 4°C. A QUIATIP column was equilibrated with 10 ml of buffer QBT (750 
mM NaCl; 50 mM 3-morpholinopropanesulfonic acid pH7 (MOPS); 15% 
isopropanol; 0.15% Triton-X 100) which was allowed to empty by gravitational 
flow. The lysate supernatant was applied to the column and allowed to enter the 
resin. The column was washed twice with 30ml buffer QC (1 M NaCl; 50 mM 
MOPS pH7; 15% isopropanol), and the plasmid DNA was eluted with 15ml of 
buffer QF (1.25 M NaCl; 50 mM Tris pH8.5; 15% isopropanol) into polypropylene 
tubes. The DNA was precipitated with the addition of 10.5ml isopropanol and 
centrifuged at 15000 x g for 20min at 4°C. The supernatant was poured off and 
pellets resuspended in 5ml of 70% ethanol and aliquoted into eppendorfs. These 
were centrifuged at 160000 x g for 10 min and once the supernatant was 
discarded, allowed to air dry for around 1 hour and DNA dissolved in 100 µl of 
nuclease free water.  
2.3.6 H295R transient transfection procedure 
H295R cells were grown as described in section 2.2. For transfection, cells were 
sub-cultured onto 24 well subculture dishes at a density of 2x105 cells/ well. 
Cells which were initially grown in 175cm flasks were counted according to the 
following protocol. The culture medium was removed and the cells rinsed with 
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phosphate buffered saline (PBS) solution. Trypsin-EDTA 0.25% (Sigma, St Louis, 
Missouri, USA) was added to cover the cells and after incubation for 
approximately 3 minutes the cells detached from the flask. Complete growth 
medium was added to inactivate the trypsin and the solution was spun at 
1500rpm for 5 minutes. The cells formed a pellet and after removing the growth 
medium, were re-suspended in 1ml of fresh complete growth medium. This was 
diluted 1:100 and cells counted using a haematocytometer. The cells were 
diluted to a concentration of 4x105 cells/ ml in a universal tube and placed back 
in the incubator until ready for use. 
 Cells were transfected with pGL3 basic (Promega, Madison, Wisconsin, USA) 
expression vectors containing 1.8kb of the CYP11B2 promoter and plasmid with T 
allele at position -1651) and C allele at -1651 (mutated by site directed 
mutagenesis) were compared. pGL4.73 (Promega, Madison, Wisconsin, USA) was 
co-transfected to control for transfection efficiency. Transfections were carried 
out using siPORT™ NeoFX™ Transfection Agent (Applied Biosystems, Foster City, 
California, USA) according to the manufacturers protocols using the reverse 
transfection method. The protocol was as follows. A solution of containing 1.5 µl 
of NeoFX™ and 48.5 µl Opti-Mem reduced serum media (Invitrogen, Paisley, 
Scotland) per well was made and allowed to equilibrate for 10min. Solutions 
containing 1000ng of pGL3 plus insert plasmid, 20ng pGL4.73 reporter plasmid 
(50:1 ratio) made up to a total volume of 50 µl per well was made and allowed 
to equlibrate for 10 min. The Opti-Mem/ NeoFX™ solution and the DNA/ Opti-
Mem solution were then combined (50 µl of each per well) and this was allowed 
to equilibriate for 10min. 100 µl of this soulition was then dispensed to each well 
and once the cells had been briefly resuspended with pippetting, 400 µl of cell 
solution was added.  
The plate was tipped gently to ensure even coverage. Positive controls were 
included and these consisted of either control pGL3 plasmid alone (containing 
the luciferase gene and a viral promoter) or pGL4.73 plasmid alone (containing 
the renilla gene and a viral promoter). Negative controls were included and 
consisted of a 50:1 ratio of pGL3 basic vector (containing the luciferase gene but 
no promoter) and pGL4.73 plasmid. Also, wells with no DNA transfected were 
included. 
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The cells were incubated at 37°C and after 24 hours the transfectant was 
removed and replaced with normal media. Transfection efficiency was not 
formally measured (but was controlled for by co-transfection with renilla 
plasmid). However, when green fluorescent protein plasmid was transfected, the 
efficiency was noted to be low (approximately 50%). When cells were 
stimulated, the concentrations of trophins used were as follows: angiotensin II 
(1x10-7M), dibutyryl cAMP (1mM) or potassium (22mM). APEX 1 inhibitor was 
added after 24 hours for the relevant experiments at a concentration of 10µM or 
vehicle.  
After a further 24 hours, the cells were lysed with 100µl passive lysis buffer, 
before the addition of Dual-Glo assay reagents (Promega, Madison, Wisconsin, 
USA).  
2.3.7  Luciferase assay 
Luciferase measurements were carried out using the DUAL luciferase assay 
(Promega, Madison, Wisconsin, USA). Buffers were allowed to thaw slowly to 
room temperature. LAR II was reconstituted by adding 10ml of buffer to the 
substrate.  
20 µl of lysate was dispensed into the bottom of a 5ml round bottom 
polypropylene tube (75 x 12mm) (Sarstedt, Leicester, UK). After priming the 
tubing of the luminometer (Lumat LB 9507, Berthold Technologies, Herts, UK) 
with the relevant reagents, the reactions were commenced. The luminometer 
was programmed to inject 100 µl of LAR II into the tube (firefly measurement) 
followed by 100 µl of Stop and Glo reagent (renilla measurement) and perform a 
2 second pre-measurement delay, followed by a 10-second measurement period 
for each reporter assay. On completion the tube was discarded and moved on to 
the next assay. Finally, the primed lines were purged and cleaned with 70% 
ethanol and distilled water. The ratio of firefly to renilla luciferase was used for 
analysis as this allowed the variation in transfection efficiency to be controlled 
for. 
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2.4 Protein:DNA binding studies 
2.4.1 H295R nuclear protein extraction 
Nuclear extracts from human adrenal carcinoma cell line (H295R) were isolated 
using a modified method based on Dignam et al (Dignam et al., 1983).Nuclear 
protein was extracted under varying salt conditions in the presence of sodium 
orthovanadate (a tyrosine phosphatase inhibitor). Cells were cultured as 
described in section 2.2, trypsinised, pelleted by centrifugation at 400g. The 
pellet was washed with PBS and spun down again before the supernatant was 
aspirated and discarded. The cells were lysed by the addition of 0.4 ml per tube 
of Buffer A (10 mM HEPES, pH 7.9, 10 mM potassium chloride, 0.1 mM EDTA, 0.1 
mM EGTA, 1 mM DTT, 0.625% (v/v) Nonidet P-40, 0.5 mM PMSF). The samples 
were then centrifuged at 48,000g for 30 s at 4°C, and the supernatant was 
removed. The pellet was resuspended in 50 µl of buffer B (20 mM HEPES, pH 7.9, 
100mM – 500 mM sodium chloride, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5 mM 
PMSF) Samples were agitated for 15 min at 4°C, centrifuged at 48,000g for 5 
min, and the protein content of the supernatant was determined using a 
Bradford assay. 
2.4.2 Protein quantification; Bradford assay  
The Bradford Reagent can be used to determine the concentration of proteins in 
solution. The procedure is based on the formation of a complex between the 
dye, Brilliant Blue G, and proteins in solution. The protein-dye complex causes a 
shift in the absorption maximum of the dye from 465 to 595 nm. The amount of 
absorption is proportional to the protein present. The Bradford Reagent is 
compatible with reducing agents, in this case, DTT. Other protein assay 
procedures (e.g. Lowry and BCA) are not compatible with reducing agents. A 
standard curve was prepared using BSA diluted in Buffer B as follows: 
Final concentration Vol of Dilutant µl  
(Buffer B) 
Volume of BSA µl  
(2mg/ml) 
0 10 0 
1 9.5 0.5 
2 9.0 1.0 
5 7.5 2.5 
10 5.0 5.0 
15 2.5 7.5 
0 10 0 
 
Chapter 2  109 
3 µl of sample was added to each tube. 500 µl of water was then added along 
with 500 µl of Bradford reagent. Absorbance was measured at 595 nm on a 
spectrophotometer. Samples were diluted to a final concentration of 2 µg/ µl.  
2.4.3 Oligonucleotide probes 
Oligonucleotides were commercially obtained (Eurofins MWG Operon, Ebersberg, 
Germany). The sequences are as follows: 5’ GGA CGA GAC TAG CCT GGC CAA C 
3’ which was complementary to 5’ GTT GGC CAG GCT AGT CTC GAA CTC C 3’, 
and 5’ GGA CGA GAC CAG CCT GGC CAA C 3’ which was complementary to 5’ 
GTT GGC CAG GCT GGT CTC GAA CTC C 3’. Oligonucleotides were diluted to a 
concentration of 10pM and end labelled with γ32P ATP. Oligos were incubated at 
37°C for 30 mins with 2ul buffer (70mM Tris-HCl pH 7.6, 10mM MgCl2, 5mM DTT), 
2µl oligo, 1 µl γ32P ATP (MP Biomedicals, Illkirch, France) and 1 µl T4 
Polynucleotide kinase (Promega, Madison, Wisconsin, USA) and 14 µl Nuclease 
free water.  
 Complementary oligonucleotides were annealed by incubating together in 1 ml 
eppendorf suspended in a water bath heated to boiling temperature and 
gradually allowed to cool. Labelled oligonucleotides were separated from free 
radioactivity on an Illustra probe quant G-50 micro column (GE Healthcare, 
Amersham, UK) according to the manufacturer’s instructions.  
2.4.4 Electromobility shift assay  
DNA: protein binding reactions were carried out in a final volume of 20 µl as 
follows: 
Chapter 2  110 
Reagent 
 
Volume 
Binding Buffer  
(HEPES pH 7.9 20mM, MgCl2 10mM, EDTA 
0.5mM, NaCl 20mM, 50% glycerol) 
5.4 µl 
Bovine serum albumin (0.001g/ml) 
 
1 µl 
Dithiothreitol 
 
100mM 
PolyDI·DC (0.01g/10ml) 
 
1 µl 
Radiolabelled probe 
 
1 µl 
NF water 
 
6.6 µl 
Nuclear protein 
 
5 µl 
 
Nuclear extract was allowed to incubate with the reaction buffer for 20 minutes 
at room temperature before the addition of radio labelled probe, then for a 
further 20 minutes also at room temperature. The protein: DNA complex was 
loaded onto a 6% resolving acrylamide gel. (10ml 30% Acrylamide mix (Sigma, St 
Louis, USA), 5ml 10x TBE buffer, 35ml dH2O; following degassing for 3 mins, 500 
µl 25% ammonium persulphate and 10 µl TEMED were also added). Loading buffer 
consisted of 500 µl TE buffer, 500 µl binding buffer, 10% glycerol, Bromophenol 
blue. The gel was run at 100mV for 3 hours (Hoefer SE600 Ruby, GE Healthcare, 
Amersham, UK) in Tris-borate EDTA buffer.  
The gel was washed twice in 5% ascetic acid and then once in 10% glycerol 
before being dryed on a gel dryer (Model 583 Gel Dryer, Bio-Rad, CA, USA) for 2 
hours. The gel was visualised after autoradiography for 4 days at -80°C. 
2.5 In vivo studies in normal volunteers 
2.5.1 Recruitment of normal volunteers 
The “Role of Genetic Variation in aldosterone synthase- physiological studies” 
(Adrenal Function Study, AFS) was submitted for ethical review to the West 
Glasgow Ethics Committee in June 2007 and received ethical approval on the 3rd 
July 2007 (REC ref no 07/S0703/70).  
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Subjects were recruited from a number of sources including advertisements and 
promotional articles in the local media, the University website and alumni 
association and via advertisements from around the University campus and local 
area. Initial screening visits were carried out by the investigator and the 
exclusion criteria are listed in Table 2-1.  
Exclusion criteria 
 
Age<18 or >70 at time of recruitment 
Resting blood pressure >145/90 
Use of any antihypertensive medication 
Pregnant or plans to become so in 6 months following participation 
in study  
Use of oral, inhaled or topical steroids in 6 months preceding study 
History of severe atopy or asthma 
Known renal or cardiac dysfunction 
Inability to comply with study instructions 
Table 2-1 Exclusion criteria for study examining the effects of variation in the promoter 
region of aldosterone synthase on corticosteroid production 
 
Study visits took place in the Glasgow Clinical research facility, tenant Memorial 
building, Church St, Glasgow. The investigator was present at each visit which 
was undertaken with the help of the Nursing staff in the Clinical research facility 
(lead study nurse Sister B McLaren). 
2.5.2 Study protocol 
Subjects were studied during careful dietary sodium control to maintain either a 
high (200 mmol per day) or low (80 mmol per day) sodium intake. A diet sheet 
was provided which gave advice on a low salt diet (approx 4.8g per day). Salt 
loading using sodium supplement (HK Pharma, Bangkok, Thailand) tablets 
containing 600mg sodium chloride, achieved a total intake of 200 mmol per day 
(approx 12g) (four tabs 3 times per day).  Placebo tablets (Western Infirmary 
Pharmacy Production Unit, Glasgow, UK) were prescribed for the duration of the 
low salt week to ensure the subjects and investigators were blinded to the salt 
status. 
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 Once in balance (after 3 days) subjects were infused with ACTH (1ng/kg/minute 
for 30 mins); on the following day subjects were given an infusion of angiotensin 
II (3 ng/kg/minute for 30 mins) (BAChem, Weil am Rhein, Germany). Infusions 
were prepared by the Western Infirmary Pharmacy Production Unit. Basal, 
stimulated and 30 minutes post stimulation plasma samples were collected, for 
renin (baseline) and steroid measurements. Blood pressure was monitored at 
baseline, after 30 minutes recumbent rest and at 10 minute intervals for the 
duration of the infusion. A final blood pressure recording was made at the end of 
the study visit after a final 30 minutes. Blood pressure was recorded using a 
Mindray VS 800 monitor. In addition, 24 hr urine collections were undertaken 
and were analysed for steroid measurements by GC:MS. Urine samples were 
measured for sodium concentration which allowed and estimate of total sodium 
excretion in 24hrs. 
Blood samples were drawn using the Vacutainer system (BD, Oxford Science 
Park, Oxford UK) at baseline blood tests before the infusion (x2 Lith Heparin and 
x 1 EDTA), at completion of the infusion, as well as 30 mins after completion (x2 
Lith Heparin and x 1 EDTA).Lithium heparin samples were stored on ice and spun 
down at 4°C and EDTA samples were stored at room temperature and spun down 
at 25°C for 15 mins at 3000g. Plasma was aspirated and stored immediately at -
80°C.  
The patient information sheet, study protocol and data collection sheet are 
included in Appendix 7.4, 7.5 and 7.6 
2.5.3 Urinary electrolyte measurements 
Aliquots of urine were measured in the NHS biochemistry laboratory Gartnavel 
Hospital for sodium concentration.  
2.5.4 Urinary steroid measurements 
24 hour urine samples were collected in plain containers and the volume 
measured before being aliquoted and stored at -20°C without preservatives. 
Steroid metabolites were measured by Miss Mary Ingram by gas chromatography 
using the method of Shackleton et al(Shackleton, 1993). 
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2.5.5 Plasma steroid measurements 
Plasma steroids were measured by Miss Mary Ingram. Samples were extracted 
from 3ml plasma using Chem Elute cartridges (Varian, CA, USA) and eluted with 
dichloromethane. The eluates were evaporated to dryness under nitrogen and 
reconstituted in 60ul acetylonitrile. Aliquots (20ul) were injected into a Polaris 5 
micron, 150mm x2mm C-18-A reversed phase HPLC column. Identification and 
quantification were accomplished by tandem mass spectrometry using a Varian 
1200L mass spectrometer with a triple quadropole detector. The internal 
standard was 16βmethylprednisolone. 
2.5.6 Plasma renin measurements 
Plasma renin concentration was measured by the Department of Clinical 
Biochemistry Glasgow Royal Infirmary by means of a Diasorin Liaison® 
immunochemiluminometric analyser (DiaSorin Ltd, Wokingham, Berkshire, 
UK)(Dorrian et al., 2010).  
2.5.7 DNA extraction and Genotyping  
DNA was extracted using an automated method (Gentra System Autopure LS, 
Large Sample Nucleic Acid Purification Automated DNA extraction, Quiagen, 
West Sussex, UK) according to the manufacturers instructions by Ms C Brock. 
Genotyping of normal volunteer DNA was carried out by Mrs Elaine Friel and 
subjects were genotyped were determined for the seven polymorphisms in the 
promoter region of CYP11B2 as well as the presence of the intron 2 conversion 
and the polymorphisms in the promoter region of CYP11B1 as described in 
section 2.1.  
2.5.8 Data analysis 
Data was collected and stored using Microsoft Access and statistical analysis was 
carried out using Minitab V 12.21. Supplementary graphs were produced using 
GraphPad Prism V4 and Microsoft Excel.   
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3. Characterisation of the CYP11B2 promoter 
region 
3.1 Introduction 
Studies linking variation of the promoter region of the aldosterone synthase gene 
and hypertension have mainly focused on the C/T polymorphism at position -344, 
with some groups reporting an association with hypertension and a low ARR and 
the T allele (Davies et al., 1999; Brand et al., 1998; Freel et al., 2007), but 
other groups have found the association to be with the C allele (Matsubara et 
al., 2004). A meta-analysis of the literature published up until 2006 concluded 
that individuals homozygous for the C allele have a 17% lower risk of 
hypertension (Sookoian et al., 2007). As discussed in the introduction to this 
work (section 1.5), some of the controversy in the literature may have arisen 
from the variation in composition of the populations studied. Although smaller 
numbers of African and Asian subjects have been studied, the association of 
hypertension with the T allele is less robust in these populations (Sookoian et 
al., 2007) and it is clear that the allele frequencies vary substantially between 
ethnic groups. There is strong linkage disequilibrium across the CYP11B2 locus in 
the Caucasian population (Alvarez-Madrazo S et al., 2009; Barr et al., 2007) 
however, there is significantly less linkage disequilibrium in the CYP11B2 locus 
amongst people of African decent (Alvarez-Madrazo S et al., 2009) presumably 
due to greater degree of recombination in this population and a loss of genetic 
variation in the Caucasian population due to bottlenecks during migration out of 
Africa.  
In vitro studies have demonstrated that the T allele binds to the transcription 
factor steroidogenic factor 1 (SF-1, NR5A1) with 4-5 fold greater affinity than 
the C allele. However, deletion of this site does not alter transcriptional activity 
suggesting it has no functional effect (Clyne et al., 1997). Given the high degree 
of linkage disequilibrium exists across this locus (Barr et al., 2007), it has been 
hypothesised that this polymorphism may be in linkage with alternative, 
functional polymorphisms. It is known that when a disease causing allele enters 
the gene pool it is often surrounded by alleles that may have no functional 
effect. Over time, with recombination, the link between the disease causing 
allele and surrounding neutral alleles becomes less strong (Conrad et al., 2006; 
Chapter 3  116 
Barnes, 2006).  It may be hypothesised that this is the phenomenon that is 
observed within the CYP11B2 locus; a disease-causing polymorphism in linkage 
disequilibrium with the -344C/T has entered the gene pool. In the African 
population, recombination has reduced the linkage disequilibrium but in the 
Caucasian population it functions as a “tag” SNP for the disease-causing allele 
elsewhere in the locus.  
Previous studies have identified seven common polymorphisms in the promoter 
region of the CYP11B2 gene each with a frequency of >1% in the population (Barr 
et al., 2007). These SNPs were identified following sequencing of twenty six 
normotensive individuals, selected from the WHO MONICA (multinational 
MONItoring of trends and determinants in CArdiovascular disease) and stratified 
according to genotype at -344 and intron conversion. None of these seven novel 
polymorphisms are in areas of the promoter region that have been previously 
been shown to be involved in regulation of the CYP11B2 gene. However, 
previously published work has predominantly focused on an area more proximal 
to the transcriptional start site and none have directly examined these sites of 
variation (Bassett et al., 2004b). In addition, more than one polymorphism may 
alter promoter activity and such variants may promote or inhibit activity. 
Classical promoter deletion studies may have obscured any differentially 
regulating effects by removing more than one polymorphic site at a time (Clyne 
et al., 1997). For these reasons the polymorphic variations in the promoter 
region deserve further analysis. 
 Characterising the pattern of inheritance is an important first step, as it is 
important to ascertain the linkage disequilibrium between the disease-
associated polymorphism at -344 and any possible causative polymorphisms. 
Although publicly available repositories of genotyping information e.g. HapMap 
(2005) (http://hapmap.gov), and latterly the 1000 genome project (Via et al., 
2010) (http://www.1000genomes.org) are available, the pattern of linkage 
disequilibrium in this region was not described in sufficient detail. Therefore in 
order to further investigate the linkage between SNPs in the promoter region of 
the CYP11B2 region in a Caucasian population, a detailed examination of the 
CYP11B2 promoter region was undertaken in the following study.  
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3.2 Aims 
To sequence seven single nucleotide polymorphisms in the promoter region of 
CYP11B2 in 300 subjects from the Oxford hypertension study cohort, in order to 
describe the allele frequencies and the pattern of linkage disequilibrium. 
3.3 Methods 
3.3.1 Subjects 
Three hundred DNA samples selected at random from the Oxford family study 
were analysed. Probands and their families were recruited in the Oxford region 
of the UK from 1993-1997. Patients were screened for secondary causes of 
hypertension according to local practice. Families consisted of at least three 
siblings (including the proband) and at least one parent, but at least four siblings 
(including the proband) were required if no parent was available for DNA 
analysis. DNA was extracted according to standard methods (Keavney et al., 
1998). 
3.3.2 Genotyping 
The CYP11B2 gene from approximately 2kb upstream of intron one to the 
beginning of intron one was amplified by PCR as described in section 2.1.1. PCR 
products were identified by resolving on a 1% agarose gel (Figure 3-1) 
 
Figure 3-1 PCR product of CYP11B2 promoter region (2000bp) length  
The product was resolved on 1% agarose gel. 1kb ladder is shown and Lane 4 is negative 
control. 
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Following PCR, three separate sequencing reactions were carried out and the 
seven polymorphisms identified as described in section 2.1.2. The resultant 
sequences were analysed using SeqScape V2.2 software (Applied Biosystems, 
Foster City, CA, USA) which displayed electropherograms of the sequencing 
sample aligned to a reference sequence (Figure 3-2). The reference sequence is 
included in Appendix 7.2. 
 
Figure 3-2 Electropherogram of polymorphisms  
Variation at position -470T/C, -645T/C, -663T/C, 1472A/G, -1513T/C, -1667G/C, upstream of 
CYP11B2 transcriptional start site are shown. 
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3.3.3 Statistical Analysis 
Data were collated on an Excel spreadsheet before being imported to Haploview 
v. 4.2. This software was used to analyse genotype frequencies and calculate 
Hardy Weinberg equilibrium as well as interpret and visualise haplotype 
structure (Barrett et al., 2005; Barnes, 2006).  
3.4  Results 
3.4.1 CYP11B2 promoter polymorphisms 
The 5’ promoter region was amplified as described to produce a 2kb fragment 
shown in Figure 3-1. Following direct sequencing, electropherograms were 
constructed to identify alleles at the sites of polymorphic variation. The 280 DNA 
samples sequenced from the Oxford cohort were from 37 families. The data 
were analysed using Haploview 4.2 software.   
Characteristics of the polymorphisms are shown in Table 3-1. All polymorphisms 
were in Hardy-Weinberg equilibrium using a p value cut off of 0.001. As the 
percentage of samples genotyped for the rs62524561 (-1513 T/C) and rs62524560 
(-1472 A/G) was below 80%, they were excluded from further analysis.  
 
Figure 3-3 Characteristics of SNPs genotyped in the promoter region of CYP11B2 
 
Patterns of linkage disequilibrium (LD) and haplotype structure were assessed for 
6 SNPs. The LD plot for the CYP11B2 promoter region for the Oxford cohort is 
shown in Figure 3-4 where D’ values are given. In Figure 3-5 the r2 values for the 
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population are shown. It can be seen from both measurements that there is high 
LD across the region. From these data, three haplotypes were constructed and 
are shown in Figure 3-6. These three haplotypes account for 95.6% of the 
population. These data have been combined with sequencing results from across 
the CYP11B1 and CYP11B2 locus and the entire pattern of linkage disequilibrium 
across this locus is included in Appendix 7.2.  
 
 
Figure 3-4 Linkage disequilibrium plot of CYP11B2 promoter polymorphisms D’ values 
 
 
Figure 3-5 Linkage disequilibrium plot of CYP11B2 promoter polymorphisms r2 values 
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Figure 3-6 Three common haplotypes and their frequencies for CYP11B2 promoter 
polymorphisms representing 95.6% of the study population.  
 
3.5 Discussion 
Linkage disequilibrium (LD) is an extremely useful concept in the area of analysis 
of single nucleotide polymorphisms and statistical genetics. LD refers to the 
association between alleles when their frequencies are significantly different 
from their predicted individual allele frequencies if they were to occur together 
(in contrast to “linkage” which refers to the tendency of markers, genes or DNA 
sequences at a specific locus to be inherited together due to their proximity on a 
single chromosome).  This concept allows certain observations to be made, 
because the linkage disequilibrium between alleles declines over generations 
with increasing recombination and mutation events. Thus, it can be used to map 
population evolution as well as a tool for genetic mapping of particular diseases 
and reduces the amount of genotyping required for association studies. 
The statistical concepts D’ or r2 are measurements of linkage disequilibrium and 
both are displayed in the LD plots for the promoter region of CYP11B2 (Figure 
3-4, Figure 3-5). For further discussion, some explanation of these values is 
necessary. The value D describes the deviation of haplotype frequencies from 
the equilibrium. D is calculated thus: If a haplotype formed by two SNPs with 
alleles (A,a) and (B,b) there would be four possible haplotypes: AB, Ab, aB and 
ab. The frequency of each haplotype can be calculated by the product of the 
frequencies of the alleles f(A)f(B), where f(A) is the frequency of allele A at the 
first locus and f(B) is the frequency of allele B at the second locus and the 
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frequency of haplotype AB is f(AB). From this D can be calculated using the 
following simple equation: 
 
LD can be said to be occurring when the value of D is significantly greater than 
zero. The value of D is important because both D’ and r2are calculated from D.  
D’ is the absolute ratio of D compared with its maximum value, Dmax (Dmax = 
f(A)f(B)). Complete equilibrium would mean a D’ of 1. D’ is a useful concept for 
the assessment of historical recombination in a population as in the absence of 
any recombination, there would be no deviation from linkage equilibrium. 
Therefore statistically significant values of D' that are near 1 provide a useful 
indication of minimal historical recombination, but intermediate values are not 
useful either for comparison of the strength of LD between studies or to measure 
the extent of LD. In terms of the data presented here it can be seen that in the 
population studied, D’ values were high in the CYP11B2 promoter region, 
suggesting little historical recombination in this locus. Given that this is the 
case, it is unlikely that the two SNPs that were not genotyped successfully would 
demonstrate LD that deviates significantly from the rest of this locus. 
In contrast, r2 is a measure of correlation between two alleles, i.e. how much 
does one allele predict the other; thus when r2=1, the genotypes of alleles of 
one SNP will perfectly predict the genotypes of another SNP. 
The r2 value is more useful in the context of association studies and can provide 
an estimate of the sample size required to provide the power to detect an 
association between a causal SNP and a disease (calculated as the inverse of the 
r2 value).  For example, the region of the promoter with less strong LD is the 
polymorphism at position -645. The r2 value for this polymorphism and -344 is 
0.25 which means that if only one were to be genotyped in an association study, 
the sample size would have to increase by a factor of 4 to maintain the same 
power (Wang et al., 2005). 
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It is useful to remember that D’ and r2 are both derived from D and in fact, r2 
describes the upper limit of D’2 and the maximum potential level of useful LD for 
the purposes of association mapping.  
This current study was undertaken to map polymorphisms in the promoter region 
of the CYP11B2 gene and assess the LD of the novel SNPs in the promoter region 
with the extensively studied polymorphism at position -344. This region has been 
implicated in previous case control/ association studies which have essentially 
used the polymorphism at position -344 as a “tag” SNP. The CYP11B2 gene is 
highly homologous to the CYP11B1 gene, making sequencing across this region 
difficult. Given the high linkage disequilibrium elsewhere in this locus (see 
Appendix 7.7.) and the close geographical proximity of the SNPs in the promoter 
region seemed likely that they were in LD with the SNP at -344 but the pattern 
of LD and the haplotype blocks remained to be established. From these results, 
it can be seen from both the D’ and r2 values that there is a high degree of 
linkage disequilibrium across the promoter region. As a consequence, three 
haplotypes account for greater than 95% of the population and, by genotyping 
only one SNP, the pattern of inheritance of the remaining SNPS can be predicted 
with reasonable accuracy. This has certain advantages in an association study as 
it reduces the amount of genotyping required; however, it does not provide any 
evidence of which SNP in the haplotype is driving the phenotype. The high 
degree of LD in the promoter region as well as across the entire CYP11B1 and 
CYP11B2 locus make it impossible to identify causative SNPs at this stage. 
Ongoing work within our group is investigating this issue in large population 
cohorts but, the 5’promoter region remains a likely region within the locus for a 
functional polymorphism to be found. Studies of the functional effect of 
polymorphisms within the CYP11B1 promoter region have demonstrated altered 
transcriptional activity and this is a potentially interesting area to study in more 
depth in the CYP11B2 gene in both in vivo and in vitro investigations. 
3.6 Conclusions 
This study confirms a low degree of historical recombination in this locus in a 
Caucasian population and high degree of linkage disequilibrium between all SNPs 
in the promoter region of CYP11B2. Although data from large genotyping studies 
which have examined polymorphisms within this locus can be extrapolated to 
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variation in the promoter region by imputation, this provides no information 
regarding selecting polymorphisms for further functional work. 
 The high degree of linkage disequilibrium also means that there is a small 
number of common haplotypes that make up the majority of the genetic 
variation at this locus in the Caucasian population, and this has implications for 
recruitment of normal subjects for dynamic studies as discussed in Chapter 6.
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4. Characterisation of the H295R cell line 
4.1 Introduction 
 The previous chapter described in detail common polymorphisms in the 
promoter region of CYP11B2 and their pattern of linkage disequilibrium in a 
Caucasian population. In order to assess CYP11B2 promoter function and 
examine DNA: protein interactions, and assess any functional effects of these 
polymorphisms, an appropriate model system of adrenocortical function is 
necessary. A number of different model systems have been used in previous 
investigation of steroidogenesis, but all have shortcomings. These shortcomings 
are an important consideration and have limited studies of many aspects of 
adrenocortical function.  
 Normal human adrenal tissue is rarely available for primary cell culture in 
laboratory studies and while recent progress has been made regarding 
generating differentiated steroidogenic cells from mesenchymal (MSC) and 
embryonic stem cells (ESC), this technique has not yet developed sufficiently to 
be widely used. Indeed, while treatment of MSC and ESC with steroidogenic 
factor 1 (SF-1) and other transcription factors have been reported to induce an 
adrenocortical phenotype, the pattern of steroidogenic enzyme expression is 
more consistent with adrenal fasciculata cells (Miyamoto et al., 2011) and 
further work is required before the expression and functionality of aldosterone 
synthase in induced stem cells can be confirmed. 
An alternative approach is to use animal models. However, they can differ 
anatomically and physiologically from their human counterparts, for example, 
bovine adrenal cells have been an attractive system to study as fresh tissue is 
readily available and the size of the gland is suitable for most practical 
purposes. However, the bovine genome contains only CYP11B1 and, although 
there are multiple forms of this gene present (Kirita et al., 1990), the gene 
product catalyses both the conversion of 11-deoxycortisol to cortisol and DOC to 
aldosterone (Morohashi et al., 1990). Rats have four CYP11B genes (Mukai et al., 
1993) with CYP11B1 and CYP11B2 functioning in a similar way to those of 
humans. CYP11B3 is only expressed in utero and in the early postnatal period 
(Mellon et al., 1995). The CYP11B4 gene appears to be non-functional and is 
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referred to as a pseudo-gene. Rodent steroidogenesis differs further from human 
steroidogenesis because it lacks 17α-hydroxylase so that the predominant 
glucocorticoid generated by CYP11B1 is corticosterone rather than cortisol. 
Despite these important interspecies differences, both rodent primary cell 
cultures as well as immortalized cell lines have provided valuable insights into 
the understanding of steroidogenesis (Rainey et al., 2004). The Y1 cell line was 
developed from an irradiated mouse and, after repeated sub-culturing, a clone 
with steroidogenic properties that displayed responsiveness to ACTH was 
obtained (Yasumura et al., 1966). The murine genome is similar to that of 
humans, in that it expresses CYP11B1 and CYP11B2. However like the rat, it lack 
the capacity of 17-hydroxylation and does not produce cortisol as its main 
glucocorticoid and instead, the main product of CYP11B1 is corticosterone.  
Clearly, given this interspecies variation, a human adrenal cell line would be an 
advantage. To this end, the H295 cell line was developed from a human 
adrenocortical carcinoma (Gazdar et al., 1990). It synthesises a range of steroid 
hormones; over thirty steroids have been identified in its secretion including the 
principal corticosteroids. However, over one third of its steroid output is adrenal 
androgens. This is much higher than would be expected in normal tissue, but is 
consistent with the clinical pathology of the donor patient. The cells respond to 
the zona glomerulosa trophins, angiotensin II and potassium, although ACTH-
dependent function must be tested with dibutyryl cAMP (Bu2cAMP) as expression 
of ACTH receptors is negligible (Rainey et al., 1994). This cell line grows in 
suspension and has a phenotype of loosely adherent clumps. A number of H295 
subtypes have been developed by different investigators with the aim of 
cultivating adherent cells or of favouring production of particular steroids by 
selectively growing in specific medium. One such subtype that has been widely 
used to study many aspects of adrenocortical function is the H295R strain. It 
grows in a monolayer and the ACTH dependant pathway responds well to cAMP 
analogues. However, aldosterone production is less responsive than in the 
original H295 cells. This sub-strain (H295R Strain 1 ATCC CRL-2128) was 
deposited in a publically available repository (American Type Culture Collection, 
available in the UK via LGC Standards, Middlesex) by Prof W Rainey; his group 
have also developed alternative sub-strains (Strain 2 and Strain 3) with greater 
aldosterone responses to agonists. Strain 2 responds to angiotensin II and 
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potassium but is cultured in a serum substitute that is difficult to obtain, leading 
to the development of a third strain. Strain 3 grows in a more easily available 
commercial calf serum and maintains its response to aldosterone agonists, 
although this decreases over time in culture (personal communication, Prof W 
Rainey, Medical College Georgia, Augusta, Georgia). The H295R cell line has 
made important contributions to the understanding the second messenger 
systems operating in the gland and the complex pattern of transcription factors 
that governs gene expression (Bird et al., 1993). It has also simplified the 
assessment of the effects of a wide range of xenobiotics (Muller-Vieira et al., 
2005). However, to use these cells for quantitative studies of the dynamics of 
corticosteroidogenesis may present problems given suggestions that the potency 
of the cells and the profile of the secretion change over time and varies 
according to medium composition and culture conditions. As the H295R cells 
have a relatively long doubling time and must be cultured for an extended time 
in order to generate sufficient numbers for experimental purposes, this may be a 
significant cause of variation between in vitro studies. In the following 
experiments, the steroid profile of the Strain 2 H295R cells was assessed and 
changes in the profile of C21 steroid production over time were followed. These 
were examined in basal culture and during stimulation with a number of 
trophins. These changes were compared with concurrent variation in the level of 
expression of steroidogenic genes. For comparison, the profile and effects of 
trophins on plasma steroid concentrations were followed in healthy human 
volunteers.  
4.2 Aims 
To assess the H295R (strain 2) cell line as a paradigm for human steroidogenesis 
by: 
1. Confirming the capacity of cells in culture to produce mineralocorticoid 
and glucocorticoid at basal levels and comparing the corticosteroid profile 
of the in vitro cell line model to in vivo steroid production 
2.  Confirming the capacity of the cells to respond to trophins of aldosterone 
and cortisol synthesis.  
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3. Quantifying the variability of these parameters over time in culture, in 
order to assess the stability of the cell line as a model of corticosteroid 
synthesis for future experiments.  
4.3 Methods 
Strain 2 H295R cells (gift from Prof W Rainey, Medical College Georgia, Augusta, 
Georgia) were sub-cultured in 100mm culture vessels as described in Methods 
Chapter 2.2. Initial assessment of H295R cell phenotype (steroid production and 
mRNA expression of steroidogenic enzymes at basal levels and in response to 
trophins) was made with cells at passage 10. This was compared to cells that had 
been passaged a further 20 times to assess the effect of time in culture. Cells 
were cultured for 24 hours in serum free media before being stimulated at both 
these time points with angiotensin II (1x10-7M), Bu2cAMP (1mM) and potassium 
(22mM). For comparison, the plasma measurements of 6 normal volunteers 
selected at random from the cohort described in Chapter 6 are shown. 
Coefficient of variation and limits of detection for the LC:MS method are shown 
in Appendix 8.4.  
Steroid concentrations were measured in media after incubation with cells for 24 
hours. Measurements were made by LC:MS after solid phase extraction as 
described in Chapter 2. Steroid measurements were obtained from 4 samples 
under each condition and total amount of steroid was normalised to total protein 
content to account for variation in cell number.  
RNA was obtained from 3 samples under each condition. Messenger RNA (mRNA) 
was first reverse transcribed to produce complementary DNA (cDNA) before 
quantifying with real time PCR (qRT-PCR) to measure the relative amounts. An 
oligonucleotide probe with a fluorescent reporter dye and quencher moiety 
attached, binds to the amplicon created by the PCR reaction. When the Taq 
polymerase replicates the template (amplicon bound to probe), the quencher 
moiety is cleaved off the probe, allowing the fluorescence to be detected. Thus, 
fluorescence increases in each cycle, proportional to the amount of probe 
cleavage. The crossing point (Ct) is the PCR cycle number at which a sample 
reaches the threshold level of fluorescence. The Ct is inversely proportional to 
the amount of target material in any given sample: the lower the Ct, the higher 
Chapter 4  130 
the amount of target material within a sample (Figure 4-1). Each sample was 
analysed in technical triplicate.  
 
Figure 4-1 Example of amplification plot showing serial dilutions of pCMVB2 plasmid 
 
The qRT-PCR data are presented as change in mRNA level relative to a reference 
gene and normalized to a housekeeping gene (2-∆∆Ct) (Livak and Schmittgen, 
2001). Given the high degree of homology between the CYP11B1 and CYP11B2 
genes, optimisation was required to ensure that no cross reactivity of the assays 
was present. Plasmids containing CYP11B1 and CYP11B2 were a gift from Dr P. C. 
White (University of Texas, Southwestern Medical Centre). Serial dilutions were 
made spanning a 105 range and assessment of the assay efficiency was made. In 
addition, CYP11B1 samples were spiked with CYP11B2 plasmid and vice versa to 
assess any cross reactivity of the assays. 
4.4 Results 
4.4.1 Steroid production and enzyme expression the H295R 
cell 
 The steroid profile of the H295R cell line was assessed under basal conditions. 
The results are shown in Figure 4-2 where the amount of each compound 
measured is expressed as a percentage of the total steroid measured. In 
interpreting these values it is important to remember that androgens were not 
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measured and do not form part of this data, although it is clear from previous 
reports that they form a significant part of the steroid output of H295R cells. It 
was confirmed that the cells produced aldosterone and cortisol. The proportion 
of cortisol relative to the total steroid measured was similar to that of human 
plasma. Similarly aldosterone was a small proportion of the total steroid output 
of the H295R cells, a situation mirrored in human plasma. However, as expected 
given that adrenal cells do not express 11βHSD, a clear difference is that 
cortisone is detected in human plasma but was not present in significant 
amounts in the steroid output of the H295R cells. A further contrast to the 
plasma pattern is that 11-deoxycorticosterone, corticosterone and 11-
deoxycortisol were proportionally much higher in the H295R cells than in vivo. 
Indeed, in normal subjects these compounds form a very minor part of the 
steroid levels measured.  
Chapter 4  132 
 
 
 Human (n=6) 
% total Mean (StDev) 
 
H295R cells (n=3) 
% total mean (StDev) 
18OH corticosterone 4.49 (1.02) 
 
1.06 (0.02) 
Aldosterone 0.45 (0.10) 
 
0.90 (0.05) 
Cortisol 30.68 (4.88) 
 
24.47 (4.64) 
Cortisone 53.73 (6.09) 
 
0.94 (0.01) 
18OH 
deoxycorticosterone 
0.11 (0.07) 1.65 (0.05) 
11-dehydrocorticosterone 3.18 (0.99) 
 
1.96 (0.24) 
Corticosterone 6.89 (1.74) 
 
40.01 (2.10) 
11-deoxycortisol 0.45 (0.11) 
 
23.94 (0.73) 
Deoxycorticosterone 0.01 (0.01) 
 
4.98 (0.11) 
Figure 4-2 Steroid production of human plasma (6 normal volunteers) and H295R cells (P10, 
basal conditions).  
Pie charts give visual representation of differences between H295R steroid production (left) 
and human plasma (right). Results in table represent the mean values of the percent of total 
steroids measured and standard deviation (brackets). 
 
These differences between human plasma and the steroidogenesis of the H295R 
cells can be further interrogated by examining the ratio of a steroid to its 
precursor compound, as seen in Table 4-1. The ratio of the concentration of 11-
deoxycortisol to cortisol (S:F) is used as an index of 11β-hydroxylation (CYP11B1) 
efficiency. The ratio of corticosterone to cortisol (B:F) can be used as an index 
of 17α-hydoxylase activity (CYP17). Aldosterone production is the best available 
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index of aldosterone synthase (CYP11B2) activity. The ratios of S: F and B: F 
were much higher in the H295R steroid output than in human plasma, reflecting 
less efficient enzyme activity.  Quantification of the expression of steroidogenic 
genes is displayed in Table 4-2. In this table, the crossing thresholds (Ct values) 
are shown along with the values obtained from RNA extracted from a normal 
human adrenal gland. The ∆∆Ct value is not used; only one measurement was 
made for the adrenal tissue as it was included as a positive control. 
Nevertheless, it provides useful values for comparison. Lower levels of 
expression (i.e. higher Ct values) in H295R cells than adrenal tissue was seen for 
all enzymes measured.  
 11-DEOXYCORTISOL: 
CORTISOL 
S:F 
 
CORTICOSTERONE: 
CORTISOL 
B:F 
Human plasma 
basal 
0.001 0.02 
H295R cells 
basal 
0.970 1.636 
H295R cells 
Angiotensin II 
0.356 1.624 
H295R cells 
Bu2cAMP 
0.639 1.144 
H295R cells 
potassium 
0.468 1.438 
Table 4-1 Ratio of steroids to precursor compounds in human plasma and H295R cells  
Human plasma obtained from 6 normal volunteers. H295R cells at P10 under basal and 
stimutated conditions. 
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ENZYME H295R 
n=4 
CT Mean (StDev) 
 
Adrenal 
n=1 
CT 
Β-actin 
 
20.75 (0.32) 21.24 
StAR 
 
20.20 (0.07) 16.06 
CYP11A1 
 
20.66 (0.07) 15.57 
CYP21A2 
 
22.74 (0.61) 17.46 
CYP17A1 
 
23.76 (0.32) 17.47 
CYP11B1 
 
31.19 (0.40) 18.11 
CYP11B2 
 
27.19 (0.80) 23.71 
Table 4-2 qRT-PCR of steroidogenic enzymes in H295R cells and normal adrenal sample.  
Results for the H295R cells at P10 (basal conditions) represent a mean (n=3) and standard 
deviation. Human adrenal results were only performed once. 
 
4.4.2 Response of the H295R cell to trophins 
 Aldosterone production by the H295R cell responds to stimulation by angiotensin 
II and potassium although not to ACTH (Bird et al., 1993). In order to stimulate 
cortisol production, intracellular cAMP must be increased by using dibutyryl 
cAMP or forskolin. The response to trophins can vary with time and culture 
conditions and therefore it was important to establish response parameters 
under our own conditions. The steroid response of the H295R cells at passage 10 
can be seen in Figure 4-3. Three biological replicates were measured from the 
same batch of cells. Aldosterone production was increased by almost 6-fold by 
angiotensin II and potassium. While Bu2cAMP had an effect on aldosterone 
production, it was not as potent as angiotensin II or potassium. This is mirrored 
in the changes in CYP11B2 expression as shown in Figure 4-5. The trophins that 
produced the greatest increase in aldosterone synthase (CYP11B2) were 
potassium and angiotensin II with Bu2cAMP producing a less potent rise in 
CYP11B2 expression.  
 However, cortisol production was stimulated to an equal extend by all three 
trophins tested, despite dibutyryl cAMP causing a more substantial increase in 
CYP11B1 expression than angiotensin II or potassium.  
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 CYP17 expression was affected only minimally by angiotensin II but was 
stimulated to some extent by both potassium and dibutyryl cAMP. This is 
consistent with the steroid data which show a slight increase in 11-deoxycortisol 
production, a reduction in 11-deoxycortisosterone production (Figure 4-3) and a 
reduction in the B:F ratio (Table 4-1) with these two trophins.  
 Finally, it is interesting to compare the responses of the H295R cell line to those 
seen in vivo by plasma analysis (Figure 4-4). While it must be remembered that 
in comparing the response in vivo to the cell model that different doses were 
used, it is relevant that angiotensin II produced a very specific rise in plasma 
aldosterone concentration, whereas a more pleiotrophic effect was observed in 
the H295R cells. In vivo ACTH produced a rise in cortisol concentration as well as 
in the concentrations of corticosterone, 11-deoxycortisol and 11-
deoxycorticosterone but not aldosterone. Again, this is in contrast to the 
response of the H295R model. 
 
Figure 4-3 H295R cell (P10) steroid response to trophins  
Data expressed as fold change in steroid production, normalised to total protein content. 
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Figure 4-4 Human steroid response to ACTH and Angiotensin II in 6 normal volunteers 
 
Figure 4-5 H295R cell (P10) change in enzyme expression in response to trophins 
Data expressed as fold change compared to basal samples (normalized to β-actin). 
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4.4.3 Effect of time in culture on basal and stimulated 
aldosterone and cortisol production 
Figure 4-6 shows cortisol production in H295R cells at passage 10 (labelled 
“Young”) and passage 30 (labelled “Old”). Three biological replicates were 
measured from the same batch of cells. Under basal as well as stimulated 
conditions, cortisol production was greater in older cells. Figure 4-7 shows 
aldosterone production for the same cells. Aldosterone production was less in 
cells passaged more times. In Figure 4-8 and Figure 4-9, the expression of 
CYP11B1 and CYP11B2 in the younger cells are displayed relative to old cells. 
The relative expression under basal and angiotensin II stimulated conditions of 
CYP11B1 and CYP11B2 was greater than 1, i.e. higher in young cells than in older 
cells for both genes. For both CYP11B1 and CYP11B2, it is the response to 
potassium and even more, the response to angiotensin II, which was more 
pronounced in young cells. In contrast, the expression of CYP17A1 did not differ 
significantly between young and older cells (Figure 4-10).  
 
 
Figure 4-6 Cortisol production in young (P10) and old (P30) cells  
Data normalised to total protein. Results represent mean and standard deviation (n=3).  
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Figure 4-7 Aldosterone production in old (P10) and young (P30) cells  
Data normalised to total protein. Results represent mean and standard deviation (n=3) 
 
 
Figure 4-8 CYP11B1 expression in young (P10) cells relative to old (P30) cells.  
Results represent mean and standard deviation (n=3). 
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Figure 4-9 CYP11B2 expression in young (P10) cells relative to old (P30) cells. 
 Results represent mean and standard deviation (n=3) 
 
 
 
Figure 4-10 CYP17A1 expression in young (P10) cells relative to old (P30) cells.  
Results represent mean and standard deviation (n=3)  
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4.5 Discussion 
The purpose of these studies was to explore the function of the H295R cell line 
in order to assess its utility as a model of human aldosterone production. To be 
acceptable as a surrogate for human adrenocortical secretion, it was necessary 
to assess the steroid production of the cell line under basal conditions and in 
response to stimulation and compare this to the in vivo steroid profile. In 
addition, it was important to establish any change in the H295R cell steroid 
pattern and response over time.  
Results have confirmed that the H295R cell line expresses the necessary enzymes 
to produce both aldosterone and cortisol and that these compounds are secreted 
from the cells in measureable quantities. In addition, both aldosterone synthase 
and aldosterone synthesis increased in response to angiotensin II and potassium, 
as did 11β hydroxylase and cortisol synthesis in response to Bu2cAMP. From this 
perspective, it has been demonstrated that the cell line is an appropriate model 
of mineralocorticoid and glucocorticoid production. This was the main purpose 
of these experiments and the data shown here is robust in this regard. 
However, there are characteristics of the H295R cell line that are less desirable 
in a model system. Firstly, the steroid profile of the H295R cell line showed clear 
differences from the human plasma steroid profile. The relative amounts of the 
C21 precursor compounds corticosterone, deoxycorticosterone and 11-
deoxycortisol were significantly higher in H295R cells than in human plasma 
where they were a minor constituent. This pattern of elevated precursors as 
compared to end products is somewhat analogous to the clinical picture of 
adrenal malignancy in general (Kikuchi et al., 2000) and the clinical presentation 
of the donor patient in particular (Gazdar et al., 1990). This pattern could be 
explained by a reduced level of expression of CYP11B1 and CYP11B2 relative to 
other steroidogenic genes in the H295R cells as compared to normal adrenal 
expression. Limited conclusions can be drawn from the comparison of normal 
adrenal mRNA compared to H295R mRNA profile as only one  normal adrenal 
sample (originally included simply as a positive control for the reaction) was only 
measured once. Nevertheless, the results do suggest that while CYP11B1 and 
CYP11B2 are expressed at a lower level than in normal adrenals, the same can 
also be said of the other steroidogenic genes measured. This part of the study 
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should be repeated to increase confidence in the results but it may suggest that 
it is not simply expression of CYP11B1 and CYP11B2 that determines the enzyme 
activity. This will be discussed in more detail later in this section.  
Secondly, cortisone makes up a significant proportion of the human plasma 
steroid profile but in the H295R cell this is present in very small quantities. This 
is not surprising as 11β-hydroxysteroid dehydrogenase (11β-HSD), the enzyme 
which catalyses the conversion of cortisol to inactive cortisone in vivo, is not 
expressed in the adrenal cortex and was not found to be expressed in 
measurable amounts in the H295R cells.  
Finally, the pattern of steroidogenesis changed over time in culture, with both 
aldosterone and cortisol production diminishing. It should be borne in mind that 
due to the scale of these experiments, the three biological replicates was from 
the same batch of cells and repetition in an independent experiment would give 
greater confidence, nevertheless, this lack of consistency over time in culture is 
clearly an important consideration when planning large scale or repeated 
experiments with this cell line. In this regard, one of the most interesting 
findings of these studies has been the discordance between enzyme expression 
and steroid production. This phenomenon was observed in two of the 
experiments described in this chapter. When the cells were stimulated with 
Bu2cAMP, a brisk increase in CYP11B1 was measured, greater than the increase 
in CYP11B1 measured in cells stimulated with either potassium or angiotensin II. 
Although cortisol rose in response to Bu2cAMP treatment, the rise was no greater 
with this trophin than with potassium or angiotensin II. Further, cells that had 
been in culture for a longer period of time and subjected to more passages 
expressed less CYP11B1 but incongruously secreted more cortisol than those that 
had been in culture for less time and expressed more CYP11B1. The mechanisms 
behind this phenomenon are not clear. Some forms of congenital adrenal 
hyperplasia, e.g. patients with 3β-hydroxysteroid dehydrogenase (3β-HSD) 
deficiency, present with a lack of cortisol and aldosterone despite normal 
CYP11B1 and CYP11B2 as a consequence of not being able to generate substrate 
for 11β-hydroxylase and aldosterone synthase. Alternatively, an increase in 
17,20 lyase activity relative to hydroxylase activity of CYP17A1 (even in the 
context of a constant amount of mRNA levels of CYP17A1 as was demonstrated in 
these experiments) would result in more androgen production and less substrate 
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for glucocorticoid production. In fact, changes in expression of 3βHSD and 
CYP17A1 have been proposed to be the mechanism for increased androgen 
production in the H296R compared to the H295A cell line (Samandari et al., 
2007). However, in these experiments it is not likely that lack of substrate was 
the rate limiting factor in the H295R cells as 11-deoxycortisol was always 
present in relatively high amounts. 
 It has been previously recognised that the characteristics of the H295R cells can 
vary with time in culture. Wang et al described a reduction in expression of 
CREB in H295R cells of late passage compared to earlier passage cells (Wang et 
al., 2000). Some investigators have found that H295R cells in their hands do not 
express CREB at all. CREB is implicated in the regulation of transcription of 
CYP11B1 (Wang et al., 2000; Bassett et al., 2000) and CYP11B2 (Nogueira and 
Rainey, 2010) (see section 1.2.8). This may be an importance mechanism 
contributing to the altered pattern of transcription of steroidogenic genes over 
time in culture.  
 The increase in CYP11B1 transcripts measured implies that the mechanisms 
controlling the up regulation of transcription of the gene in response to trophins 
is intact. The dissonance between amount of CYP11B1 mRNA measured and the 
amount of product of the 11β-hydroxylase enzyme in the form of cortisol may be 
as a result of mechanisms that regulate translation of the mRNA to functional 
protein, or as a result of processes that affects the function of the 11β-
hydroxylase enzyme itself. It would clearly be useful to be able to measure the 
levels of 11β-hydroxylase protein in order to establish if there is reduced 
translation of mRNA to protein, but due to the high degree of homology between 
the coding regions of the CYP11B1 and CYP11B2 genes there are no antibodies 
currently available that can reliable distinguish between the 11β hydroxylase 
and aldosterone synthase protein products. Therefore it is not possible to 
conclude whether the unexpectedly low cortisol occurred as a result of not 
enough enzyme or of an inefficient enzyme. 
Once mRNA is transcribed in the nucleus, it is capped, spliced, cleaved and 
polyadenylated prior to being exported to the cytoplasm (McKee and Silver, 
2007). In the cytoplasm, it can be transcribed, stored and transcribed later or 
degraded (Shyu et al., 2008). Clearly, there are many steps which can be 
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disrupted and could lead to reduced transcription of protein. One such 
mechanism that has received increasing attention in recent years is the action of 
microRNA. MicroRNAs are short (around 21 base pairs) strands of RNA that have 
been cleaved from longer (around 70 base pairs) hairpin structured molecules. 
They have imperfect complementarity for a target sequence and controversy 
remains as to their precise mechanism of action. Current consensus suggests that 
there is likely to be more than one mechanism of action and that microRNAs are 
able to inhibit translation as well as cause degradation of mRNA (Jackson and 
Standart, 2007). Another mechanism of RNA interference (RNAi) that causes 
degradation of mRNA is siRNA; these are also short strands of RNA but are 
derived from longer double stranded RNA precursors. Given that qRT-PCR 
detects amplified fragments of mRNA, it will not distinguish between degraded 
and intact mRNA, and thus RNAi may be an explanation for why increase in 
CYP11B1 mRNA is not associated with increased cortisol in the experiments 
described above.  
 Alternatively, there are a number of reasons why the protein may not catalyse 
the conversion of 11-deoxycortisol to cortisol efficiently. Alterations in the gene 
sequence could affect the function of the protein while not altering its rate of 
production. However, both the CYP11B2 and B1 gene in the H295R cell line have 
been sequenced in our laboratory and no mutations were detected. CYP11B1 
along with CYP11B2 and CYP11A1 are cytochrome P450 enzymes and require 
electron transfer from the NADPH/adrenodoxin/adrenodoxin reductase (Miller, 
2005) system (see Section 1.2.5). Changes in this electron transfer system may 
impact on enzyme activity; indeed co-transfecting adrenodoxin with the 
cytochrome P450 enzyme CYP11A1 increases enzyme activity (Zuber et al., 1988) 
and there is evidence that the availability of adrenodoxin and adrenodoxin 
reductase has rate limiting effects on the activity of CYP11B1 (Cao et al., 2000; 
Hakki et al., 2008). It is interesting to note that adrenodoxin expression is 
increased with exposure to dibutyryl cAMP but not to the same extent as the 
effect observed on expression of CYP11B1 (Sewer and Waterman, 2002). The 
availability of electron donors may be responsible for the blunted production of 
cortisol in the face of substantially increased expression of CYP11B1. However; it 
is not clear why a similar phenomenon is not seen with CYP11B2 which depends 
on the same system for reducing equivalents. There is some evidence using 
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bovine CYP11B1 that truncated forms of adrenodoxin can specifically increase 
aldosterone production without increasing cortisol production (Cao and 
Bernhardt, 1999), but this has not been tested for human CYP11B1 and CYP11B2. 
Alternatively, there could be competition for reducing equivalents between 
CYP11B1, CYP11B2 and CYP11A1.  
Finally, protein-protein interactions may also have an effect that could be 
specific to CYP11B1 or CYP11B2 beyond competition for NADPH. Bovine CYP11A1 
increases 11β-hydroxylation and reduces 18-hydroxylation and 18-oxidation 
leading, to increased cortisol and reduced aldosterone when co-transfected with 
bovine adrenodoxin and CYP11B1 in COS-1 cells (Cao and Bernhardt, 1999). It has 
been proposed that CYP11A1 induces conformational change of the CYP11B1 
enzyme, leading to altered function (Lisurek and Bernhardt, 2004). However it 
should be said that the only evidence that exists for this is in a bovine model 
system and human CYP11B1 and B2 co-transfected with bovine adrenodoxin did 
not show the same relationship (Cao and Bernhardt, 1999). 
4.6 Conclusion 
These studies of the H295R cell line have confirmed and extended previous 
work. The H295R cell line remains the best and most widely used model for 
adrenal cell function and its ability to produce steroid from all three 
biochemical pathways and respond to stimulation makes their utility 
unquestionable. However, these data raise some interesting and useful points for 
their further use. The changes in gene expression and steroid production over 
time in culture have been previously acknowledged but not comprehensively 
described and it has not previously been well recognised that the rate and 
pattern of this change across the steroid pathway can be diverse. In addition, by 
examining both the mRNA expression as well as the indices of steroid conversion, 
is it apparent that there are other rate limiting steps in the production of the 
end points of mineralocorticoid and glucocorticoid synthesis than the levels of 
enzyme expression of the terminal steps in steroidogenesis. How comparable 
these in vitro findings are to the in vivo systems is not yet known, particularly as 
the H295R cell collectively expresses components of the glomerulosa, fasiculata 
and reticularis, in contrast to the distinct functional zonation seen in mammals. 
However, as the major human adrenal cell line, it is the most informative model 
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at our disposal currently. Further studies could provide greater insight into the 
intricate sequence of events leading to human mineralocorticoid and 
glucocorticoid production.  
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5. In vitro studies of CYP11B2 transcription 
5.1 Introduction 
As there is virtually no storage of steroid hormones within the adrenal gland, 
increased synthesis of products from cholesterol in response to trophins is the 
main mechanism for increasing circulating steroid hormone levels. Thus, 
regulation of transcription is the pivotal point of homeostatic control of 
steroidogenesis. This chapter aims to investigate the functional effects of 
polymorphic change in the promoter region of CYP11B2 on gene transcription.  
Transcriptional regulation of CYP11B2 has been studied in some detail and has 
been previously described in depth (see Section 1.2.8). However, to recap 
briefly, both angiotensin II and potassium produce an increase in transcription of 
CYP11B2 beginning with increase intracellular calcium. Angiotensin II achieves 
this by binding to the Type 1 angiotensin receptor (AT1) which is coupled to a 
heterotrimeric G-protein (Gq) (Higuchi et al., 2007). This causes activation of 
phospholipidase C and consequent rise in diacylglycerol (DAG) and inositol 
trisphosphate (IP3) (Neves et al., 2002) and activation of protein kinase C (PKC). 
Increased extracellular potassium initiates a depolarisation of the glomerulosa 
cell membrane. Both processes culminate in an increased intracellular calcium 
flux which activates calmodulin (CaM), in turn activating CaM protein kinases to 
regulate CYP11B2 transcription (Clyne et al., 1996). Adrenocorticotrophin 
stimulating hormone (ACTH) acutely increases aldosterone production directly 
via cAMP (Bassett et al., 2004a).  
Several regulatory elements in the 5’ flanking region of the gene have been 
localised (Clyne et al., 1997),  proteins that bind to them have been identified 
(Bassett et al., 2004b), and the influence of post translational modification of 
transcription factors e.g. phosphorylation (Nogueira and Rainey, 2010), have 
been described. The acknowledged sites of transcription factor binding in the 
CYP11B2 promoter region are illustrated in Chapter 1 Figure 1.17 and were first 
described by Clyne et al (Clyne et al., 1997) but the effects of polymorphic 
variation at the sites under investigation in this work on transcription are not 
known. The positions of the known regulatory sites in relation to these 
polymorphisms are displayed in Figure 5-1.  
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Figure 5-1 Schematic diagram of promoter region of CYP11B2.  
CREB and ATF1 bind to the CRE and this binding is increased after phosphorylation by 
CamKinases as a result of Angiotensin II receptor activation. Ad5 and NBRE-1 bind the 
transcription factors NURR1 and NGFIB and these are increased in response to angiotensin 
II. The -344 polymorphism is shown as Ad4. However, deletion of this site has no effect on 
transcriptional activity. The red arrows demonstrate the polymorphisms described in 
chapter 3 in relation to these known transcription factor binding sites.  
 
 In order to investigate the functional effects of the polymorphic variants in 
CYP11B2 promoter region, a number of approaches were undertaken. A 
bioinformatics search strategy was used to prioritise the polymorphisms to be 
studied in more detail, reporter gene assays undertaken to assess any effect of 
allelic variation on transcriptional activity and transcription factor binding 
studies to begin to identify proteins that may play a role.  
5.2 Aims 
To investigate functional effects of polymorphic variation in the promoter region 
of CYP11B2 by:  
1. Identifying putative transcription factor binding at the sites of 
polymorphic variation using a bioinformatic database (Transfac® 
Professional) and compare polymorphic variants in order to prioritise 
further in vitro studies.  
2. Establishing if promoter activity is altered by single nucleotide 
polymorphic variation at candidate site within the promoter region of 
CYP11B2 using an in vitro reporter gene system 
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3. Investigating alterations in transcription factor binding with contrasting 
alleles in candidate polymorphic sites using electromobility shift assay 
system. 
5.3 Bioinformatics 
5.3.1 Methods 
 To investigate whether the polymorphisms altered putative transcription factor 
binding sites the DNA sequences flanking the SNPs were entered into the 
Transfac® Professional V 10.1 database. This is a commercial, subscription only 
database which contains experimental data extracted from peer reviewed 
journals to provide a searchable database for transcription factor binding 
sequences. Within Transfac® Professional is Match, a web-based tool which 
identifies transcription factor binding sites in DNA sequences by weight matrix 
search (Matys et al., 2006). Matrices are constructed using both experimentally 
confirmed transcription factor binding sequences and data extrapolated from 
biological studies to produce a measurement of the relative likelihood of a 
transcription factor binding to a particular sequence. The frequency that a 
particular nucleotide appears at a certain position in a binding sequence is 
recorded and consensus binding sequence is produced for the matrix. The five 
most highly conserved bases are called the “core”. Thresholds can be set for 
“core” and “matix” matching with 1.0 corresponding to 100% similarity. If the 
sequence passes the threshold for core similarity it is then aligned for matrix 
similarity. If this threshold is also passed, the transcription factor is included in 
the output.  
 Searches were undertaken between Tuesday 23/10/07 and Monday 12/11/07.  
Thresholds were set at 0.75 for core binding and 0.70 for matrix binding. Only 
vertebrate matrices were analysed. The input sequences are shown in Table 5-1.  
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SNP 
POSITION 5’ 
SNP 
POSITION 
EXON 1 
SEQUENCE 
357 G/C (331-
380) 
-1667 >ccgaggtgggcagatcacctgaggtcaggagttcgagact 
>ccgaggtgggcagatcacctgacgtcaggagttcgagact 
 
373 T/C 
(351-400) 
-1651 >cctgaggtcaggagttcgagactagcctggccaacacggt 
>cctgaggtcaggagttcgagaccagcctggccaacacggt 
 
511 C/T 
(491-530) 
-1513 >tgaacccgggagacagaggtcgcagtgagccgagatcaca 
>tgaacccgggagacagaggttgcagtgagccgagatcaca 
 
552 G/A 
(531-570) 
-1472 >ccattgcactctagcctgggcgacagagtgagactctgtc 
>ccattgcactctagcctgggcaacagagtgagactctgtc 
 
1361 A/T 
(1341-1380) 
-663 >ctggggcaggagggatgagcaggcagagcacaggttttct 
>ctggggcaggagggatgagctggcagagcacaggttttct 
 
1379 C/T 
(1361-1400) 
-645 >aggcagagcacaggttttcttttcctctttttaagacagt 
>aggcagagcacaggtttttttttcctctttttaagacagt 
 
1554 C/T 
(1533-1573) 
-470 >tcacatggaaccagtgcgctcctgtggtggagggtgtacc 
>tcacatggaaccagtgcgctcttgtggtggagggtgtacc 
 
Table 5-1 Flanking sequence entered in bioinformatics search for putative transcription 
factor binding around sites of polymorphic variation 
 
Output files from Transfac® Professional searches were converted to Microsoft 
Excel files and the results for each sequence containing contrasting alleles at the 
site of polymorphic variation were compared.  
5.3.2 Results 
All SNPs were associated with variation in predicted transcription factor binding. 
In total, over 900 alterations in bindings were introduced across the seven 
polymorphisms. Most suggested an altered binding affinity for one allele 
compared to the other. However, there were 131 incidences of where 
transcription factor binding was predicted to be introduced on the basis of a 
single base change and was not predicted to be present in the presence of the 
alternate allele. These results for each SNP are shown in Table 5-2, Table 5-3, 
Table 5-4, Table 5-5, Table 5-6, Table 5-7, and Table 5-8.  
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357 (-1667) C 
 
357 (-1667) G 
ATF1 
(Nogueira 
and 
Rainey, 
2010; 
Clyne et 
al., 1997; 
Bassett et 
al., 2004a; 
Bassett et 
al., 2000) 
 
activating transcription 
factor 1 
RUNX1 
 
runt-related transcription 
factor 1 
 
ATF6 
 
activating transcription 
factor 6 
AREB6 zinc finger E-box binding 
homeobox 1 
 
C/EBP 
 
CCAAT/enhancer binding 
protein 
COUP-TF  
(Bassett 
et al., 
2004a; 
Wang et 
al., 1989; 
Clyne et 
al., 1997)  
nuclear receptor subfamily 
2, group F 
 
Myc 
 
v-myc myelocytomatosis 
viral oncogene homolog 
 
deltaEF1 zinc finger E-box binding 
homeobox 1 
E4F1 E4F transcription factor 1 GR 
 
Glucocorticoid receptor 
ER 
 
Oestrogen receptor HEN1 nescient helix loop helix 1 
HIF1 
 
Hypoxia inducible factor 1 LXR direct 
repeat 
 
nuclear receptor subfamily 
1, group H, member 2 
Pax-2 
 
paired box 2 RUNX2 runt-related transcription 
factor 2 
SREBP-1 
 
sterol regulatory element 
binding transcription 
factor 1 
PEBP phosphatidylethanolamine 
binding protein 1 
v-ErbA 
 
Also known as thyroid 
hormone receptor, alpha 
 
  
v-Jun 
 
Jun protoconcogene, also 
known as AP-1 
 
  
XBP-1 X-box binding protein 1 
 
  
Table 5-2 Transcription factors predicted to bind to only the C allele or the T allele at 
position 373 (-1667) of CYP11B2.  
Transcription factors implicated in the literature in the transcriptional regulation of 
aldosterone synthase are highlighted. 
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373 (-1651) C 373 (-1651) T 
AP-4 activating enhancer 
binding protein 4 
AP-3 activating enhancer 
binding protein 3 
AR Androgen receptor AREB6 
 
zinc finger E-box binding 
homeobox 1 
 
ER Oestrogen receptor Pax-2 
 
Paired box 2 
GR Glucocorticoid receptor Pitx2 
 
paired-like homeodomain 2 
Pax-6 Paired box 6 SF1 (Ye et 
al., 2009; 
Bassett et 
al., 2002; 
Clyne et 
al., 1997) 
 
Steroidogenic factor 1 
PR Progesterone receptor SMAD 
 
SMAD family member 
Zic3 Zic family member 3 (odd-
paired homolog) 
SREBP sterol regulatory element 
binding transcription 
factor 
 
  VDR 
(Romero 
et al., 
2007; 
Romero 
et al., 
2010) 
 
Vitamin D receptor 
Table 5-3  Transcription factors predicted to bind to only the C allele or the T allele at 
position 357 (-1651) of CYP11B2. 
 Transcription factors implicated in the literature in the transcriptional regulation of 
aldosterone synthase are highlighted. 
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510 (-1513) C 
 
510 (-1513) T 
COUP-TF 
(Bassett et 
al., 2004b; 
Clyne et 
al., 1997; 
Wang et 
al., 1989) 
nuclear receptor subfamily 
2, group F 
C/EBP CCAAT/enhancer binding 
protein 
Egr 
(Nogueira 
et al., 
2007) 
Early Growth response Gfi1 growth factor independent 1 
transcription repressor 
 
GR Glucocorticoid receptor HIC1 hypermethylated in cancer 1 
 
HNF4 Hepatocyte nuclear factor 4 HMG IY 
(Romer
o et al., 
2010; 
Romero 
et al., 
2007) 
high mobility group AT-
hook 1 
 
RORalpha1 RAR-related orphan 
receptor A 
HOXA7 homeobox A7 
SMAD SMAD family member MYB v-myb myeloblastosis viral 
oncogene homolog 
 
  Nkx2-5 NK2 transcription factor 
related, locus 5 
 
  Pax-3 Paired box 3 
 
  RFX regulatory factor X, 1 
 
  SOX10 SRY (sex determining 
region Y)-box 10 
 
Table 5-4 Transcription factors predicted to bind to only the C allele or the T allele at 
position 510 (-1513) of CYP11B2.  
Transcription factors implicated in the literature in the transcriptional regulation of 
aldosterone synthase are highlighted. 
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551 (-1472) G 
 
551 (-1472) A 
AP-2 
 
 
activating enhancer 
binding protein 2 
 
AP-4 
 
 
Activating enhancer binding 
protein 4 
ATF (Bassett 
et al., 
2000; 
Sirianni et 
al., 2010; 
Clyne et 
al., 1997) 
 
 
activating transcription 
factor 
 
C/EBP 
 
 
CCAAT/enhancer binding 
protein 
CREB 
(Clyne et 
al., 1997)  
 
cAMP responsive element 
binding protein 
 
FOXO1 
 
 
forkhead box O1 
Egr 
(Nogueira 
et al., 
2007)  
 
Early Growth response FOXO4 
 
forkhead box O4 
MEIS1 
 
 
 
Meis homeobox 1, myeloid 
ecotropic viral 
integration site 1 
homolog  
HIC1 
 
 
 
hypermethylated in cancer 1 
MZF1 
 
myeloid zinc finger 1 HNF3 
 
Hepatocyte nuclear factor 3 
EGR4 
 
early growth response 4 IRF-1 
 
interferon regulatory factor 1 
SMAD3 
 
SMAD family member 3 LEF1 
 
lymphoid enhancer-binding 
factor 1 
 
WT1 
 
Wilms tumor 1 MYB 
 
v-myb myeloblastosis viral 
oncogene homolog 
 
YY1 
 
 
YY1 transcription factor RBP-
Jkappa 
 
recombination signal binding 
protein for 
immunoglobulin kappa J 
region 
 
  RFX1 
 
regulatory factor X, 1 
  SOX10 
 
SRY (sex determining region 
Y)-box 10 
Table 5-5 Transcription factors predicted to bind to only the G allele or the A allele at 
position 551 (-1472) of CYP11B2.  
Transcription factors implicated in the literature in the transcriptional regulation of 
aldosterone synthase are highlighted. 
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1361 (-663) A 
 
1361 (-663) T 
AhR 
 
aryl hydrocarbon receptor AP-4 
 
activating enhancer 
binding protein 4 
 
HIC1 
 
 
hypermethylated in cancer 
1 
C/EBP 
 
 
CCAAT/enhancer binding 
protein 
HSF1 
 
 
heat shock transcription 
factor 1 
DBP 
 
 
D site of albumin promoter 
(albumin D-box) 
binding protein 
KAISO 
 
 
 
zinc finger and BTB 
domain-containing 
protein 33 
E2A 
 
 
 
transcription factor 3 (E2A 
immunoglobulin 
enhancer binding factors 
E12/E47) 
MAF 
 
 
 
v-maf musculoaponeurotic 
fibrosarcoma oncogene 
homolog 
HNF4 
 
 
 
Hepatocyte nuclear factor 4 
Msx-1 
 
 
msh homeobox 1 MEIS1 
 
 
Meis homeobox 1, myeloid 
ecotropic viral 
integration site 1 
homolog 
 
NERF1a 
 
E74-like factor 2 (ets 
domain transcription 
factor) 
NF-1 
 
 
neurofibromin 1 
p53 
 
tumor protein p53 RFX 
 
regulatory factor X, 1 
HIC1 
 
 
hypermethylated in cancer 
1 
RORalpha1 
 
RAR-related orphan 
receptor A 
SMAD 
 
SMAD family member TGIF 
 
TGFB-induced factor 
homeobox 1 
VDR 
(Romero 
et al., 
2007; 
Romero et 
al., 2010) 
 
 
Vitamin D receptor YY1 
 
YY1 transcription factor 
Table 5-6 Transcription factors predicted to bind to only the A allele or the T allele at 
position 1361 (-663) of CYP11B2. 
 Transcription factors implicated in the literature in the transcriptional regulation of 
aldosterone synthase are highlighted.  
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1379 (-645) T 1379 (-645) C 
 
AR 
 
 
Androgen receptor BLIMP1 
 
 
PR domain containing 1, with 
ZNF domain 
 
FAC1 
 
 
 
bromodomain PHD finger 
transcription factor 
 
C/EBP 
 
 
CCAAT/enhancer binding 
protein 
FOXD3 
 
 
forkhead box D3 Elf-1 
 
 
E74-like factor 1 (ets domain 
transcription factor) 
FOXJ2 
 
forkhead box J2 GATA-1 
 
GATA binding protein 1 
(globin transcription factor 
1) 
 
FOXO1 
 
 
forkhead box 01 GATA-2 
 
 
GATA binding protein 2 
(globin transcription factor 
2) 
FOXO3A 
 
 
forkhead box 03A HSF 
 
 
Heat Shock factor 
FOXO4 
 
 
forkhead box 04 ICSBP 
 
 
interferon regulatory factor 8 
HNF3alpha 
 
 
 
Hepatocyte nuclear factor 3 
alpha 
NF-AT 
 
 
 
nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 2 
interacting protein 
HNF3beta 
 
Hepatocyte nuclear factor 3 
beta 
NIT2 
 
nitrilase family, member 2 
TBP 
 
 
TATA box binding protein 
 
  
ZBRK1 
 
zinc finger protein 350   
Table 5-7 Transcription factors predicted to bind to only the T allele or the C allele at 
position 1379 (-645) of CYP11B2.  
Transcription factors implicated in the literature in the transcriptional regulation of 
aldosterone synthase are highlighted. 
 
Chapter 5  157 
1554 (-470) C 1554 (-470) T 
 
AP-2 
 
 
activating enhancer 
binding protein 2 
 
AP-3 
 
 
activating enhancer 
binding protein 4 
 
 
AP-4 
 
 
activating enhancer 
binding protein 4 
 
C/EBP 
 
 
CCAAT/enhancer binding 
protein 
 
 
AREB6 
 
 
zinc finger E-box binding 
homeobox 1 
 
FAC1 
 
 
bromodomain PHD finger 
transcription factor 
 
AREB6 
 
zinc finger E-box binding 
homeobox 1 
 
HNF3 
 
Hepatocyte nuclear factor 3 
 
E2A 
 
 
 
transcription factor 3 (E2A 
immunoglobulin 
enhancer binding factors 
E12/E47) 
 
LRH1 
 
 
 
nuclear receptor subfamily 
5, group A, member 
 
 
Elk-1 
 
 
ELK1, member of ETS 
oncogene family 
 
MRF-2 
 
 
Modulator recognition 
factor 2 
 
 
Eve 
 
SH3 domain containing 19 
 
Nkx2-5 
 
 
NK2 transcription factor 
related, locus 5 
 
 
LEF1 
 
lymphoid enhancer-binding 
factor 1 
 
p53 
 
 
tumor protein p53 
 
 
p54 
 
 
 
non-POU domain 
containing, octamer-
binding 
 
SOX10 
 
 
 
SRY (sex determining 
region Y)-box 10 
 
 
 
Sp1 
 
Sp1 transcription factor SOX9 
 
SRY (sex determining 
region Y)-box 9 
 
Spz1 
 
spermatogenic leucine 
zipper 1 
 
TBP 
 
 
TATA box binding protein 
 
 
USF 
 
 
upstream transcription 
factor, c-fos interacting 
  
Eve 
 
 
SH3 domain containing 19   
Table 5-8 Transcription factors predicted to bind to only the T allele or the C allele at 
position 1554 (-470) of CYP11B2.  
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 Candidate transcription factors identified above were further investigated with 
literature search to explore the possibility that they may be involved in the 
regulation of aldosterone synthase. Transcription factors implicated in the 
literature in the transcriptional regulation of aldosterone synthase are 
highlighted.  
The role of ATF1 and CREB has been previously investigated with regard to the 
regulation of CYP11B2. As described in Chapter 1.2.8, a CRE site at position -64 
is known to be crucial for basal expression of aldosterone synthase. COUP-TF has 
been identified as binding to oligonucleotide spanning -129/114 (known as the 
Ad5 element) (Bassett et al., 2004b; Wang et al., 1989; Clyne et al., 1997). SF-1 
is involved in the regulation of a number of steroidogenic enzymes and its role in 
the transcriptional regulation of aldosterone synthase is controversial; the 
extensively investigated polymorphism at -344 is a putative SF-1 site with the C 
allele binding more avidly than the T allele. However, SF-1 at the -344 site does 
not appear to influence transcription of the gene (Bassett et al., 2002; Ye et al., 
2009). Finally, recent data has been published examining angiotensin II 
responsive genes and suggested that Vitamin D receptor and HMG1Y and 
angiotensin II responsive and may play a role in regulating aldosterone synthase 
(Romero et al., 2010; Romero et al., 2007).  
5.3.3 Discussion 
 Numerous transcription factor binding sites are predicted to be introduced or 
abolished with the substitution of a single nucleotide change. In the first 
instance, a literature search was undertaken to identify transcription factors 
known to be involved in the regulation of aldosterone synthase as a means to 
prioritise further in vitro investigation of functional effects of SNPs. The SNPs 
and relevant transcription factors are summarised in Table 5-9.  
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Position Allele Predicted binding Sequence Transcription factor 
357 C 
G 
tGACGTcagga 
gcagatcacctgaGGTCAggagt 
ATF-1 
COUP-TF 
373 T tagCCTGGc 
tagcctggccAACAC 
SF-1 
VDR 
 
510 
510 
C 
T 
ggagacagaGGTCG 
agGTTGC 
COUP-TF 
HMG1Y 
551 G gggCGACAg CREB 
 
1361 A ggaggGATGAgcaggcagagc VDR 
 
Table 5-9 Transcription factors implicated in the regulation of aldosterone synthase. 
 Putative binding sites relative to single nucleotide polymorphisms are given. Nucleotide 
sequence deemed to be “core” five nucleotides are in upper case.  
 
However, there are a number of points that should be made regarding the 
published literature. Initial information regarding possible transcription factor 
binding sites were identified by reporter gene deletion assays and DNAse I 
footprint studies of the bovine CYP11B gene (Takayama et al., 1994; Kirita et 
al., 1990). This raises obvious issues regarding the validity of animal models with 
regard to human steroidogenesis, as previously mentioned in Chapter 4. There is 
only one bovine CYP11B gene and its transcript codes for a protein with both 
glucocorticoid and mineralocorticoid functions. As a result, the regulation of this 
gene may not be comparable to the human CYP11B2, or indeed the human 
CYP11B1. Later work was carried out by Clyne et al (Clyne et al., 1997) used the 
H295R cell model, extensively described in Chapter 4. Some of the results 
observed in the bovine model were indeed confirmed in these investigations. 
However, promoter deletion assays, by removing relatively large sections of the 
promoter in an iterative process, may remove positive and negative regulating 
regions simultaneously, obscuring any individual effect. Further, it has been 
suggested that the binding and action of transcription factors can vary 
depending on the three dimensional structure of the DNA, the conformation of 
which can be altered by protein: DNA interactions up or down stream of the 
binding site of interest. Thus, promoter deletion assays may provide incomplete 
data regarding sites involved in gene regulation.  Recently published data has 
looked at the effect on aldosterone production of H295R cells of over expression 
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of genes previously shown to respond to angiotensin II (Romero et al., 2007). 
These included HMGA1 and VDR, both of which increased aldosterone production 
in response to angiotensin but not under basal conditions (Romero et al., 2010). 
These and other transcription factors may be involved in the regulation of the 
gene and clearly require further study however, the genotype dependant 
difference may not be angiotensin II mediated and may in fact be under basal 
conditions. 
 The parameters of the bioinformatics search were deliberately permissive and 
as a result, are likely to have generated a significant proportion of false positive 
results. In addition, the Transfac® Professional database is based only on 
experiments that have been undertaken and the extrapolation of published 
results, therefore it is difficult to quantify the false negative rate for this type of 
investigation. Transfac® Professional, by necessity, makes certain assumptions 
in order to compile the database and create search results. These assumptions 
may also be a source of error. For example, as mentioned above, the 5 most 
highly conserved bases are designated the “core” binding site and the logarithm 
that is followed requires a user determined threshold to be passed regarding 
alignment with the binding site. However, this may not accurately reflect the 
biological binding process as not all transcription factors have a core binding 
sequence of just five nucleotides. In addition, transcription factors often form 
homo or heterodimers before binding to DNA and the three dimensional 
structure is central to the specificity of binding. Further, the three dimensional 
structure of the DNA strand is also crucial and this may be affected by up or 
down stream protein:DNA interactions (Sarai and Kono, 2005). The results 
described above must be interpreted with this in mind. Whilst the in silico 
investigation should not be seen as definitive evidence of biological interactions 
it raises a number of further lines of enquiry and certainly provides a rational for 
ongoing investigations around the functional effect of SNPs in this region.   
One of the objectives of the bioinformatics search was to prioritise which SNP to 
proceed with for further in vitro studies. On the basis that the SF-1 is a 
transcription factor most heavily implicated in the regulation of steroidogenic 
genes, albeit with a less clear role in the transcriptional regulation of CYP11B2, 
it was decided that further work would continue with the SNP which putatively 
introduced a new SF-1 site (-1651).  
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5.4  Reporter gene assays 
Reporter gene assays can be used to study the function of promoter regions of a 
gene of interest. The promoter region is cloned into a plasmid, upstream of a 
“reporter gene”, in this case firefly luciferase. The plasmid is then transfected 
into a cell line along with a control plasmid, this allows for normalisation of 
results to account for variables like transfection efficiency or variation in cell 
handling/ survival. The cell line, which should be chosen to contain the 
necessary signal transduction pathways and transcription factors necessary to 
induce transcription, is cultured under controlled conditions. A strong promoter 
will produce more luciferase mRNA than a weak promoter and this is translated 
into protein which can be detected using a simple luciferase assay. 
5.4.1 Methods 
 Based on the results of the bioinformatics search, reporter constructs of the 2 
polymorphic variants at position -1651 were designed (Figure 5-2).  
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Figure 5-2 pGL3-CYP11B2 promoter construct.  
1880 bp of the CYP11B2 promoter was cloned into the pGL3 plasmid containing a luciferase 
reporter gene. Features on the plasmid are origin of replication (Col E1 origin) for 
replication of plasma in bacteria, viral late polyadenylation signal (SV40 late polyA), Firefly 
luciferase gene (Firefly luciferase), 1.8kb section of the CYP11B2 promoter (CYPB2 
promoter), LacZ alpha gene (LacZ alpha) for blue-white screening and the F1 origin of 
replication sequence (F1ori). The site of polymorphic variation (rs13268025 T/C) of interest 
is shown in red.  
 
The wild type construct was used as a template and the allele at -1651 was 
mutated from T to C (Eurofins MWG Operon, Ebersberg, Germany) (Section 
2.3.1). Plasmids were prepared and sequence confirmed as described in section 
2.2.2-2.3.5. (Plasmid sequence is shown in Appendix 7.9). Transient transfection 
was carried out as described (section 2.3.6) and a renilla luciferase containing 
control plasmid pGL4.73, (Promega, Wisconsin, USA) was co-transfected at a 
ratio of 50:1, to enable adjustment for transfection efficiency. Control wells 
containing untransfected cells, Renilla luciferase plasmid alone (pGL4.73), 
firefly luciferase plasmid alone (pGL4.10) as well as the empty vector (pGL3 
basic) with renilla luciferase plasmid (pGL4.73) were also included in each 
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experiment. Transfected H295R cells were incubated under basal conditions, and 
with the addition of agonists of aldosterone production: angiotensin II (1x10-7M), 
Bu2cAMP (1mM) and potassium (22mM). After 24 hrs, cells were lysed and 
assayed for firefly and Renilla luciferase using Dual Luciferase assay (Promega, 
Wisconsin, USA) (section 2.3.7). The Dual-Luciferase Reporter (DLR) Assay 
System allows the activities of firefly and Renilla luciferases to be measured 
sequentially from a single sample. The firefly luciferase reporter is measured 
first by adding Luciferase Assay Reagent II (LAR II) to generate a “glow-type” 
luminescent signal. After quantifying the firefly luminescence, this reaction is 
quenched, and the Renilla luciferase reaction is initiated by adding Stop & Glo 
Reagent to the same tube. As both measurements can be made from the same 
sample of lysate, there is a reduction in variation and simplification of the 
experimental procedure over other methods (e.g. β-galactosidase). Six biological 
replicates were included in each experiment and this was repeated in 3 
independent experiments. 
5.4.2 Results 
The two plasmids, identical with the exception of a single base change at 
position -1651 (T/C) were compared. Transfection efficiency is influenced by the 
number and density of cells in each well and in order to control for this variable, 
constructs were co-transfected with pGL4.73, a plasmid which produces renilla 
luciferase. The results are expressed as firefly luciferase activity (relative light 
units)/ renilla luciferase activity (relative light units).  There were six biological 
replicates in each experiment and the experiment was repeated three times. A 
graph showing representative results is displayed in Figure 5-3.  
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Figure 5-3 Basal expression of -1651 C and T constructs. 
 H295R cells were transfected with luciferase reporter constructs. Basic plasmid contains 
the pGL3 empty vector only. WT CC plasmid is TT at position -1651 and 1651C plasmid is 
CC at position -1651. Results are displayed as relative light units (RLU) of firefly luciferase 
relative to RLU renilla luciferase. Data expressed as mean plus standard deviation of the 
mean, t-test. Representative graph of 3 independent experiments, each with n=6.  
 
 These results demonstrate that the C allele (1651 C basal) has an approximately 
80% increased transcriptional activity compared to the T allele (WT CC basal) 
under basal conditions. This is statistically significant with a p value of 0.02. The 
transcriptional activity of the empty vector (Basic Basal) is shown to 
demonstrate that the transcriptional activity arises as a result of the insertion of 
1.8kb of the CYP11B2 promoter and not the vector backbone.  
The response of the reporter constructs to stimulation with trophins of 
aldosterone was assessed and results are shown in Figure 5-4.  
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Figure 5-4 Basal and stimulated expression of -1651 C and T constructs.  
H295R cells were transfected with luciferase reporter constructs. Basic plasmid contains 
the pGL3 empty vector only. WT CC plasmid is TT at position -1651 and 1651C plasmid is 
CC at position -1651. Reporter constructs were studies under basal conditions and in 
response to angiotensin II (1x10-7M), Bu2cAMP (1mM) and potassium (22mM). Results are 
displayed as relative light units (RLU) of firefly luciferase relative to RLU renilla luciferase. 
Data expressed as mean plus standard deviation of the mean, t-test. Representative graph 
of 3 independent experiments, each with n=6. 
 
 The difference in transcriptional activity between the constructs carrying the T 
and C allele at position -1651 is present under all conditions and particularly 
exaggerated with stimulation with angiotensin II and Bu2cAMP. Figure 5-5 
displays this data as fold change and this clearly demonstrates that the change 
in transcriptional activity in response to stimulation with all trophins does not 
differ between the constructs with the T or C allele. It does not appear, 
therefore that the response to trophins is altered by the allele at -1651 but 
rather there is an increased basal transcription associated with the C allele at 
position -1651 which is exaggerated when transcription is increased by 
stimulation with trophins. 
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Figure 5-5 Fold change in transcriptional activity of of -1651 C and T constructs.  
Graph shows comparison of C allele (1651C plasmid) and T allele at -1651 (WT CC plasmid) 
in response to stimulation with angiotensin II (1x10-7M), Bu2cAMP (1mM) and potassium 
(22mM). Data expressed as mean and plus standard deviation of the mean, t test. * indicates 
no statistically significant change. 
 
5.4.3 Discussion 
 The reporter gene assays described above are useful biological tools to assess 
transcriptional activity in an in vitro system. However, there are a number of 
considerations when interpreting the results. Transfection can vary considerably 
from well to well, both as a result of variation in cell number and density as well 
as a result of cell death due to toxicity from the transfectant. The H295R cells 
proved to be difficult to transfect and optimisation was a lengthy process. 
Toxicity and cell death remained a problem and as a result, 6 biological 
replicates were included in each experiment to ensure that adequate numbers of 
representative wells were available for analysis at the end of the experiment. 
The use of the dual luciferase assay where both renilla and firefly luciferase 
were measured on one sample of lysate meant that this number of biological 
replicates was feasible. As a result of the lengthy optimisation procedure, the 
large number of biological replicates and the use of a robust method for 
controlling for transfection efficiency, the variability in transcriptional 
efficiency under basal conditions were minimised. The results were reproducible 
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and convincing. However, the response to stimulation was more variable and 
greater variability as can be observed in the wider error bars for these 
experiments. There may be an alteration in response to trophins (in particular in 
response to angiotensin II) which is obscured as a result of the limitations of the 
experimental model. However, this is not supported by the data presented 
above.  
 In summary, it has been demonstrated that a single base change at position -
1651 in the promoter region of the CYP11B2 gene leads to an alteration in 
transcriptional activity under basal conditions but does not induce a greater 
responsiveness to trophins. This is consistent to some extent with the in vivo 
results in Chapter 6 which demonstrated that subjects who were homozygote for 
the T allele at position -344 (corresponds to the C allele at position -1651) had a 
higher excretion of tetrahydroaldosterone that those who were homozygote for 
the C allele at -344, but that there was no demonstrable difference in response 
to trophins. Clearly the complexities of the in vivo system are very poorly 
reproduced in the reporter gene assays described above; nevertheless the 
consistency of the results gives encouragement for further investigation.  
5.5 Electromobility shift assay 
 Having established that there is allelic dependant increase in transcriptional 
activity at the -1651 site, further work was undertaken to establish the 
mechanism. The electromobility shift assay, or gel retardation assay, is based on 
the principle that a complex of double stranded oligonucleotide and protein will 
move more slowly through a polyacrylamide gel under an electric current than 
free double stranded oligonucleotide (Garner and Revzin, 1981) (Figure 5-6). 
Free oligonucleotides and oligonucleotide: protein complexes can be detected if 
they are end labelled with γ32P. As H295R cells have been demonstrated to 
produce aldosterone they must also produce the nuclear proteins necessary to 
drive aldosterone synthase transcription, therefore nuclear extracts from H295R 
cells were hybridised with oligonucleotides containing contrasting alleles at the 
site of polymorphic variation (-1651 base pairs upstream of the transcription 
start site). The hypothesis that there will be a difference in the bands seen on a 
polyacrylamide gel in the oligonucleotide containing the C allele at -1651 
compared to the T allele at -1651 was tested in the following experiments.   
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Figure 5-6 Principles of the electromobility shift assay. 
 The oligonucleotide containing the T allele at -1651 is shown in panel A and the 
oligonucleotide containing the C allele in panel B. If the single base change obliterates a 
binding site for a transcription factor the free probe in panel B will move more rapidly 
through the gel than the probe bound to transcription factor.  
 
5.5.1  Methods 
Cells were lysed and cellular compartments fractionated as described in section 
2.4.1, according to a method based on Dignam et al (Dignam et al., 1983). 
Oligonucleotides containing contrasting alleles at the site of polymorphic 
variation were commercially obtained (Eurofins MWG Operon, Ebersberg, 
Germany). Oligonucleotides were end labelled with γ32 P as described in section 
2.4.3. 
 Oligonucleotides were incubated with nuclear extracts containing transcription 
factors from H295R cells obtained under 3 different sodium chloride conditions 
as well as with and without sodium orthovanadate, a phosphotase inhibitor. 
Culture conditions for the H295R cells are described in Chapter 2 and the cells 
were lysed without stimulation at passage number 22.  
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5.5.2 Results 
The results of the electromobility shift assay are shown in Figure 5-7. Firstly, it 
can be seen that the phosphorylation state of the proteins significantly affects 
binding. Bands of the lowest molecular weight (marked arrow 1) are consistent 
regardless of the presence or absence of sodium vanadate. However, the 
remainder of the complexes are significantly dependant on the phosphorylation 
state. This is particularly striking with regard to the complexes marked arrow 3 
which are not apparent under any sodium chloride concentration in the presence 
of sodium vanadate. 
 The sodium chloride concentration of the extraction buffer also has a strong 
effect on binding. This is best seen in the highest molecular weight complexes 
(arrow marked 2) where in the presence and absence of sodium vanadate, the 
strongest binding is seen with the extraction buffer of 250mM sodium chloride. 
The most consistent difference between the T and C allele, in the presence and 
absence of sodium vanadate and across all sodium chloride concentrations can 
be seen in the complexes of the lowest molecular weight (arrow marked 1). 
Strong protein- DNA complexes of a low molecular weight can be seen in all 
lanes with probes containing T allele with only very weak binding seen in the 
lanes with C allele probes.  
 The relevance of the variation in binding with phosphorylation and in the 
context of varying concentrations of sodium chloride is not clear. However, the 
main aim was to assess if there was a difference in DNA: protein binding 
between oligonucleotides containing the T and the C allele and this has been 
clearly demonstrated. It is somewhat unexpected that greater binding is seen in 
the T allele as the plasmid carrying this allele demonstrated less transcriptional 
activity and it is possible that the protein bound to the T allele acts as a 
transcriptional repressor in this context. 
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Figure 5-7 Electomobility shift assay. 
 γ32P end labelled oligonucleotide probes, spanning polymorphism at position 373 (-1651) 
were hybridised with nuclear extract from H295R cells extracted under varying salt 
conditions with and without the presence of sodium orthovanadate (a tyrosine phosphatase 
inhibitor). Complexes were run on 6% gel and film exposed for 4 days at -80°C.  
  
5.5.3 Discussion 
The in vitro model system of reporter gene assays demonstrated that a single 
base change of a T to a C allele at position -1651 causes increased 
transcriptional activity. The substitution of a T allele for a C allele at position -
1651 was predicted to alter binding of numerous transcription factors in silico 
but the EMSA demonstrated that there is indeed altered protein: DNA binding in 
this region in an in vitro system. However, the identity of the proteins bound to 
the DNA can not be identified as it is not clear whether the bands contain only 
one transcription factor or a complex of numerous factors, making the molecular 
weight an unreliable guide.  
 One approach to identifying the transcription factor or factors in the protein: 
DNA complex is by the use of a “super-shift assay”. This involves incubating the 
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protein: DNA complex with an antibody to a candidate protein. If the protein has 
been correctly identified, the larger protein: DNA: antibody complex will move 
even more slowly through the gel under current and the band will be observed 
“shifted” higher up the gel. An antibody to SF-1 is available but based on the 
bioinformatics study, there were a further seven transcription factors which 
were predicted to bind to the T allele only and a there are a further nine that 
have reduced but not absent affinity for the C allele. Even if all 16 “supershift” 
assays were performed, given the uncertainties regarding the bioinformatics 
databases and the possibility of false negative results described earlier, there 
was significant concern that this approach could overlook the correct protein.  
 An alternative approach is to identify the protein by direct sequencing. This can 
be achieved by using a mass spectrometer to separate ions by their mass: charge 
ratio. The band from the EMSA gel can be isolated and the protein digested with 
a proteolytic enzyme (trypsin) which selectively cleaves the protein at specified 
amino acid sites. The resulting products from the proteolytic digestion are then 
separated on a liquid chromatography column and transferred to the mass 
spectrometer. The protein fragments are subjected to electron spray ionisation 
and broken down to form the individual component amino acids which are 
identified by the mass spectrometer. From these data the identity of the protein 
can be confirmed by checking the sequence tag and molecular weight against a 
database. This technique was felt to be more robust and reliable and was carried 
out by Dr W Sands (MRC Blood Pressure Group). Nuclear extracts prepared as 
described previously were incubated with 5’biotinylated double-stranded DNA 
probes and streptavidin-agarose beads. The protein-DNA complexes were 
separated on SDS-PAGE gel and following trypsin digestion, peptides were 
analysed by tandem mass spectrometry by FingerPrints Proteomics Facility 
College of Life Sciences, University of Dundee. 
Two peptides were identified which bound to the T oligo only, apyrimidinic 
endonuclease (APE 1) and Heterogeneous Nuclear Ribonucleoprotein K 
(HNRNPK). Although neither of these is known to be involved in transcriptional 
regulation of CYP11B2, they both have known generic functions as 
transcriptional regulators. APE 1 has functions as a redox factor, maintaining 
transcription factors in an active reduced state (Evans et al., 2000), and HNRNPK 
interacts with RNA polymerase II transcription machinery to stimulate 
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transcription(Michelotti et al., 1996). The availability of a commercially 
available APE 1 inhibitor made it an attractive candidate for further study. 
5.6 APE 1 inhibitor assay 
5.6.1 Methods 
 Plasmids were prepared and sequence confirmed as previously described 
(section 2.3.2-2.3.5). The protocol for transient transfection was not altered. 
Transfected H295R cells were incubated under basal conditions, and with the 
addition of agonists of aldosterone production: angiotensin II (1x10-7M), Bu2cAMP 
(1mM) and potassium (22mM). However, in this experiment, they were also 
incubated with either 1µM APE 1 inhibitor E3330 (Sigma- Alderich, Missoiuri, 
USA) or vehicle. After 24 hrs, cells were lysed and assayed for firefly and Renilla 
luciferase as previously described (section 2.4.7). Six biological replicates were 
included.  
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5.6.2 Results 
 
Figure 5-8 Effect of APEX-1 inhibitor on transcriptional activity of reporter constructs  
Graphs show reporter constructs containing the C (1651C plasmid) and T (WT CC plasmid) 
allele at position -1651 under basal (Panel A), angiotensin II (1x10-7M) (Panel B), Bu2cAMP 
(1mM) (Panel C) and potassium (22mM) (Panel D). Data expressed as mean plus standard 
deviation of the mean, t-test. * indicates no statistically significant change. Representative 
graph of 3 independent experiments, each with n=6.  
 
As previously shown in section 5.4, the plasmid with T allele at position -1651 
produced less luciferase that the plasmid with C allele at -1651 under basal 
conditions. The addition of the APE 1 inhibitor produced a trend to increased 
transcriptional activity in both plasmids. There difference did not reach 
statistical significance under basal conditions, possibly as the transcriptional 
activity was too low to be able to detect a significant difference. However, 
under stimulated conditions (angiotensin II: Panel B, Bu2cAMP: Panel C and 
potassium: Panel D) the plasmid carrying the T allele demonstrated a 
statistically significant increase in transcriptional activity in the presence of the 
APE1 inhibitor as compared to vehicle. This is consistent with the previous 
results and the hypothesis that the T allele binds APE 1 which functions as a 
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negative regulator of transcription of CYP11B2. Thus inhibition of this protein 
leads to an up regulation of transcription. The effect would be expected to be 
less in the C allele as no APE 1 was detected bound to the sequence containing 
the C allele (Section 5.5).  
5.6.3 Discussion 
The regulation of aldosterone production is a heritable trait (Inglis et al., 1999), 
yet the genetic determinants of increased aldosterone and a consequent rise in 
blood pressure are poorly understood, particularly at a mechanistic level. These 
data demonstrate a clear, plausible means by which an alteration in a single 
base in the promoter region of CYP11B2 may alter transcription via allele 
dependent binding of a repressive transcription factor. They provide evidence 
that the presence of the C allele at position -1651 in the CYP11B2 promoter is 
associated with decreased transcriptional activity and that the mechanism of 
this is likely to be mediated by the transcription factor APE 1. This hypothesis is 
supported by further work within our group demonstrating the association of 
APE1 to the promoter of CYP11B2 in H295R cells using a chromatin 
immunoprecipitation assay (personal communication, Dr W Sands).  
APE 1 (apurinic/apyrimidinic endocunlease, also known as APEX 1, Ref-1, HAP-1) 
is encoded on chromosome 14 and is ubiquitously expressed. It was first 
described as a key enzyme in the base excision repair (BER) pathway (Levin and 
Demple, 1990). It responds to damage by reactive oxygen species by 
participating in a four step process; firstly, excision of a damaged base by a DNA 
glycosylase which results in the generation of an AP site due to cleavage of the 
N-glycosidic bond of the damaged base. APE 1 cleaves the AP site in the second 
step, to generate 3′ OH and 5′ deoxyribose phosphate terminus. The third 
reaction in the pathway involves the DNA polymerase to fill in the single 
nucleotide gap generated due to lesion base removal and finally the gap is 
sealed by the DNA ligase in the final step (Hegde et al., 2008). Essentially, APE1 
functions as an “end cleaning” molecule in the repair process. It is thought that 
the C-terminus of the protein mediates this function and it is interesting to note 
that this is the most highly conserved region (Xanthoudakis et al., 1994). 
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 However, there is evidence that APE 1 has a dual function and also plays a role 
as a redox co-activator in mammals (Xanthoudakis and Curran, 1992). Several 
transcription factors possess a redox sensitive cysteine residue which can be 
reduced by APE1, enhancing their DNA binding activity. Members of the 
CREB/ATF and AP1 family have been shown to be reduced by APE1 (Xanthoudakis 
and Curran, 1992; Xanthoudakis et al., 1992), and these, as discussed previously, 
are known to bind to the CRE element in the CYP11B2 promoter to increase 
transcription of aldosterone synthase. The N-terminus of the protein is thought 
to contain the structure necessary for the redox reactions (Xanthoudakis et al., 
1994). The small molecule inhibitor of APE 1 (E3330) used in the experiments 
described in this chapter selectively inhibits the redox function of APE 1 (Luo et 
al., 2008), probably via the cysteine residue at position 65, although this 
remains controversial (Ordway et al., 2003; Georgiadis et al., 2008). Thus it may 
be that the APE 1 effect on transcriptional regulation of CYP11B2 is mediated via 
a redox interaction with activating transcription factors. However, most 
interactions between APE and transcription factors described in the literature 
suggest that APE1 converts transcription factors from an oxidised to reduced 
state, allowing them to bind to their target promoters and switch on the 
transcription of genes (Tell et al., 2009) rather than functioning as a negative 
regulator. It is not clear therefore, how increased binding of APE1 in the 
CYP11B2 T allele leads to reduced transcriptional activity. It is possible that 
binding of APE at the -1651 prevents it from participating in the redox reactions 
of CREB/ ATF -1 transcription factors, thus leading to reduced transcription but 
further evidence would be required to support this hypothesis. It would be 
interesting to repeat the reporter construct experiments described above after 
mutation of the CRE site; if APE 1 is acting via CREB/ATF there should be no 
difference between the T allele which binds APE 1 and the C allele which does 
not. 
 APE 1 has a further mode of action. It has been shown to act as a negative 
transcription factor in its own right and this has been demonstrated in the 
context of its regulation of the parathyroid hormone gene (PTH) (Okazaki et al., 
1994), and the process by which APE 1 appears to regulate its own expression 
(Kuninger et al., 2002). In these circumstances APE 1 binds to the negative 
calcium response elements (nCaRE) in the promoters of these genes and the 
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sequence of the nCaRE site is demonstrated below along with the sequence 
within the CYP11B2 promoter for comparison. 
GGA CGA GAC TAG CCT GGC  CYP11B2 T allele 
 
GGA CGA GAC CAG CCT GGC  CYP11B2 C allele 
 
TTT TGA GAC AGA GTT TCA  nCaRE-B 
     
TTT TGA GAC AGG GTC TCA  nCaRE-A  
 
 
 It seems that APE 1 is incapable of binding alone and must form heterodimers 
with other proteins. In the case of the PTH gene, it dimerised with the Ku 
antigen p70 and p86 to nCaRE-A (Chung et al., 1996), and with heterogeneous 
nuclear ribonucleoprotein L (hnRNP-L) in the APE gene itself (Kuninger et al., 
2002). It is interesting that the complex that was analysed in the experiments 
described above identified not only APE 1 but also hnRNP-K in the association 
with the T allele but not the C allele. Thus, the mechanism by which APE 1 
regulates the expression of aldosterone synthase may be analogous to these 
examples.  
A potential mechanistic link between the regulation of the PTH gene and 
aldosterone is particular interest given the long recognised but poorly 
understood relationship between hyperparathyroidism and hypertension (Yu et 
al., 2010; Hedback et al., 1990). It could be speculated that if APE 1 was down 
regulated in some way in patients with hyperparathyroidism, leading to the 
development of parathyroid adenomas, they may also develop hypertension as a 
result of the lack of inhibition of aldosterone synthase. Bearing in mind that the 
excess of cardiovascular death appears to persist in hyperparathyroid patients 
even after a surgical “cure” (Hedback et al., 1991; Hedback et al., 1990), this 
hypothesis, while highly speculative, may be worthy of further investigation.  
 Attempt have been made to generate an APE 1 null mouse however these 
animals have been found to die in utero (Xanthoudakis et al., 1996). Animals 
heterozygous for the APE 1 allele survive to adulthood. It is particularly 
interesting to note that the APE+/- mouse is hypertensive (Jeon et al., 2004), 
although to date, there has been no exploration of their renin angiotensin 
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system and the blood pressure phenomenon is thought to be mediated at least in 
part by endothelial nitric oxide production and increased vascular tone. It would 
be interesting to investigate whether the APE+/- mouse has evidence of up-
regulated aldosterone production and measuring plasma renin, aldosterone and 
adrenal CYP11B2 expression would help to elucidate the potential link.  
Clearly the issues specific to the investigation of steroidogenesis regarding 
animal models that were discussed at greater length in chapter 4 would remain 
problematic. It is therefore pertinent to note that a case control study 
examining the association of polymorphic variation in the human APE 1 gene and 
hypertension has suggested that it may be a susceptibility gene for high blood 
pressure (Naganuma et al., 2010). Although there are methodological flaws in 
this report and importantly, it remains a single association study that has not 
thus far been replicated in another population, it contributes to the body of 
evidence to suggest that the role of APE 1 in hypertension deserves further 
analysis. 
5.7 Conclusion 
The studies described above suggest a plausible molecular mechanism to explain 
the association between genetic variation in the aldosterone synthase gene and 
hypertension. By providing evidence that a single nucleotide change can alter 
transcriptional activity and subsequent identification of possible protein: DNA 
complexes, they suggest a novel hypothesis of regulation of aldosterone synthase 
transcription. A number of exiting avenues for future investigation and 
clarification of the role of APE1 in the regulation of aldosterone synthase and 
subsequent development of hypertension have been raised. In addition, 
numerous questions remain regarding the mechanism by which APE 1 may exert 
its effect either alone or in combination with other proteins. Nevertheless, the 
evidence presented here makes a compelling case for further study in this area. 
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6. Phenotypic consequences of variation in the 
CYP11B2 promoter region on corticosteroid 
production in normal volunteers 
6.1 Introduction 
 Variation in the promoter region of CYP11B2, most commonly stratified by 
genotype at position -344, is associated with hypertension and a relatively higher 
aldosterone to renin ratio (ARR)(Sookoian et al., 2007; Lim et al., 2002); 
however, this relationship between genotype and biochemical phenotype is not 
consistent. A more reliable finding is a phenotype of reduced 11β-hydroxylase 
activity (Davies et al., 2001; Freel et al., 2008; Inglis et al., 1999; Keavney et 
al., 2005; Freel et al., 2007). A possible mechanism for this has been identified 
in functional polymorphisms in the promoter of CYP11B1, which are in linkage 
disequilibrium with the polymorphism at -344 in CYP11B2, and are associated 
with reduced transcriptional activity in vitro (Barr et al., 2007). While this could 
be a plausible mechanism to explain the phenotype of inefficient 11β-
hydroxylation, the mechanism behind the development of hypertension and an 
elevated ARR is not apparent.  One hypothesis is that the reduced 11β-
hydroxylation leads to a subtle, long term rise in ACTH drive to the adrenal 
cortex which maintains cortisol at appropriate levels. This increased ACTH drive 
leads to hyperplasia of the adrenal gland and increased synthetic capacity for 
corticosteroids either at basal levels or in response to trophins. An alternative 
hypothesis is that the functional variations in the CYP11B1 promoter is in linkage 
disequilibrium with further functional variations at the promoter region of the 
CYP11B2 gene, as identified in the previous chapter. These may lead to 
increased transcriptional efficiency of aldosterone synthase and increased 
aldosterone production, and the digenic phenomenon where the phenotype 
depends on functional change at more than one point across the locus. Given 
that there is little robust evidence to suggest an absolute genotype-dependant 
difference in the end products of the corticosteroid pathway (aldosterone is not 
elevated but the ARR is; cortisol is not altered but the ratio of 11deoxycortisol 
to cortisol is higher), it seems likely that the difference is associated with 
altered enzyme efficiency and responsiveness to stimulation or suppression. 
These relationships are currently poorly understood. 
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 The effects of environmental factors are likely to be important in the 
development of the phenotypic consequences of the genotype. In particular, the 
effect of dietary sodium intake may be a crucial factor in the development of 
the ultimate physiology. For example, the strain of Dahl hypertensive rat which 
has 5 mutations in the in 11β-hydroxylase gene (Cicila et al., 2001), develops 
hypertension only in response to a high salt diet. Similarly, an animal model of 
increased aldosterone synthase activity develops a phenotype of hypertension 
and relative mineralocorticoid excess only under high salt conditions (Makhanova 
et al., 2008).  
 The studies set out in this chapter aim to explore these issues further in a study 
of the regulation of corticosteroid production in normal volunteers.  
6.2 Aims 
 To examine the aldosterone production of a group of normal volunteers  
1. Under standard salt intake in response to stimulation of their (RAAS) 
renin-angiotensin-aldosterone system by angiotensin II and 
adrenocorticotrophin stimulating hormone  
2. Under conditions designed to suppress the RAAS (high salt intake) and in 
response to stimulation of their (RAAS) renin-angiotensin-aldosterone 
system by angiotensin II and adrenocorticotrophin stimulating hormone 
 To examine the effect of genetic variation at the CYP11B1/2 locus on these 
responses.  
6.3 Methods 
6.3.1 Study volunteers and protocol 
Normal volunteers were recruited by advertisement in local media as well as 
around the university campus. In order to recruit across a range of ages, the 
university’s retired staff was also contacted via e mail. Volunteers were required 
to be in good health and between the ages of 18-70 at the time of recruitment 
and not on any antihypertensive or steroid containing medication. Full exclusion 
criteria are listed in Table 2-3. It was calculated that 60 volunteers would be 
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needed to achieve 80% power to detect a difference in plasma concentration of 
aldosterone of 20% in response to trophins of aldosterone production, with α of 
0.05.  
 Full details of the study protocol are described in Chapter 2.5.2 and Appendix 
7.5. In brief, the design was that of a double blind cross over study. The subjects 
were asked to adhere to a low salt diet for 5 days and were given either salt 
tablets (aim of total salt intake of 200mmol/day) or placebo (aim of total salt 
intake of 80mmol/day). On day 3 they began a 24hr urine collection and on day 
4 they attended the Clinical Research Facility. Intravenous cannulation was 
performed and, after 30 minutes recumbent rest, blood was drawn for steroid 
measurements. ACTH was administered at a rate of 1ng/kg/min and after 30 
minutes the infusion was stopped and further blood sampling was performed. 
After a further 30 minutes rest (60 mins from baseline), a third blood sample 
was obtained.  The volunteers returned on day 5 for the same protocol at which 
time, the infusate was angiotensin II, administered at a rate of 3ng/kg/min. 
Blood pressure was monitored at 10 minute intervals throughout both infusions. 
At least one week for a wash out period was allowed before volunteers crossed 
over to the salt/ placebo arm of the study. 
6.3.2 Genotyping and Haplotype analysis 
Subjects were genotyped across 8 polymorphisms in CYP11B2 promoter region as 
well as the Intron 2 conversion and two polymorphisms in the CYP11B1 promoter 
(1889G/T and -1859 A/G). Details of the DNA extraction, PCR and sequencing 
reactions, as well as haplotype analysis, are given in Chapter 2.5.7 and 2.5.8.  
6.3.3 Corticosteroid phenotype measurements 
24 hour urine samples were collected in plain containers and the volume 
measured before being aliquoted and stored at -20°C without preservatives. 
Steroid metabolites were measured by gas chromatography using the method of 
Shackleton (Shackleton, 1993) with minor modifications described in Chapter 
2.5.4. Blood samples for plasma steroids analysis was drawn in lithium heparin 
tubes and separated by centrifugation at 4°C and snap frozen at -80°C. Plasma 
steroids were extracted from 3ml plasma using Chem Elute cartridges (Varian, 
CA, USA) and eluted with dichloromethane. The eluates were evaporated to 
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dryness under nitrogen and reconstituted in 60ul acetylonitrile. Aliquots (20ul) 
were injected into a Polaris 5 micron, 150mm x2mm C-18-A reversed phase HPLC 
column. Identification and quantification were accomplished by tandem mass 
spectrometry using a Varian 1200L mass spectrophotometer with a triple 
quadropole detector. The internal standard was 16βmethylprednisalone.  
6.3.4 Renin measurements 
Blood was drawn in EDTA tubes and plasma separated by centrifugation at room 
temperature for 15mins at x3000g and snap frozen at -80°C. Care was taken to 
ensure the samples did not thaw until renin measurements were undertaken in 
order to avoid cryoactivation. Plasma renin concentration was measured by 
means of a Diasorin Liaison® immunochemiluminometric analyser (DiaSorin Ltd, 
Wokingham, Berkshire, UK) (Dorrian et al., 2010).  
6.3.5 Urinary electrolytes 
Urinary sodium was measured in the 24 hr urine sample by the Department of 
Biochemistry (Gartnavel General Hospital, Glasgow, UK) using an ion selective 
electrode.  
6.3.6 Data analysis 
Biochemical data that were not normally distributed were log transformed (log 
10) to enable the option of the use of parametric hypothesis tests. Statistical 
analysis was carried out by Minitab 12.21 and Graph Pad Prism 4. Haploview v4.2 
software was used to analyse genotype frequencies for Hardy Weinberg 
equilibrium and to calculate the haplotype structure. 
6.4 Results 
6.4.1 Demographic characteristics 
The demographic characteristics of the volunteers are shown in Table 6-1, 
stratified according to their genotype at the -344 locus.  The numbers of men 
and women were equal and the gender ratio did not vary significantly across the 
genotype groups. Similarly, age, weight and blood pressure were not statistically 
different between the genotyped groups, although there was a trend to younger 
age in the -344 CC group.  
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Demographic 
characteristics 
All subjects 
N=60 
-344 CC 
Subjects 
N=13 
-344 TC 
Subjects 
N=33 
-344 TT 
Subjects 
N=14 
p 
-344 
Polymorphism 
     
 *Age, y 51  
(32- 67) 
36  
(30-58) 
57  
(30-65) 
57  
(49-69) 
 
NS 
Gender, 
 Male 
Female 
 
27 
33 
 
6 
7 
 
15 
18 
 
6 
8 
 
 
NS 
*Weight, kg 70  
(61 -76) 
65  
(57-85) 
71  
(62-76) 
71  
(68-77) 
 
NS 
 
†SBP, mmHg 127  
(+/- 13.91) 
121.46 
 (+/- 14.07) 
128.85  
(+/-14.33) 
127.29   
(+/- 12.22) 
 
NS 
†DBP, mmHg 76  
(+/- 10.26) 
74.85 
(+/- 8.38) 
74.76  
(+/- 11.51) 
80.43  
(+/- 7.66) 
 
NS 
Table 6-1 Demographic information on all study subjects. 
Subjects divided according to -344C/T. *Median and IQ range, Kruksal-Wallis. †Mean and 
StDev, ANOVA. 
 
6.4.2 Genotype and Haplotype data 
 The polymorphisms in the promoter region of CYP11B2, as well as in the intron 2 
region and the promoter region of CYP11B1 were sequenced and the results are 
shown in Table 6-2. The genotyping success rate was high (between 95-100%) 
and all SNPs were in Hardy-Weinberg equilibrium. 
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# Name Position Obs. 
Het 
Pred. 
Het 
HWE p % 
Genotyped 
MAF Alleles 
1 B1-1859 143963455 0.52 0.48 0.84 100 0.408 A:G 
 
2 B1-1889 143963486 0.48 0.48 1 100 0.392 G:T 
 
3 B2_IC 143997133 0.50 0.48 1 100 0.400 A:C 
 
4 B2 -344 143999600 0.55 0.50 0.65 100 0.492 T:C 
 
5 B2 -470 143999726 0.55 0.50 0.65 100 0.492 C:T 
 
6 B2 -645 143999901 0.39 0.35 0.74 98.3 0.229 C:T 
 
7 B2 -663 143999919 0.54 0.50 0.74 98.3 0.492 T:A 
 
8 B2 -1472 144000727 0.58 0.50 0.38 95 0.482 A:G 
 
9 B2 -1513 144000786 0.56 0.50 0.53 95 0.474 T:C 
 
10 B2 -1651 144000906 0.56 0.50 0.53 95 0.474 T:C 
 
11 B2 -1667 144000922 0.56 0.50 0.53 95 0.474 G:C 
 
Table 6-2 Characteristics of polymorphisms in CYP11B2 and CYP11B1.  
Position in base pairs derived from NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP) 
Genome build 37.1, Group term GRCh37. Obs.Het, observed hetrozygosity; Pred.Het, 
predicted hetrozygosity; HWE, Hardy Weinberg Equilibrium p value; MAF, minor allele 
frequency. 
 
Haplotypes were generated with Haploview V4.2 and the linkage disequilibrium 
plot and haplotype frequencies are shown in Figure 6-1. The high degree of 
linkage disequilibrium and the haplotype frequencies is consistent with that 
found in Chapter 3.  
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Figure 6-1 Haplotype frequencies and Linkage disequilibrium plot of 60 normal volunteer 
subjects. 
 Values shown are R2 values.  
 
 From these results, it can be seen that in this population the polymorphisms in 
the promoter region are in such strong linkage disequilibrium that any individual 
SNP can be used as a proxy for several other SNPS with the exception of the 
polymorphism at position -645 and the polymorphism at -663 of CYP11B2. 
However, the minor allele frequency of these haplotypes is low. Therefore, the 
phenotypic data presented in this chapter will be stratified according to the 
allele present at position -344 in the CYP11B2 promoter as a proxy for the other 
5 SNPS (-470, -1472, -1513, -1651 and -1667) that are in 100% linkage 
disequilibrium. 
6.4.3 Standard salt and high salt study phase 
 The urinary sodium collections demonstrate a clear difference in the mean 
urinary sodium excretion between the sodium loading phase and the standard 
sodium phase, although the range of urinary sodium was wide in both phases of 
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the study. As expected, plasma aldosterone and renin concentrations are lower 
under high salt conditions than under standard salt intakes. While the difference 
between tetrahydroaldosterone excretion rate in the high and low salt arms was 
not statistically different, the trend was for excretion rate under high salt 
conditions to be lower than under standard salt conditions. The 24 hour urine 
collections were commenced on day 3 and completed by day 4; this may have 
been too early for the subjects to have achieved salt balance.  
 High salt 
 
Standard salt p 
Urinary Na  
mmol/24 Hr 
200.73  
(+/-66.7) 
 
97.99  
(+/- 40.35) 
<0.001 
*Plasma aldosterone  
ug/ml 
1.93  
(+/-3.17) 
 
3.66  
(+/-3.11) 
<0.001 
Tetrahydroaldosterone  
ug/ 24 Hr 
51.85  
(+/-20.53) 
55.05 
 (+/-20.14) 
NS 
*Plasma renin concentration 
mIU/l 
8.00 
(+/-1.95) 
15.23  
(+/-1.99) 
<0.001 
 
Table 6-3 Biochemical effect of high salt and standard salt conditions.  
Measurements made under high salt and standard salt conditions for all subjects shown as 
mean and standard deviation.  Data marked * were log10 transformed prior to paired t-test. 
 
6.4.4  Measurement of aldosterone production stratified by 
genotype 
The hypotheisis that aldosterone production varies in association with variation 
in the CYP11B2 promoter was examined by measuring plasma aldosterone 
concentration, plasma aldosterone to renin ratios and 24hr urinary excretion of 
aldosterone metabolites. As demonstrated in 6.4.2, given the high LD at the 
CYP11B1 and CYP11B2 locus, the -344 polymorphism can be used as an effective 
proxy for the 5 other SNPs in the promoter region. The plasma aldosterone and 
aldosterone to renin ratios measurements under standard salt conditions are 
illustrated in Figure 6-2 and Figure 6-3.  
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Figure 6-2 Log10 plasma aldosterone concentration under standard salt conditions.  
Data displayed as mean and standard deviation, ANOVA. 
 
 
Figure 6-3 Log 10 plasma aldosterone concentration: plasma renin concentration ratio 
standard salt conditions.  
Data displayed as mean and standard deviation, ANOVA. 
 
It can be seen that there is no significant difference between the plasma 
aldosterone levels or the aldosterone/ renin ratio according to genotype at the 
CYP11B2 promoter. The 24hr urinary excretion of tetrahydroaldosterone is 
displayed according to genotype in Figure 6-4. There is a genotype-dependent 
increase in THAldo excretion which rises in a “dose-response” manner.  
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Figure 6-4 Urinary 24 Hr THAldo excretion under and standard salt conditions. 
 Data displayed as mean and standard deviation, ANOVA 
 
 The 24hr urinary excretion rate is a more robust measurement of aldosterone 
production given that it integrates aldosterone production over a longer period 
of time than a single plasma measurement. While attempts were made to 
standardise the conditions under which the plasma aldosterone concentration 
was sampled with regards to posture, the level may have been affected by other 
factors, e.g. diurnal rhythm. 
6.4.5  Effect of salt loading on aldosterone 
The effect of salt on suppression of aldosterone was examined in both plasma 
and urine to test the hypothesis that variation in the CYP11B2 promoter may 
affect suppressibility of aldosterone in response to salt. Change in urinary 
tetrahydroaldosterone (THAldo) excretion rate in response to salt suppression is 
displayed in Figure 6-5 and change in plasma aldosterone in response to high salt 
intake is displayed in Figure 1-6.  
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Figure 6-5 Change in urinary tetrahydroaldosterone excretion in response to salt loading.  
Data displayed as mean and standard deviation, ANOVA. 
 
Figure 6-6 Change in plasma aldosterone concentration in response to salt loading.  
Data displayed as mean and standard deviation of Log10 transformed data, ANOVA. 
 
Neither parameter displayed a genotype dependant difference in the suppression 
of aldosterone levels in response to salt. The change in plasma and urinary 
THAldo excretion in response to salt suppression is small across all genotypes 
and as such, the study may not have been large enough to detect a significant 
difference. 
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6.4.6  Effect of stimulation of the CYP11B2 pathway by 
trophins of aldosterone 
The hypothesis that variation in the promoter of the CYP11B2 gene may be 
associated with altered response to trophins of aldosterone was also tested. The 
response of plasma aldosterone to angiotensin II under standard salt and high 
salt conditions are shown in Figure 6-7. 
 Neither raw data, nor log transformed data were normally distributed which 
excluded analysis by ANOVA; therefore non parametric testing was employed 
(Kruskal Wallis test). As expected, there was a marked increase in plasma 
aldosterone measurements following the administration of angiotensin II (30 
mins) which then fell over time (60 mins), likely to be due to increased 
expression of CYP11B2 (Spyroglou et al., 2009). There is no observable 
difference in response to angiotensin II between individuals carrying contrasting 
alleles in the CYP11B2 promoter, either under salt loaded or standard salt 
conditions. The rise in aldosterone in response to angiotensin II was blunted 
under high salt conditions but there was no gene dependant effect, as assessed 
by comparison of the difference in response to angiotensin II (baseline and 30 
min) under high and low salt conditions (Table 6-4) (see Matthews et al 
(Matthews et al., 1990) for a discussion of the use of summary statistic in this 
context). 
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Figure 6-7 Response to angiotensin II (3ng/kg/min) under high and standard salt conditions. 
 Due to the non-normal distribution of the data, graphs are displayed as median and inter-
quartile range. Hypothesis tests (Kruskal Wallis) were performed comparing genotypes at 
each time point (Basal, 30 min and 60 min). 
 
GENOTYPE 
CYP11B2 -344 
MEAN DIFFERENCE IN RISE IN PLASMA 
ALDOSTERONE 
P VALUE 
CC 8.38 
TC 5.62 
TT 5.56 
0.11 
Table 6-4 Difference in rise in plasma aldosterone following angiotensin II stimulation 
between high salt and low salt conditions.  
Hypothesis test (AVOVA) was performed comparing response for each genotype. 
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The response of plasma aldosterone to adrenocorticotrophin stimulating 
hormone (ACTH) under standard salt and high salt conditions is shown in Figure 
6-8.  Data were similarly non-normally distributed and the same non-parametric 
testing was used for data analysis. Aldosterone was stimulated by the 
administration of ACTH, although to a lesser extent than with angiotensin II. As 
with angiotensin II stimulation, there was no genotype dependant difference 
between plasma aldosterone concentrations following ACTH stimulation either 
immediately following ACTH administration at 30 minutes or after a further 30 
minute period.  
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Figure 6-8 Response to ACTH (1ng/kg/min) under high and standard salt conditions. 
 Due to the non-normal distribution of the data, graphs are displayed as median and inter-
quartile range, Hypothesis tests (Kruskal Wallis) were performed comparing genotypes at 
each time point (Basal, 30 min and 60 min).  
 
The ratio of the plasma concentration of a compound to that of its precursor 
may be a better index of the efficiency of enzyme activity. Aldosterone is 
synthesised from deoxycorticosterone (DOC) by three separate “hydroxylations” 
(see chapter 1.2.4), catalysed by aldosterone synthase in the adrenal 
glomerulosa. The response of this index, (DOC:Aldo) to angiotensin II, a specific 
inducer of the CYP11B2 pathway is worthy of examination. However, 
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interpretation of this index is compromised by the fact that DOC is also a 
product of the zona fasciculata, which secretes higher quantities than does the 
zona glomerulosa. The basal DOC:Aldo ratios are shown in Figure 6-9. 
 
Figure 6-9 Log10 Deoxycorticosterone:aldosterone (DOC:Aldo) ratio under standard salt 
conditions.  
Graphs displayed as mean and standard deviation, ANOVA. 
 
Under standard salt conditions there is a genotype-dependant effect in DOC: 
Aldo ratio. The DOC: Aldo ratio is higher with TT>TC>CC (p=0.029). This could 
suggest that TT individuals have less aldosterone synthase activity and are less 
efficient at converting DOC into aldosterone. However, it could also be a 
consequence of less efficient 11β-hydroxylase activity, which also uses DOC as a 
substrate. The effect on DOC: Aldo of stimulation of the CYP11B2 pathway with 
angiotensin II is shown in Figure 6-10. 
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Figure 6-10 Deoxycorticosterone: Aldosterone (DOC:Aldo) ratio, response to angiotensin II 
(3ng/kg/min) under standard salt conditions.  
Data are displayed as mean and standard deviation. Hypothesis tests (ANOVA) were 
performed comparing genotypes at each time point (Basal, 30 min and 60 min). 
 
Following administration of angiotensin II the DOC: Aldo ratio would be expected 
to fall due to stimulation of CYP11B2 transcription and increased aldosterone 
synthase activity. The difference between individuals of different genotypes 
seen under standard salt conditions loses statistical significance following 
administration of angiotensin II. It seems likely that the increased DOC: Aldo 
ratio observed at baseline arises as a result of inefficient 11β-hydroxylase 
activity rather than aldosterone synthase activity. However, it is interesting to 
note that while the DOC: Aldo ratio falls in response to AII in TT individuals, 
indicating a clear response to AII and increased aldosterone synthase activity, 
the response in CC individuals is less marked. The change between DOC: Aldo 
ratios in TT Vs CC individuals is not statistically significant but the trend raises 
the possibility that TT individuals are more sensitive to the effects of AII.  
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6.4.7 Effect of stimulation of the CYP11B1 pathway by 
trophins of aldosterone 
Whilst previous evidence has suggested that 11β-hydroxylase activity is less 
efficient in individuals who carry the T allele at position -344 in the promoter 
region of CYP11B2 than those carrying the C allele, there is no evidence of any 
absolute difference in the level of cortisol produced. The cortisol measurements 
at baseline for study participants stratified according to genotype are shown in 
Figure 6-11 which confirms these previous findings with no genotype dependant 
difference in plasma cortisol concentration. 
 
Figure 6-11 Log 10 Basal cortisol under standard salt conditions. 
 Data displayed as mean, standard deviation, ANOVA. 
 
The ratio of 11-deoxycortisol (S) to cortisol (F) can be used as a measure of 11β-
hydroxylase efficiency. This was measured at baseline and in response to 
stimulation of the CYP11B1 pathway with ACTH to test the hypothesis that 
carriers of the -344 TT polymorphism in CYP11B2 display a phenotype of relative 
CYP11B1 inefficiency. S:F ratios stratified according to genotype are displayed in 
Figure 6-12 while the response of the S:F ratio to stimulation of the CYP11B1 
pathway by ACTH is shown in Figure 6-13. 
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Figure 6-12 Log 10 Basal 11-deoxycortisol (S): cortisol (F) under standard salt conditions. 
 Data displayed as mean, standard deviation, ANOVA. 
 
 
Figure 6-13 Log 10 11-deoxycortisol (S): cortisol (F), response to ACTH (1ng/kg/min) under 
standard salt conditions. 
 Data displayed as mean, standard deviation. Hypothesis tests (ANOVA) were performed 
comparing genotypes at each time point (Basal, 30 min and 60 min). 
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There is less efficient 11β-hydroxylation in individuals carrying the T allele at 
position -344 in the CYP11B2 promoter than those carrying the C allele at 
baseline. Stimulation with ACTH causes S:F to rise, i.e. there is relatively more 
precursor (11-deoxycortisol) relative to its product, cortisol. However, the 
genotype-dependant difference remains relatively constant at baseline, 
immediately following ACTH (30 minutes) and after a further 30 minutes. 
As mentioned above, DOC is a substrate for both aldosterone synthase and 11β-
hydroxylase, thus, both can generate corticosterone (B). However, in the 
glomerulosa, aldosterone synthase can also perform an 18-oxidation (to produce 
aldosterone) and 18-hydroxylation (to produce 18-hydroxycorticosterone). As the 
fasciculata is a higher capacity system than the glomerulosa, it is likely that the 
ratio of DOC: B relates more to 11β-hydroxylase activity than aldosterone 
synthase activity. DOC: B ratios response to ACTH is shown in Figure 6-14 and in 
order to discern whether this is a CYP11B1 or CYP11B2 effect, the response to 
angiotensin II, a specific trophin of CYP11B2 is also displayed Figure 6-15.  
 
Figure 6-14 Log 10 Deoxycorticosterone (DOC): corticosterone (B) ratio response to ACTH 
(1ng/kg/min) under standard salt conditions. 
 Data displayed as mean, standard deviation. Hypothesis tests (ANOVA) were performed 
comparing genotypes at each time point (Basal, 30 min and 60 min). 
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Figure 6-15 Log 10 Deoxycorticosterone (DOC): corticosterone (B) ratio response to 
Angiotensin II (3ng/kg/min) under standard salt conditions. 
 Data displayed as mean, standard deviation. Hypothesis tests (ANOVA) were performed 
comparing genotypes at each time point (Basal, 30 min and 60 min). 
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Figure 6-16 Log 10 Deoxycorticosterone (DOC) ACTH (1ng/kg/min) under standard salt 
conditions. 
 Data displayed as mean, standard deviation. Hypothesis tests (ANOVA) were performed 
comparing genotypes at each time point (Basal, 30 min and 60 min). 
 
Administration of ACTH reveals a genotype-dependant difference in DOC: B 
ratios with TT individuals demonstrating less efficient conversion of precursor 
(DOC) to product (B) at 30 minutes than TC or CC individuals (P<0.0001). The 
ratio is driven by a higher DOC in TT individuals Figure 6-16. As this is not 
observed on stimulating the CYP11B2 pathway with angiotensin II, it can be 
concluded that this is likely to be an effect of less efficient 11β-hydroxylation. 
There are no statistically significant differences between genotype groups on 
stimulation with angiotensin II.  
6.5 Discussion 
 Polymorphic variation in the CYP11B2 promoter region at position -344 has 
previously been shown to be associated with reduced 11β-hydroxylation (Davies 
et al., 2001; Freel et al., 2008; Inglis et al., 1999; Keavney et al., 2005; Freel et 
al., 2007) and the data above confirm these findings in a normal population. The 
association with indices of aldosterone production have been more controversial, 
and clarification of this issue was one of the main aims of this study. 24 Hr 
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urinary THAldo excretion was significantly higher in TT genotyped individuals in 
this study, confirming that they are exposed to higher levels of aldosterone than 
CC individuals. Although plasma measurements showed no genotype dependant 
difference, the longer duration of sampling makes the urine collection a more 
robust measurement of aldosterone production than plasma concentration 
measurement which may be more sensitive to confounding factors. 
 There was no genotype-dependant difference in the extent of suppression of 
aldosterone levels by salt loading. However, the study methodology may have 
been a limiting factor here, particularly given the greater reliance on urinary 
measurements to detect differences in aldosterone production bearing in mind 
that the difference between THAldo excretion under high salt and standard salt 
conditions was not statistically significant. Subjects commenced the 24 hour 
urine collection on day 3 and the 24 hour urine collection in the salt loading 
phase may have been more useful if subjects were given longer to achieve 
sodium balance. Further, the plasma aldosterone to renin ratio has been more 
reliably associated with -344 polymorphism (Lim et al., 2002) but in this study, 
the method chosen to measure plasma renin was plasma renin concentration 
(PRC), using a chemiluminescent method, rather than plasma renin activity 
(PRA). The chemiluminescent method has the advantage of low cost and high 
throughput capacity, but is less specific especially at the lower end of the 
normal range than PRA (Dorrian et al., 2010). This would have been particularly 
relevant for measurements during the high salt phase of the study and may be a 
possible explanation for why there was no detectable difference in ARR between 
the genotyped groups. 
 The relationship between aldosterone production and genetic variation in the 
CYP11B2 promoter was further explored and the hypothesis that individuals with 
TT genotype are more sensitive to trophins of aldosterone that CC individuals 
was tested. No evidence to support this hypothesis was found with regard to 
plasma aldosterone concentration response to either angiotensin II or ACTH. It 
has previously been suggested that chronic subtle increase in ACTH as a 
consequence of inefficient 11β-hydroxylation lead to increased synthetic 
capacity of the glomerulosa resulting in increased sensitivity to trophins. As the 
age range of the study participants was wide (in particular of the TT individuals 
who had a mean age of 57 years, StDev 49-69 years), there is no reason to 
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believe that the negative result is due to inadequate time to develop this 
phenotype. However, the dose of ACTH used (1ng/kg/min) may have provoked a 
maximal adrenal response (Arvat et al., 2000) and in order to detect a genotype 
dependant difference, a much lower, sub-maximal dose may be necessary.   
 Although there were no genotype dependant differences in absolute aldosterone 
levels in response to stimulation, interesting trends were observed in the ratios 
of product to precursor which can be used as a marker of enzyme efficiency. In 
particular, the contrasting response of DOC:Aldo ratio following stimulation of 
the CYP11B1 and CYP11B2 pathways between TT and CC individuals raises 
intriguing questions. Bearing in mind the ambiguities of this ratio as a marker of 
aldosterone synthase activity as well as the relatively small magnitude of change 
of the DOC:Aldo ratio means that these results should be interpreted with 
caution. In addition, the study is significantly underpowered for this 
measurement. Although these results should not be over interpreted, the 
difference in response to stimulation may be worthy of further study in larger 
numbers.  
 An alternative explanation for the lack of a consistent association between 
aldosterone and variation in CYP11B2 could be the existence of another 
compound with mineralocorticoid properties, leading to lower renin without an 
elevated aldosterone. This can be seen in the syndrome of apparent 
mineralocorticoid excess where deficiency of 11βhydroxysteroid dehydrogenase 
type 2 (11βHSD2) allows cortisol to occupy the mineralocorticoid receptor 
illicitly (Stewart et al., 1996). In the situation of relative 11β-hydroxylase 
deficiency, a relative excess of DOC could function as a mineralocorticoid, freed 
from the regulation of the RAS system. In this study, plasma DOC concentration 
is higher in TT individuals although there is no significant difference in THDOC 
excretion rate. However, although DOC is present in roughly equivalent 
concentrations to aldosterone and although the mineralocorticoid activity of the 
compound is similar (Porter and Edelman, 1964), the affinity for the MR is 
significantly less than aldosterone (Baxter et al., 1976). Thus the physiological 
relevance of these genotype dependant differences is questionable, although it 
is possible that the increased DOC in TT individuals in response to increased 
ACTH in combination with the basal increase in aldosterone seen in the same 
individuals could lead to greater activation of the mineralocorticoid receptor. It 
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would be useful to have more accurate measurement total body sodium in order 
to have a better understanding of total mineralocorticoid activity.   
How could these studies be taken further to explore whether the corticosteroid 
phenotype is a result of functional changes in CYP11B1 alone or in combination 
with functional variation in CYP11B2? ACTH measurements may provide 
additional evidence to support the hypothesis of chronic, low grade increased 
ACTH drive, but the limits of assay sensitivity and sampling difficulties are likely 
to limit this approach. Increased ACTH drive to the adrenals should also result in 
increased adrenal androgens; indeed earlier work has suggested an association 
between variation in the CYP11B1/2 locus and adrenal androgen production 
(Imrie et al., 2006). However, this study population may not be the most 
suitable for this analysis given the inclusion of both men and women of a range 
of ages. Inhibitors of CYP11B1 and CYP11B2 are available but are promiscuous 
and it is not possible to replicate with pharmacological agents the clinical 
hypothesis of decreased CYP11B1 activity with preserved or increased CYP11B2 
activity. Patients with increased ACTH as a result of Cushing’s disease may 
provide useful insights in terms of whether they are more responsive to trophins 
of the CYP11B2 pathway. But this extreme situation is quite dissimilar to the 
subtle, long term increase that is being proposed as a mechanism in this 
situation. An alternative situation where ACTH drive is increased may be the use 
of 11 beta hydroxysteroid dehydrogenase (11βHSD1) inhibitors. 11 βHSD1 
converts cortisone to cortisol and inhibition of this enzyme has been shown to 
lead to increased ACTH and adrenal volume in animal models (Kotelevtsev et al., 
1997). A recent study on the use of 11 βHSD1 inhibitors in humans with type 2 
diabetes confirms a dose dependant elevation in ACTH level (Rosenstock et al., 
2010). Basal cortisol levels did not alter and adrenal androgens were unchanged, 
however it would interesting to observe the effect of this increased ACTH drive 
on long term mineralocorticoid production under basal conditions as well as in 
dynamic studies.  
In conclusion, the studies outlined above have confirmed and extended current 
knowledge regarding the relationship between the CYP11B1/2 locus and ultimate 
phenotype. They have confirmed the relationship between CYP11B2 
polymorphisms and relative aldosterone excess and provided further evidence to 
support the phenotype of relative 11β-hydroxylase deficiency. No evidence was 
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found to support the notion of an increased response to trophins of aldosterone 
production in this study. Further questions have been raised; in particular the 
role of intermediate corticosteroids should be further examined in order to 
discern whether they could play any meaningful role in the pathophysiology of 
hypertension.
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7. General Discussion 
 The investigations presented in this thesis were designed to explore the 
hypothesis that there are functional polymorphisms in the aldosterone synthase 
promoter region that are co-inherited with the much studied site of variation at 
-344 (rs1799998) of CYP11B2, and that these functional SNPs in the promoter 
region of CYP11B2 contribute significantly to the phenotype of hypertension and 
an elevated aldosterone to renin ratio. Starting with a descriptive study of the 
pattern of linkage disequilibrium in this locus, followed by the validation of an in 
vitro model system and identification of a functional variation at -1651 
(rs13268025) of CYP11B2, the data presented here support this original 
hypothesis.  
 It could be argued that the in vitro studies presented in Chapter 5 are limited in 
that only one SNP from the haplotype structure was investigated in an artificial 
context i.e., the normal pattern linkage disequilibrium would suggest that this a 
T at -1651 would be inherited along with a C at -344 as well as a predictable 
pattern of variation at a number of other sites. In examining the effects of an 
individual SNP out of the context of the haplotype block, the possible functional 
effects (potentially of opposite effect) may be overlooked. Thus, in 
combination, the cumulative effect of the haplotype may be neutral. However, 
there is validity in the experimental approach undertaken here. In particular, it 
should be borne in mind that the data from the normal volunteers in Chapter 6 
demonstrates a genotype-dependant effect on THAldo excretion (in the context 
of the entire promoter haplotype). This confirms that the cumulative effect of 
the SNPs in the haplotype is not neutral. In addition, the influence of rare alleles 
and haplotypes in the population determinants of blood pressure should be borne 
in mind; the individual effects on single polymorphic variation may exert a 
bigger physiological impact, albeit in a small number of individuals. However 
certainly, there has been no data presented here to suggest that the SNP at -
1651 of CYP11B2 is the only functional variation and further assessment of the 
remaining SNPs is warranted. 
One aspect of the hypothesis was not supported in the data from chapter 6. That 
is, that polymorphic variation in the aldosterone synthase promoter region leads 
to altered responsiveness to trophins of aldosterone production or suppression 
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under high salt intake. There were no genotype-dependant differences observed 
in any of these phenomena in the data presented. The hypothesis is therefore 
not supported by the results. There are a number of possible reasons for this.  
The experimental design could have made it difficult to observe a significant 
effect. For example, as mentioned in the discussion section in Chapter 6, the 
period of salt loading may not have been long enough for the subjects to achieve 
salt balance. While a longer period of dietary restriction would be difficult in 
terms of subject recruitment and compliance, it may be that this is required to 
discern any genotype dependant difference. Other mechanisms of salt excretion 
(sweat, gastrointestinal losses) were not controlled for. While these may be 
minor in comparison to the effect of renal mechanisms of salt handling, they 
were unquantified in this study. On the other hand, there was evidence that the 
experimental design was sufficient to observe physiological changes in response 
to salt intake. For example, there was a clear difference observed between the 
high salt and standard salt phase of the study in terms of responsiveness to 
angiotensin II. Specifically, under lower salt intake, subjects had a greater rise 
in plasma aldosterone concentration in response to angiotensin II as compared to 
the change in plasma aldosterone concentration under salt loading conditions. 
This demonstrates that the experimental design was robust enough for these 
changes to be observed. It is certainly clear that any genotype differences are 
likely to be small and may even be obscured by technical variability, thus 
requiring a significant increase in the number of individuals studied to be able to 
discern. 
In addition, the participants of the experiments described here were all 
normotensive and covered a wide range of ages. It may be that older, 
hypertensive individuals would be most likely to demonstrate these responses 
than younger participants, having had more time to develop the genotype-
phenotype relationship. Or it may be that in selecting older, normotensive 
subjects, they may have contributed to a “survivor bias” and therefore less 
likely to display the phenotype of increased responsiveness to trophins or less 
aldosterone suppression in response to salt loading, possible due to 
undetermined compensatory, protective mechanisms. In practice, this 
hypothesis would be difficult to test; older hypertensive subjects are likely to be 
taking antihypertensive medications which will make interpretation of 
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biochemical measurements difficult and changing or stopping medications for 
the purposes of research studies would be ethically questionable.  
 Despite the difficulties of delineating the phenotype in terms of response to 
suppression and stimulation of aldosterone, it seems clear that the hypothesis 
that there is an allele specific effect on transcription mediated by APE1 is 
strongly supported by these studies and should be further investigated. The 
mechanism by which APE1 exerts its effects has not been addressed here 
although a number of possibilities have been discussed.  Further experiments 
would be necessary to explore this. Firstly, whether APE1 acts by activating or 
inactivating other transcription factors known to be involved in the regulation of 
aldosterone synthase, could be tested by mutating the known transcription 
factor binding sites and comparing a plasmid with -1651 T and C with and 
without APE1 inhibitor or SiRNA. Secondly, the role of HNRNPK remains unclear. 
Given the previous reports that APE1 heterodimerises with members of the 
HNRNP family, the hypothesis that it is also involved in the regulation of 
aldosterone synthase is attractive. Again, some simple experiments could 
increase understanding here, for example SiRNA knock down of HNRNPK in 
combination reporter gene assays using plasmids containing the T and C alleles 
at -1651. Finally, looking back again at the shift assay gel from chapter 5 (Figure 
5-7), it would be worth investigating the identity of the other DNA: protein 
complexes, given the numerous complexes that can be observed. It may be that 
APE1 is only one of a number of transcriptional proteins that bind at this site. 
 The APE1 deficient mouse is hypertensive (Jeon et al., 2004) and provides an 
exciting opportunity to explore the relevance of my hypothesis in vivo. The first 
stage in exploiting this system would be to assess the renin-angiotensin-
aldosterone system. If the mouse displayed increased aldosterone levels (in 
combination with reduced renin) or increased transcription of aldosterone 
synthase compared to its wild type littermates, this would provide compelling 
evidence to support the role of APE1 in the regulation of CYP11B2.  
Is this relationship of clinical utility? Given that APE1 is a multifunctional protein 
with roles in fundamental processes regulating DNA repair, preventing mutations 
and oncogenesis as well as redox regulation of numerous transcription factors 
with disparate function, the idea of this as a focused therapeutic target does not 
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seem promising, due to the huge scope for off target actions and side-effects. 
One possibility could be to find a means of targeting the adrenal gland 
specifically. The possibility of using viral vectors for this purpose has been of 
much interest but remains a theoretical strategy in the laboratory rather than a 
practical technique in the clinic. A greater understanding of the role of APE1 
may reveal other steps in the regulatory process which could be targeted in 
order to inhibit aldosterone synthase transcription, particularly if, as mentioned 
above, APE1 acts as part of a complex of regulatory proteins. There is currently 
much interest in developing a specific aldosterone synthase inhibitor but 
progress is hindered by the sequence homology between aldosterone synthase 
and 11β-hydroxylase, (LaSala et al., 2009). Targeting aldosterone synthase by an 
alternative mechanism, for example by manipulating the transcriptional 
machinery, may result in less off-target effects.  
 Another possible area of interest is pharmacogenomics or stratified medicine, 
developing techniques to better select pharmacological therapies specific for 
individuals, tailored to their genetic predispositions. There has been no evidence 
to date to suggest that variation in the CYP11B1/B2 locus is associated with a 
differential response to pharmacotherapy. Indeed, there is mounting evidence 
that MR blockade is a useful strategy in an ever increasing range of clinical 
indications, regardless of genotype. However, there remains controversy as to 
whether this is as a result of blocking MR activation by aldosterone or preventing 
activation by another ligand (e.g. Cortisol in non-epithelial sites lacking 
11βHSD). A better and more specific inhibitor of aldosterone synthase would 
better answer this question, and it may be that individuals carrying polymorphic 
variation in CYP11B2 leading to greater enzyme transcription respond better to 
therapy than those without such a genetic pattern. 
This thesis began with an overview of investigations to date in the field of 
genetic determinants of hypertension, and presented data resulting from two 
contrasting methods of enquiry, namely the hypothesis-driven candidate gene 
approach and, more recently, the unbiased genome wide association studies. 
However, despite large investments of time as well as economic resources, the 
genes responsible for the large, heritable component of blood pressure variation 
are unknown and the genetic mechanisms underpinning essential hypertension 
remain elusive. Much specultation has been made in the literature regarding the 
Chapter 7  209 
next leap in technology and potential advances possible with next generation 
sequencing with massive parallel sequencing platforms and the prospect of 
detecting rare variants with larger physiological effects. However, what is often 
overlooked is the crucial element of phenotyping of subjects. For example, salt 
sensitivity, response to angiotensin II, age of onset, etc. 
 In this thesis I have explored the significant advances that have been made in 
understanding the pathophysiology of hypertension using well developed, robust 
hypotheses and careful phenotyping. As discussed in Chapter 1, many of these 
advances have originated in the study of monogenic conditions in individuals, 
and some have lead to insights into mechanisms that influence the blood 
pressure of populations, such as the analysis by Ji et al of the Framingham 
cohort and frequency of rare alleles in genes associated with Gordon’s, Liddle’s 
and Bartter’s syndrome (Ji et al., 2008). A similar success can be observed in the 
recent discovery of the KCNJ5 mutation in a proportion of aldosterone producing 
adrenal adenomas (Choi et al., 2011), which arose from careful examination of a 
series of patients with familial hyperaldosteronism (Geller et al., 2008) but may 
be involved in the development of this important, curable cause of 
hyperaldosteronism and hypertension. The success of future work examining the 
role of aldosterone synthase in hypertension (as well as progress in many other 
area of hypertension research) will depend on similar careful clinical studies 
with high fidelity phenotyping and a clear hypothesis. The idea that 
hypertension is a homogeneous entity and that it is reasonable to study 
“hypertensive” subjects without further description is in some ways analogous to 
the idea that all patients with a fever are suffering from identical 
pathophysiological processes and will be cured by paracetamol. While it is 
tempting to pursue ever larger screens of genetic analysis, including more 
samples, and covering a greater number of sites of variation, it seems unlikely 
that progress will be made until studies taking greater account of factors like 
age of onset, gender and salt status are undertaken. Knowledge of the roles of 
epigenetic modification including methylation, histone modification and the 
actions of microRNA remain rudimentary and a greater understanding of the 
transcriptional process is needed. Until greater attention is paid to the spectrum 
of pathophysiological mechanisms involved, including epigenetic phenomenon 
and environmental factors, and greater attention paid to the consequent 
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intermediate phenotypes, progress will be limited, despite advancing technology 
and resources.  
 In conclusion, as a result of a combined approach, utilising laboratory 
techniques and in vivo observations, I have demonstrated a plausible mechanism 
behind the phenotype of hypertension with an elevated aldosterone to renin 
ratio and the associated genetic motifs in aldosterone synthase/ 11β 
hydroxylase. I have presented data which identify a role for APE1 in the 
regulation of aldosterone synthase gene transcription. Further investigation is 
warranted to clarify the mechanisms involved and explore the potential for 
therapeutic intervention.  
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8. Appendix 
8.1 Monogenic disorders affecting blood pressure 
DISORDER GENE BLOOD 
PRESSURE 
CLINICAL FEATURES 
Liddle’s Syndrome SCNN1B, 
SCNN1G 
High Gain of function of ENaC, leading 
to increased sodium reabsorption, 
low renin, low aldosterone, 
hypokalaemia and metabolic 
alkalosis. 
 
Gitelman’s 
syndrome 
SCL12A3 Low Constitutative activity of thiazide 
sensitive channel (distal convoluted 
tubule) causing hypokalemic 
alkalosis with hypocalciuria and 
hypomagnesemia 
 
Bartters’ 
syndrome 
SCL12A1, 
ROMK, 
CLCNKB 
Low Defect in sodium chloride channel 
in thick ascending limb, causing 
hypokalemic alkalosis, 
hypercalcuria, normal serum 
magnesium 
 
Pseudo-hypo-
aldosteronism 
type 1 (autosomal 
dominant) 
NR3C2 Low Resistance of the mineralocorticoid 
receptor. Increased sodium loss and 
hyperkalaemic acidosis despite 
aldosterone and renin levels. 
Neonatal salt wasting but adults 
may be asymptomatic. Mutation 
L810 associated with hypertension 
exacerbated by pregnancy as 
progersterone able to activate 
mutant mineralocorticoid receptor. 
 
Pseudo-hypo-
aldosteronism 
type 1 (autosomal 
recessive) 
SCNN1A, 
SCNN1B, 
SCNN1G 
Low Loss of function of ENaC leading to 
increased sodium loss from urine, 
sweat, stool, and saliva despite 
increased aldosterone and renin 
levels with hyperkalaemia. 
 
Gordon’s 
syndrome 
(Pseudo-hypo-
aldosteronism 
type 2) 
 
WNK1, 
WNK4 
High Increased activity of  Na-Cl co-
transporter in distal nephron 
causing increased sodium retention 
and hyperkalaemia 
Syndrome of 
apparent 
mineralocorticoid 
excess 
HSD11B2 High Lack of conversion of cortisol to 
cortisone, leading to activation of 
the MR by cortisol. Low aldosterone 
and suppressed renin.  
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Glucocorticoid 
remediable hyper-
aldosteronism 
CYP11B1/  
CYP11B2 
High Ectopic expression of aldosterone 
synthase under the control of 
ACTH, leading to elevated 
aldosterone, low renin.  
 
21α-hydroxylase 
deficiency 
CYP21A1 Low Loss of function of 21α 
hydroxylation leads to lack of 
conversion of 17OHP 11-
deoxycortisol, and progesterone to 
DOC. Reduced cortisol and 
aldosterone leads to increased 
ACTH drive causing 
hyperandrogonism. 
 
11β- hydroxylase 
deficiency 
CYP11B1  Loss of function of 11β 
hydroxylation leads to lack of 
conversion of 11deoxycortisol to 
corticosterone and cortisol. 
Increased precursors lead to 
increased blood pressure 
 
Aldosterone 
synthase 
deficiency 
CYP11B2 Low Loss of function of aldosterone 
synthase, leading to a lack of 
aldosterone production, increased 
renin, reduced sodium 
reabsorption, hyperkalaemia and 
metabolic alkalosis 
 
17α-hydroxylase 
deficiency 
CYP17A1 High Loss of function of 17α 
hydroxylation leads to lack of 
conversion of progesterone to 
17OHP. Loss of 17, 20 lyase 
function leads to lack of conversion 
of 17OHP and 17OHPreg to DHEA 
and androstenedione.  
 
3β-hydroxysteroid 
dehydrogenase 
deficiency 
HSD3B2 Low Variable clinical presentation. 
Reduced aldosterone and cortisol 
production can result in salt 
wasting. Variable degrees of 
abnormal androgen production.  
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8.2 Nucleotide sequence of human CYP11B2 5’ 
untranslated region.  
Contructed from Entrez Nucleotide database in 2002 
(http://www.ncbi.nlm.nih.gov/gene , Accession number D10170)  
Location of primers and SNPs highlighted in green.  
 
1 Gaattctgca tcctgtgaaa ttatccttca aaagtgaaca  
41 taaatatttt ctcaggtaaa taaaaattga ggggattcgc  
   B2PROMF2 
81 tgccaataga actgacttgc cagaaatgtt ttttaaaagt 
121 tctgcagaga gaaagaaaat gatacaggtc agcaaccctg  
161 agctacataa agaaaggaag agcatttcag aaggaatcag  
201 taaagagaaa atgaagtctt ttattttttc ttaatcttaa  
241 ttgatctaag agtttgctaa aacaaaacaa caacaataaa  
281 aataggccgg gcgcggtgac tcaccacacc tgtaatccca  
321 gcactttggg aggccgaggt gggcagatca cctgaggtca  
361 ggagttcgag actagcctgg ccaacacggt gaaaccccgt  
401 ctctactaaa aatacaaaaa ttagctgggc gtggtggtgg 
        B2Pro494 
441 cacatgcctg taatcccagc tacttgggag gctgaggcgg  
481 gagaattgct tgaacccggg agacagaggt cgcagtgagc  
521 cgagatcaca ccattgcact ctagcctggg cgacagagtg  
561 agactctgtc tcaaaaataa ataaataaat aaataaataa  
601 ataataaaaa taaataaata aaagccagaa agtgtatttg  
641 atgatcatag ttatgtatat gtgaaatgaa ggacagcaat  
681 gatgcaaggg atgggtgagt ggaattaaaa atatcttatt  
721 atttatttat tttgagatgg agtcttgctt tgctgcccag  
  B2 5’783  
761 gttggagtgc agtgggatga tctcaactca ctgcaacctc  
801 cgcctccttg attcaagcat tcatcttgac tcagcctgct  
841 gagaagccga gattacaggc atgcgccacc acacctggct  
881 aattttgtat ttttagtaga gacagggttt tgccatgttg  
921 gccaggctgg tctcgaactc ctgacctcag gtgatccacc   
961 tgcatcagcc tcccaaagtg ctgggatgac agacatgagc  
1001 cactatgccc agcctaagaa tatctgatga ttataaagtg  
1041 cttgcattac ctctgaagct gtatagtgtt atatgaaggt  
1081 ggagttggag agatgagttt taagcgtata ttgcaaactc  
1121 tagggcaacc actaaagaag tgagacccag cctctagaaa 
1161 aaaaaaaaaa aaaggaaatt agctatcaag ccacgaaaag  
1201 aaatggagga accttaaacg catattacta actgagatac 
1241 gtcactttga aaaggctaca aacggtgtca ttccaactat  
1281 acaacatttt ggaaaaggcc aaagcatggt gatgataaaa  
1321 aagatcggag atgtcaggga ctggggcagg agggatgagc  
1361 aggcagagca caggttttct tttcctcttt ttaagacagt  
1401 gaaaatactc ctaggatcct gcaaggaggg atacaaatta  
1441 catacatttg tcaaaaccca cagcatgttg accaccagga  
1481 ggagacccca tgtgactcca ggaccctggt tgataacaac  
1521 gtatcgagat tcctcacatg gaaccagtgc gctcctgtgg  
 
     SF1 F 
1561 tggagggtgt acctgtgtca gggcaggggg tacgtggaca  
1601 ttttctgcag tttttgatca attttgcaat gaactaaatc  
214 
1641 tgtggtataa aaataaagtc tattaaaaga atccaaggct  
1681 ccctctcatc tcacgataag ataaagtccc catccatttt  
1721 actcctctca gccctggaga aaggagaggc caggtcccac 
 
        SF1_R 
1761 caccttccac cagcatggac ccccagtcca gaccccacgc  
1801 cttttctcag catcctcaga ccagcaggac ttgcagcaat 
1841 ggggaattag gcacctcact tctccttcat ctacctttgg  
1881 ctgggggcct ccagccttga ccttcgctct gagagtctca  
1921 ggcaggtcca gagccagttc tcccatgacg tgatatgttt  
       B2-R1 
1961 ccagagcagg ttcctgggtg agataaaagg atttgggctg  
2001 aacagggtgg agggagcatt gga 
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8.3  Consensus sequence for CYP11B1 and CYP11B2 5’ untranslated region and exon 1   
    1                                                                                                                                          
130 
  b1b1b1b1  TCCTTC-GCA TCCCTTGTAA GTTGGATTCC TAAGTAT--- TTTATTCTCT TTGAAGCAAT TGTGAAT--- GGGAGTTCAC TCATGATTTG GCTCTCTGTT TGTCTGTTAA GTGTGTATAA GAATGCTTGT 
  b2b2b2b2  GAATTCTGCA TCCTGTGAAA TTATCCTTCA AAAGTGAACA TAAATATTTT CTCAGGTAAA TAAAAATTGA GGGGATTCGC TGCCAATAGA ACTGACT--- TGCCAGAAAT GTTT-TTTAA AAGTTCTGCA 
 Consensus  gaaTTC.GCA TCCcgTGaAA gTagcaTTCa aAAGTaa... TaaATacTcT cTcAaGcAAa TaaaAAT... GGGaaTTCaC TcacaATaga aCTcaCT... TGcCaGaaAa GTgT.TaTAA aAaTgCTgca 
 
               
    131                                                                                                                                        
260 
  b1b1b1b1  GATTTTTGTA CGTTGATTTT GTATCCTGAG ACTTTGCTGA AGTTGCTTAT CAGCTTAAGG AG-ATTTTGG GCTGAGACAA TGGGGTTTTC TAGATATACA ATCATGTCGT CTGCAAACAG AGACAATTTG 
  b2b2b2b2  GAGAGAAAGA AAATGATACA GGT--CAGCA ACCCTG---- AGCTACATAA AGAAAGGAAG AGCATTTCAG AAGGAATCAG TAAAGAGAAA ATGAAGT-CT TTTATTTTTT CTTAATCTTA ATTGATCTAA 
 Consensus  GAgagaaagA aaaTGATaca Gga..CaGaa ACccTG.... AGcTaCaTAa aaaaagaAaG AG.ATTTcaG aagGAaaCAa TaaaGagaaa aaGAaaT.Ca aTcATgTcgT CTgaAaacaa AgacAacTaa 
 
            261                                                                                                                                        390 
  b1b1b1b1  ACTTCCTCTT TTCCTAATTG AATACCCTTT ATTTCCTTCT CCTGCC-TAA TTGCCCTGGC CAGAACTTCC AACACTATGT TGAATAGGAG TGG------- ---TGAGAGA GGGCATTCCT GTCTTGTACC 
  b2b2b2b2  GAGTTTGCTA AAACAAAACA ACAACAATAA AAATAGGCCG GGCGCGGTGA CTCACCACAC CTGTAATCCC AGCACTTTGG GAGGCCGAGG TGGGCAGATC ACCTGAGGTC AGGAGTTCGA GACTAG--CC 
 Consensus  aagTccgCTa aaaCaAAaca AaaACaaTaa AaaTacgcCg cccGCc.TaA cTcaCCacaC CaGaAaTcCC AaCACTaTGg gaaacaGaaG TGG....... ...TGAGaga aGGaaTTCca GaCTaG..CC 
 
            391                                                                                                                                        520 
  b1b1b1b1  AGTTTTCAAA GGGAATGCTT CCAGTTTTTG ACCATTCAGT ATGATATTGG CTGTGGGTTT GCCATAGATA GCTCTTATTA TTTTGAGATA CGTCCCATCA A-TACCTAAT TTATTGAGAG TTTTTAGCAT 
  b2b2b2b2  TGGCCAACAC GGTGAAAC-- CCCGTCTCT- ACTAAAAATA CAAAAATTAG CTGGGCGT-- ---GGTGGTG GCACATGCCT GTAA------ --TCCCAGCT ACTTGGGAGG CTGAGGCGGG AGAATTGCTT 
 Consensus  aGgccaaaAa GGgaAaaC.. CCaGTcTcT. ACcAaaaAga aaaAaATTaG CTGgGcGT.. ...agaGaTa GCaCaTacca gTaa...... ..TCCCAgCa A.TaccgAag cTaagGaGaG agaaTaGCaT 
 
            521                                                                                                                                        650 
  b1b1b1b1  GAAGGTTGTT GAATTTTGTC AAAG---GCC TTTTCTGCAT CTATTGAGAT AATCATGTGG TTTTTGTCTT TGGTTCTGTT TATATGCTGG ATTAC--ATT TATTGATTTG CATATATTGA ACCAGCCTTG 
  b2b2b2b2  GAACCCGGGA GACAGAGGTC GCAGTGAGCC GAGATCACAC CATTGCACTC TAGCCTG-GG CGACAGAGTG AGACTCTGTC TCAAAAATAA ATAAATAAAT AAATAAATAA ATAATAAAAA TAAATAAATA 
 Consensus  GAAcccgGga GAaagagGTC aaAG...GCC gagaccaCAc CaaTgcAcac aAgCaTG.GG cgacaGacTg aGacTCTGTc TaaAaaaTaa ATaAa..AaT aAaTaAaTaa aaaATAaaaA aaaAgaaaTa 
 
            651                                                                                                                                        780 
  b1b1b1b1  CATCCCAGGG ATGAAGCCCA CTTGATCATG GT---GGATA AGCTTTTTGA TGTGCTGCTG -GATTC--GG TTTGCCAGTA TTTTATTGAG GATTTTTGCA TCAATGTTCA TCAAGGATAT TGGTCTAAAA 
  b2b2b2b2  AAAGCCAGAA A-GTGTATTT GATGATCATA GTTATGTATA TGTGAAATGA AGGACAGCAA TGATGCAAGG GATGGGTGAG TGGAATTAAA AATATCTTAT TATTTATTTA TTTTGAGATG GAGTCTTGCT 
 Consensus  aAacCCAGaa A.Gaagacca caTGATCATa GT...GgATA aGcgaaaTGA aGgaCaGCaa .GATgC..GG gaTGccaGaa TggaATTaAa aATaTcTgaa TaaaTaTTcA TcaaGaaaag gaGTCTaaaa 
 
            781                                                                                                                                        910 
  b1b1b1b1  TTCTCTTTTT TGGTTGTGTC TCTGCCCGGC TTTGGTATCA GGATGATGCT GGCCTCATAA AATGAGTTAG GGAGGATTCC CT--CTCTTT CTATTGATTG GAATAGTTTC AGAAGGAATG GTACCAGTTC 
  b2b2b2b2  TT-GCTGCCC AGGTTGGAG- --TGCAGTGG GATGATCTCA ACTCACTGCA ACCTCCGCCT CCTTGATTCA AGCATTCATC TTGACTCAGC CTGCTGAGAA GCCGAGATTA CAGGCATGCG CCACCACACC 
 Consensus  TT.gCTgccc aGGTTGgag. ..TGCacgGc gaTGaTaTCA acacaaTGCa acCccCacaa aaTgaaTTaa aGaagacacC cT..CTCagc CTacTGAgaa GaagAGaTTa aaaacaaacG ccACCAcacC 
             
            911                                                                                                                                       1040 
  b1b1b1b1  CTCCTTGTAC -GTCTGGTAT AATTCGGCTG TGAAT--CCA TCTGGTCATG GACTCTTTTT GGTTGGTAAT CTATTGATTA TTGCCACAAT TTCAGATCCT GTTATTGGTC TATTCAGAGA TTCAACTTCT 
  b2b2b2b2  TGGCTAATTT TGTATTTTTA GTAGAGACAG GGTTTTGCCA TGTTGGCCAG GCTGGTCTCG AACTCCTGAC CTCAGG--TG ATCCACCTGC ATCAG--CCT CCCAAAGTGC TGGGATGACA GACATGAGCC 
 Consensus  cgcCTaaTac .GTaTggTaa aaagaGaCaG gGaaT..CCA TcTgGgCaaG GacgcTcTcg aacTccTaAc CTaagG..Ta aTcCaaCaac aTCAG..CCT cccAaaGggC TaggaaGAcA gaCAacagCc 
 
 
    1041                                                                                                                                      
1170 
  b1b1b1b1  TACTGGTTTA GTCTTGGGAG AGTGTATGTG TCGAGGAATT TATCCATTTC TTCTAGATTT -TCTAGTTTA TTTGCGTAGA GGTGTTTGTA GTATTC--TC TGATGGTAGT TTGTATT-TC TGTGGGATC- 
  b2b2b2b2  ACTATGCCCA GCCTAAGAAT ATCTGATGAT TATAA-AGTG CTTGCATTAC CTCTGAAGCT GTATAGTGTT ATATGAAGGT GGAGTTGGAG AGATGAGTTT TAAGCGTATA TTGCAAACTC TAGGGCAACC 
 Consensus  aacagGcccA GcCTaaGaAg AgcggATGag TagAa.AaTg caTcCATTaC cTCTaaAgcT .TaTAGTgTa aTagcaaaGa GGaGTTgGaa agATga..Tc TaAgcGTAga TTGcAaa.TC TagGGcAaC. 
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            1171                                                                                                                                      1300 
  b1b1b1b1  -----GGTGG TGATATCC-- CCTTTATCAT TTTTTATTGC ATC---TATT TGAT-TCTTC TCTCTTTTTT TCTTT-ATTA GTCTTGCTAG CGGTCTATCA ATTTTGTTGA -TCCTTTCAA AAAACCAGCT 
  b2b2b2b2  ACTAAAGAAG TGAGACCCAG CCTCTAGAAA AAAAAAAAAA AAAGGAAATT AGCTATCAAG CCACGAAAAG AAATGGAGGA ACCTTAAACG CATATTACTA ACTGAGATAC GTCACTTTGA AAAGGCTACA 
 Consensus  .....aGaaG TGAgAcCC.. CCTcTAgaAa aaaaaAaaaa Aaa...aATT aGaT.TCaac cCaCgaaaag aaaTg.AggA acCTTaaaaG CagacTAccA AcTgaGaTaa .TCacTTcaA AAAacCaaCa 
 
 
            1301                                                                                                                                      1430 
  b1b1b1b1  CCTGGATTCA TTAATTTTTT GAAGGGTTTT TTGTGTCTCT ATTTCCTTCA GTT-CTGCAC TGATTTTAGT TATTTCTTGC CTTCTGCTAG TTTTGAATGT GTTTGCTCTT GCTTTTCTAG TTCTTTTAAT 
  b2b2b2b2  AACGGTGTCA TTCCAACTAT ACAACATTTT GGAAAAGGCC AAAGCATGGT GATGATAAAA AGATCGGAGA TGTCA-GGGA CTGGGGCAGG AG--GGATGA GCAGGCA-GA GCACAGGTT- TTCTTTTCCT 
 Consensus  aacGGagTCA TTaaaacTaT aaAacaTTTT ggaaaacgCc AaagCaTgca GaT.aTaaAa aGATcggAGa TaTca.ggGa CTgcgGCaaG ag..GaATGa GcagGCa.ga GCacagcTa. TTCTTTTaaT 
 
            1431                                                                                                                                      1560 
  b1b1b1b1  TGTGATGTTA GGGTGTCAGT TTTGGATCTT TCCTGCTTTC TCTTGTGGGC ATTTAGTGCT ATAAATTTCC CTCTACACAC TGCTTTGAAT GTGTTCCAGA GATTCTGGTA TGCTGTGTCT TTGTTCTCGT 
  b2b2b2b2  CTTTTTAAGA CAGTGAAAAT ACTCCTAGGA TCCTGCAAG- ----GAGGGA TACAAATTAC ATACATTTGT CAAAACCCAC AGCAT--GTT GACCACCAGG AGGAGACCCC ATGTGACTCC AGGACCCTGG 
 Consensus  cgTgaTaagA caGTGaaAaT acTccaacga TCCTGCaag. ....GaGGGa aacaAaTgac ATAaATTTcc CaaaACaCAC aGCaT..aaT GaccaCCAGa aagacaccca agcTGacTCc agGacCccGg 
 
          
            1561                                                                                                                                      1690 
  b1b1b1b1  TGGTTTCAAG AACATCTTTA TTTCTGCCTT CATTTTGTTA CGTACCCA-- ---GTAGTCA TTCAGGAG-C AGGTTGCTCA GTTTCCATGT AA---TTGAG CGGTTTTGAG TGAGTTTCTT AATCCTGAGT 
  b2b2b2b2  TTGATAACAA CGTATCGAGA TTCCTCACAT GGAACCAGTG CGCTCCTGTG GTGGAGGGTG TACCTGTGTC AGG--GCAGG GGGTACGTGG ACATTTTCTG CAGTTTTTGA TCAATTTTGC AATGAACTAA 
 Consensus  TgGaTaaaAa aacATCgagA TTcCTcaCaT caaaccagTa CGcaCCca.. ...GaaGgca TaCagGaG.C AGG..GCaca GggTaCaTGg Aa...TTcaG CaGTTTTgaa TcAaTTTcgc AATcaacaaa 
 
            1691                                                                                                                                      1820 
  b1b1b1b1  TCTAGTTTGA TTGCACTAAA ATTTTTAAAA AGTAAAAAAA ATACATGTGG TTTAATACAA TTCATGCCAA CTCATTCCCT CGTTTTTTGC TATAAACCTT G---CAAGGA GATGAATAAT CCAAGGCTCT 
  b2b2b2b2  ATCTGTGGTA TAAAAATAAA GTCTATTAAA AGAATCCAAG GCTCCCTCTC ATCTCACGAT AAGATAAAGT CCCCATCCAT --TTTACTCC TCTCAGCCCT GGAGAAAGGA GAGGCCAGGT CCCACCACCT 
 Consensus  accaGTgggA TaaaAaTAAA aTcTaTaAAA AGaAaaaAAa acaCacgcgc aTcaaaacAa aacATaaaaa CcCaaTCCaT ..TTTacTcC TaTaAaCCcT G...aAAGGA GAgGaaaaaT CCaAccacCT 
 
                 
            1821                                                                                                                                      1950 
  b1b1b1b1  TGGATAAGAT AAGGGCCCCA -TCCA--TCT TGCTCCT--- ---------C TCAGCCCTGG AGGA-----G GAGGGAGAGT CCTTTTCCCC TGTCTACGCT CATGCACCCC CAATGAGTCC CTGCCTCCAG 
  b2b2b2b2  TCCACCAGCA TGGACCCCCA GTCCAGACCC CACGCCTTTT CTCAGCATCC TCAGACCAGC AGGACTTGCA GCAATGGGGA ATTAGGCACC TGACTTCTC- CTTCATCTAC CTTTGGCTGG GGGCCTCCAG 
 Consensus  TccAcaAGaa aaGacCCCCA .TCCA..cCc caCgCCT... .........C TCAGaCCaGc AGGA.....a GaaagaGaGa acTaggCaCC TGaCTaCgC. CaTcaaCcaC CaaTGacTcc cgGCCTCCAG 
 
             
            1951                                                                                                                                      2080 
  b1b1b1b1  CCCTGACCTC TGCCCTCGGT CTCTCAGGCA GATCCAGGGC CAGTTCTCCC ATGACGTGAT CCCTCTCGAA GGCAAGGCAC CAGGCAAGAT AAAAGGATTG CAGCTGAACA GGGTGGAGGG AGCATTGGAA 
  b2b2b2b2  CCTTGACCTT CGCTCTGAGA GTCTCAGGCA GGTCCAGAGC CAGTTCTCCC ATGACGTGAT ATGTTTCCAG AGCAGGTTCC TGGGTGAGAT AAAAGGATTT GGGCTGAACA GGGTGGAGGG AGCATTGGAA 
 Consensus  CCcTGACCTc cGCcCTcaGa cTCTCAGGCA GaTCCAGaGC CAGTTCTCCC ATGACGTGAT accTcTCcAa aGCAaGgcaC caGGcaAGAT AAAAGGATTg caGCTGAACA GGGTGGAGGG AGCATTGGAA 
 
 
 
            2081                                                                                                                                      2210 
  b1b1b1b1  TGGCACTCAG GGCAAAGGCA GAGGTGTGCA TGGCAGTGCC CTGGCTGTCC CTGCAAAGGG CACAGGCACT GGGCACGAGA GCCGCCCGGG TCCCCAGGAC AGTGCTGCCC TTTGAAGCCA TGCCCCGGCG 
  b2b2b2b2  TGGCACTCAG GGCAAAGGCA GAGGTGTGCG TGGCAGCGCC CTGGCTGTCC CTGCAAAGGG CACGGGCACT GGGCACTAGA GCCGCTCGGG CCCCTAGGAC GGTGCTGCCG TTTGAAGCCA TGCCCCAGCA 
 Consensus  TGGCACTCAG GGCAAAGGCA GAGGTGTGCa TGGCAGcGCC CTGGCTGTCC CTGCAAAGGG CACaGGCACT GGGCACgAGA GCCGCcCGGG cCCCcAGGAC aGTGCTGCCc TTTGAAGCCA TGCCCCaGCa 
 
            2211                                                                                                                                      2340 
  b1b1b1b1  TCCAGGCAAC AGGTGGCTGA GGCTGCTGCA GATCTGGAGG GAGCAGGGTT ATGAGGACCT GCACCTGGAA GTACACCAGA CCTTCCAGGA ACTAGGGCCC ATTTTCAGGT AAAGCCCTCC CTGGCCCTCG 
  b2b2b2b2  TCCAGGCAAC AGGTGGCTGA GGCTGCTGCA GATCTGGAGG GAGCAGGGTT ATGAGCACCT GCACCTGGAG ATGCACCAGA CCTTCCAGGA GCTGGGGCCC ATTTTCAGGT AAAGCCCTCC CTGGCCCTCG 
 Consensus  TCCAGGCAAC AGGTGGCTGA GGCTGCTGCA GATCTGGAGG GAGCAGGGTT ATGAGcACCT GCACCTGGAa aTaCACCAGA CCTTCCAGGA aCTaGGGCCC ATTTTCAGGT AAAGCCCTCC CTGGCCCTCG 
 
Exon 1 highlighted.  
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8.4 Coefficient of variation and limits of detection for 
LC:MS plasma corticosteroid measurements  
CORTICOSTEROID ADDED 
STANDARD 
CV % PLASMA % LIMITS OF 
DETECTION 
18 OH 
corticosterone  
 
50pg 15.1 18.7 * 
Aldosterone 
 
50pg 11.8 13.4 3.0pg 
Cortisol 
 
25ng 6.1 9.1 1.1µg 
Cortisone 
 
5ng 5.0 7.9 0.7 µg 
Corticosterone 
 
500 pg 10.9 8.2 61.3pg 
11-deoxycortisol 
 
250 pg 11.1 14.5 15.0pg 
Deoxycortcosterone 
 
50 pg 9.4 20.1 2.7pg 
CV, coefficient of variation; Plasma, between batch variations. (* No value for limits of 
detection for 18OH corticosterone is shown due to difficulty obtaining standard.)  
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8.5 Patient information sheet 
Patient Information Sheet 
 
1. Study Title 
“Role of Genetic variation in aldosterone synthase and hypertension.” 
“A study of the control of blood pressure.” 
2. Invitation to take part 
You are invited to take part in a study looking at how blood pressure is 
controlled. Before you decide whether or not to take part, it is important for 
you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with 
others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take 
part. 
Thank you for reading this. 
3. What is the purpose of this study? 
High blood pressure affects a large number of people and increases the risk of a 
number of medical problems (heart disease, stroke etc). Why some people have 
high blood pressure and others do not, is not known. The hormones that are 
produced by the adrenal glands (steroid hormones) affect blood pressure. One of 
these hormones regulates fluid and salt balance in the body and it has been 
suggested that variation in this gene may play a role in high blood pressure. This 
study aims to examine more closely how people with different genetic patterns 
respond to stimulation of their adrenal glands in terms of blood pressure and 
hormones. 
4. Why have I been chosen? 
You have been asked to take part because you do not have any conditions that 
are affected by taking too much salt (kidney problems, heart problems, high 
blood pressure.) We will look at approximately 60 to 80 people to get an overall 
picture of how different people respond. 
5. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. If you withdraw, information that has already 
been gathered will form part of the analysis. If you decide not to take part it 
will not affect the care you receive at any time in the future. 
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6. What will happen to me if I take part? 
This study will involve 5 visits to the Glasgow Cardiovascular Research Centre 
(travel expenses will be paid). The first visit will take around 15 mins. The next 
visits will take 1.5-2 hours. 
1) On the first visit, a blood sample (approx one tablespoon) will be 
taken. This will take only a few minutes. Your DNA will be analysed to 
see what pattern of genes you carry with regard to the steroid 
regulating genes. It may take a few days/weeks to get these results. 
We are interested in looking at specific patterns. If you carry the 
pattern of genes we are interested in, we will ask you to participate in 
the second section. 
2)  You will be asked to follow a diet without excess salt for 4 days. You 
will be given advice about this. You will be asked to take some tablets 
which may contain either salt supplement or placebo (A placebo is a 
pill which looks like the real thing but contains no active ingredient). 
You will not know which you have been given. 
3)  On the third day you will be asked to take a urine collection for 24 
hours. After the third day you will be asked to visit the Glasgow 
Cardiovascular Research Centre where, after 30 minutes rest, another 
blood sample will be taken (approx one tablespoon). You will receive a 
drip containing a hormone that naturally occurs in the body. This will 
take 30 minutes. When it is complete we will take a further blood 
sample (one tablespoon). Your blood pressure and heart rate will be 
monitored during this time. 
4) You will be asked to return the following day to repeat this procedure. 
5) The following week the experiment will be repeated however the 
tablet will be switched from a salt table to placebo or vice versa. 
The attached diagram helps to explain exactly what will be involved. 
7. What are the possible disadvantages and risks of taking part? 
The procedures described above are very safe. The main potential side effect is 
a rise in your blood pressure which may be associated with a headache. This 
is most likely to happen during the high salt phase with one of the infusions (a 
hormone called angiotensin II). Your blood pressure and pulse will be monitored 
throughout this period and the study will be stopped if it rises above a certain 
level. The effects of the hormone infusions are very short and there are no 
known long term effects 
Blood samples will be taken. This is a safe and commonly practiced procedure 
however bruising may occur at the site of the needle, some people may feel 
faint. 
You have been asked to participate as you no not have a chronic disease that 
may deteriorate by taking extra salt in your diet (e.g. kidney problems, heart 
problems, high blood pressure). If you think you may have any of these 
conditions, please let the research doctor know. 
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It is possible that if this study is carried out on a woman who is pregnant it could 
harm the unborn child. Women who could be pregnant may be asked to take a 
pregnancy test before the study commences. Women who could become 
pregnant should use effective contraception for the duration of the study. 
Women who think they may have become pregnant during the duration of the 
study should immediately let their research doctor know. 
8. What are the possible benefits of taking part? 
You will receive no direct benefit from taking part in this study. The information 
that is collected during this study will give us a better understanding of how high 
blood pressure develops and how best to treat it. 
 
9. What if something goes wrong? 
 
There are no special compensation arrangements if you are harmed by taking 
part in this research project. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action but you may have to pay for it. If 
you have a concern about any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions. If you remain 
unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. 
 
10. Will my taking part in this study be kept confidential? 
 
If you consent to take part in the research your medical records may be 
inspected by the research doctor for purposes of analysing the results. Only 
government regulatory authorities and the research doctor will have access to 
your medical notes. 
 
All information collected about you during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital 
will have your name and address removed so that you cannot be recognised from 
it. Reports or publications resulting from the study will not contain any personal 
details. Your General Practitioner will be informed of your participation. 
 
11. What will happen to the results of the research study? 
 
The results of the research study will be stored on a computer database and are 
likely to be published in medical journals. Reports or publications resulting from 
the study will not contain any personal details. The research doctor will provide 
a copy of the results on request. 
12. Who is organising and funding the research? 
The research is being organised by the Division of Cardiovascular and Medical 
Science, University of Glasgow. The Medical Research Council funded Blood 
Pressure Research Group is the section responsible for this study. 
13. Who has reviewed the study? 
This study has been reviewed and approved by Glasgow West Local Research 
Ethics Committee which is an independent panel set up to protect your safety, 
rights, wellbeing and dignity. 
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Contact 
If you have any further questions please contact 
Dr Frances McManus 
British Heart Foundation Glasgow Cardiovascular Research Centre 
126 University Place, 
G12 8TA  
0141 330 1933 
www.gla.ac.uk/bhfgcrc 
Questionnaire 
 
Do you have any of the following conditions? (Y/N) 
 
High blood pressure? 
Heart disease (including angina, previous heart attack 
 or heart failure)? 
Kidney disease? 
Are you pregnant of likely to become so in the next 6 months?   
Have you used of systemic or topical steroids  
within the last 6 months? 
Do you have a history of severe allergies? 
Are you on any regular medication?  
Please list below: 
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Subject Identification Number for this trial: 
CONSENT FORM 
Title of Project:  Role of Genetic Variation in Aldosterone Synthase and 
Hypertension 
   Please initial box 
1. I confirm that I have read and understand the information sheet dated 
August 2007 (version 2) for the above study and have had the opportunity   
to ask questions. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my legal rights 
being affected. 
3.    I agree to take part in the above study.   
4.     I understand that the DNA in my blood will be analysed as part of this  
study 
5.     I agree that to my GP being informed of my participation in this study 
 
           
Name of subject Date Signature 
    
Name of Person taking consent  Date Signature 
(If different from researcher) 
   
Researcher Date Signature 
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Week 1   
Day 1. Start low salt diet and 
take tablets from box 1 
Day 4.  
Attend Clinical Research 
Facility 38 Church St, 1st floor, 
for  
1. 30 minutes rest 
2. Venflon and blood test 
3. Drip for 30 mins 
4. Further blood test 
immediately and 
30mins later 
Day 5. 
Continue low salt diet and 
tablets. Attend Clinical 
Research Facility 38 Church St, 
1st floor, for  
1. 30 minutes rest 
2. Venflon and blood test 
3. Drip for 30 mins 
4. Further blood test 
immediately and 
30mins later 
Stop low salt diet and tablets 
 
Day 3  
Start 24Hr Urine collection 
224 
8.6 Clinical study protocol 
Clinical Study Protocol: Version 2 
 
 
 
Study Title: Role of Genetic Variation in Aldosterone Synthase in Hypertension. 
Physiological Studies 
 
 
 
 
Chief Investigators:  Professor J Connell MBChB MD FMedSci FRCP FRSE 
     Glasgow Cardiovascular Research Centre 
     126 University Place 
University of Glasgow, 
Glasgow, G12 8TA  
 
 
 
 
 
Dr Frances McManus MBChB BSc (Med Sci) MRCP 
     Glasgow Cardiovascular Research Centre 
     126 University Place 
University of Glasgow, 
Glasgow, G12 8TA 
Tel: 0141 330 1933 
e-mail: F.McManus@hotmail.com 
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Background: Hypertension is a common condition that contributes to the global 
burden of cardiovascular disease. In the majority of patients no single cause is 
found and its pathogenesis reflects a complex interaction of genes and 
environment. 
 It is recognised that aldosterone is an important cardiovascular hormone across 
a range of disorders. However, aldosterone is also recognised as an important 
contributor to the pathogenesis of hypertension and its consequences. 
Approximately 15% of patients with essential hypertension have evidence of 
dysregulation of aldosterone production so that there is an abnormally high ratio 
of aldosterone to renin (ARR). There is uncertainty about whether such patients 
have genuine primary aldosterone excess; in the majority of instances 
aldosterone is still responsive to Angiotensin II, and it is likely that the raised 
ARR reflects increased sensitivity of aldosterone release to its usual trophins. For 
this reason it is important to understand better the mechanism(s) that underlies 
this biochemical abnormality: the planned studies seek to investigate possible 
mechanisms that may contribute to the regulation of aldosterone in 
hypertension. 
Adrenal corticosteroid secretion is strongly heritable, consistent with genetic 
determination, stimulating a search for candidate genes that may account for 
this. Attention has focussed on the late steps in adrenal steroid synthesis.  
 The late stages of aldosterone synthesis are catalysed by the enzyme 
aldosterone synthase, encoded by the gene CYP11B2, and expressed in zona 
glomerulosa of the adrenal cortex. This gene is located in chromosome 8 in man, 
and lies in close proximity to the gene CYP11B1, which encodes the enzyme 11β-
hydroxylase to catalyses the conversion of deoxycortisol to cortisol within the 
zona fasciculata. (Figure 1)  
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1 7 -O H -P re g neno lo ne
C o rt is o l (F )
17 -O H -P ro ge s te ro ne
11 -D eox yco rt is o l (S )
1 1 β -H y d r o x y la se
(C Y P 1 1 B 1 )
C ho le s te ro l
P re gneno lo ne
P ro ge s te ro ne
11 -D eox yc o rt ic o s te ro n e
A ld o s te ro n e
A ld o s te r o n e  
sy n th a se
(C Y P 1 1 B 2 )
C o rt ic o s te ro ne  (B )
1 8 -H yd ro x yco rt ic o s te ro ne
Figure 1 Corticosteroid biosynthesis in the human adrenal 
gland 
 
 
 
 
 
 
 
Figure 1: Steroid synthesis pathway 
 These genes are plausible candidates for contributing to the population 
variation in aldosterone and cortisol production, and development of 
hypertension and cardiovascular disease.  
 Previous studies have identified a common single nucleotide (-344 C/T) 
polymorphism in CYP11B2. Studies have shown that this polymorphism is 
associated with hypertension, particularly with a phenotype of a raised ARR.  
 Recent data confirm that polymorphisms in the 5’ regulatory region in CYP11B1 
are in strong linkage disequilibrium with those in the regulatory regions of 
CYP11B2. It is not clear what the individual effects of the polymorphisms within 
the two separate genes are on the phenotypes of aldosterone excess and the 
development of hypertension, however, as in the Dahl rat, it is possible that 
there is an interaction between CYP11B1 and CYP11B2 (essentially, a digenic 
effect) that results in increased ACTH drive to the adrenal (due to changes in 
CYP11B1) and abnormal sensitisation of regulation of expression of CYP11B2 to 
agonists including potassium, ACTH and Angiotensin II, leading to the  phenotype 
of chronically altered aldosterone regulation. 
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Hypothesis:  Polymorphisms in the genes encoding aldosterone synthase and 11β-
hydroxylase are inherited in haplotype blocks and lead to altered production of 
mineralocorticoids and glucocorticoids in affected individuals.  
Aims: To measure steroid response (plasma and urine) to its conventional trophin 
(angiotensin II) of aldosterone production in high and low salt intake in normal 
volunteers with contrasting haplotypes. 
To measure steroid response to its unconventional trophin (ACTH) of aldosterone 
production in high and low salt intake in normal volunteers with contrasting 
haplotypes. 
Study Design: The study will be carried out at the BHF Glasgow Cardiovascular 
Research Centre. The study duration will be 3 years. The length of participation 
of each subject will be 2 weeks.  
 Volunteers will be recruited via poster campaign and through advertisements 
using local media.  
Screening: Subjects will be screened for participation in the study initially.  
 Volunteers will sign a consent form indicating their willingness to participate in 
screening. Consent will be taken by Dr Frances McManus. Consent forms will be 
stored in the site file in the Glasgow Cardiovascular Research Centre. Volunteers 
will be given a copy of the patient information sheet and consent form. This will 
be documented and filed in the project folder. Volunteers will be asked if they 
suffer from any medical conditions likely to deteriorate as a result of 
participation in this study (heart failure, hypertension, renal impairment).  
Exclusion criteria are as follows 
Age greater than 75 years or less than 18 years. 
Cardiac failure 
Renal impairment 
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Uncontrolled hypertension (BP > 160/90) 
Treatment with beta blockers, ACE inhibitors, diuretics. 
Use of systemic or topical steroids within the last 6 months 
Pregnancy 
Inability to comply with study protocol 
History of severe allergy 
Screening blood tests are as follows: 
Baseline biochemistry to assess renal function (6ml gel tube).   
DNA will be extracted from blood sample (5ml EDTA) and genotyped for the 
polymorphisms of interest.  
 Study: Volunteers with the polymorphisms of interest will be invited to return 
for the second phase of the study. Subjects will be studied during careful dietary 
sodium control to maintain either a high (200 mmol per day) or low (80 mmol 
per day) sodium intake. They will be given a diet sheet to follow which will give 
advice on a low salt diet (approx 4.8g per day). Salt loading will aim for an 
intake of 200 mmol per day (approx 12g) using sodium supplement tablets 
containing 600mg sodium chloride (four tabs 3 times per day).   
 Once in balance (after 3 days) subjects will be infused with ACTH 
(1ng/kg/minute for 30 mins); on the following day subjects will be given an 
infusion of angiotensin II (3 ng/kg/minute for 30 mins). Infusions will be made by 
pharmacy. Basal and stimulated plasma aldosterone levels, as well as a range of 
other steroids will be measured.  This will require baseline blood tests before 
the infusion (x2 Lith Heparin and x 1 EDTA), at completion of the infusion, as 
well as 30 mins after completion (x2 Lith Heparin and x 1 EDTA). 
 In addition, 24 hr urine collections will be analysed for steroid measurements. 
Spot urine samples will be measured for sodium excretion. 
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 The study will last for two weeks to allow volunteers to complete both the salt 
loading and salt restricted (placebo) arms.  
Results will be entered onto the Clinical Record sheet by Dr Frances McManus or 
a research nurse. Observations (BP, HR) will be documented by the nursing staff 
of the clinical studies unit at the GCRC. 
Risks: The risks relating to venepuncture are low and standard precautions will 
be taken. The participant may experience some local bruising. 
 The recommended daily salt intake is 6g per day. Salt loading may be associated 
with mild nausea however slow release tablets will be used to minimise this 
effect. Patients with uncontrolled hypertension, significant renal disease and 
heart failure may experience a small, reversible deterioration in their condition 
with prolonged salt loading however; volunteers will be screened for these 
conditions and excluded from the study.  
 Angiotensin II can cause the blood pressure to rise. This could cause potential 
harm if it was allowed to continue however the blood pressure will be monitored 
and the study will be stopped if it the mean arterial pressure (MAP) rises more 
than 20mmHg. The length of time it takes for Angiotensin II to wear off is very 
short.   
 ACTH can cause blood pressure to rise however, this effect is transient and 
blood pressure will be regularly monitored and stopped if MAP rises more than 
20mmHg. Short term exposure to ACTH in adults has not been reported to be 
associated with any further complications. ACTH is commonly used in hospitals 
as a diagnostic tool, with no reported complications.  
Adverse Events Adverse events are likely to be rare and mild given the nature of 
this study. All serious adverse events will be reported to the sponsor (North 
Glasgow NHS Trust). 
Pharmacy: Pharmaceutical products will be dispensed from the pharmacy 
department of the Western Infirmary Glasgow/ Clinical Trials Pharmacy Unit and 
this has been agreed with the pharmacy department.  
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 Placebos will be matched as closely as possible to the active substance.  
 Products will be manufactured to the standards of Good Medical Practice. 
 Labelling of the placebo and active substances will be managed by pharmacy 
and checked with clinicians involved. 
 Volunteers will be requested to return unused products to the Glasgow 
Cardiovascular Research Centre, where they will be passed on to pharmacy. 
Patients will be informed of this when the product is being dispensed.   
Randomisation:  Randomisation will be computer generated.  
Patient Data: All patient data will be held on a password locked computer file in 
anonymised form. This will be stored in a locked cabinet in the Glasgow 
Cardiovascular Research Centre. Patient identifier data and Clinical Record 
Forms will be kept in a locked cabinet. 
Withdrawal: Volunteers can withdraw at any time. This is explained in the 
patient information sheet. Information gathered up to the date of withdrawal 
will be used in the analysis. Once a volunteer has withdrawn they will not be 
invited for further blood or stimulation tests. This will be recorded in the site 
file and on the Clinical Record Form.  
Results and Statistics: Large scale clinical studies have not been performed in 
this area and power calculations are hindered by this lack of information. 
However, we estimate that a sample size of 20 individuals per haplotype (likely 
to be 3 common haplotypes) will be necessary to identify a significant difference 
in the aldosterone response to angiotensin II, and we base this estimate on a 
recent study which was able to demonstrate significant differences in 
angiotensin responses with low salt intake using around 10 individuals in each 
contrasting genotype.  A total of 60 individuals will be required to participate. 
This will require around 100 individuals to be screened. 
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Staff: Dr Frances McManus (Research Fellow) has attended a Good Clinical 
Practice course (4th April 2007 Clinical Trials Unit North Glasgow/ Glasgow 
University). 
 Dr Marie Freel (Clinical Lecturer) has experience in similar studies. 
 Prof J Connell has had extensive experience as a lead investigator in similar 
studies  
 Dr Eleanor Davies (Senior Lecturer) will be involved in the data analysis.  
 The staff in the clinical unit of the Glasgow Cardiovascular Research Centre are 
familiar with the principles and practices involved in Good Clinical Practice. 
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8.7 Clinical Records form 
Clinical Record Form 
 
 
Patient Study no: 
 
AFS 064 
Patient name: 
 
 
Address: 
 
 
E mail 
 
 
Telephone: 
 
 
 
Date of Birth: 
 
 
 
 
Consent form signed Yes/ No 
 
Patient copy of consent form 
 
Yes/ No 
 
Co-morbidities excluded 
 
Yes/ No 
 
 
Slow sodium/ placebo prescription? Yes/ No 
 
Ang II/ ACTH Prescription? Yes/ No 
 
Infusions prescribed? Yes/ No 
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Initial resting blood pressure  
Height (cm)  
Weight (Kg)  
 
 
Initial Bloods taken 
 
Biochemistry (yellow x 1)  
Result (eGFR)  
DNA extraction (purple x 1 )  
24 Hr Urine bottle given ?  
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Visit 1/ 2/ 3/ 4 
 
 
Date of visit: 
 
Negative pregnancy test    Yes/ No / NA 
 
24 hr Urine collection completed?    Yes/ No 
 
Total Volume/ Weight = _____________  
 
 
ACTH = 1 ng/kg/min 
 
 Batch No; __________________  Exp Date____________ 
 
Infusion 1 
ACTH 
Time 
from 
start of 
infusion 
Heart 
Rate 
MAP BP 
mmHg 
Bloods taken 
Lithium Heparin (green) x 
3 
EDTA (Purple) 9ml x 1  
Blood 
pressure 
1 
- 30 min    Start Time:  
Blood 
pressure 
 0 min    Li 
Hep 
Li 
Hep 
Li 
Hep 
EDTA  
Blood 
pressure 
10 min    
Blood 
pressure 
20 min     
 
Blood 
pressure 
30 min    Li 
Hep 
Li 
Hep 
Li 
Hep 
EDTA 
Blood 
pressure 
60 min    Li 
Hep 
Li 
Hep 
Li 
Hep 
EDTA 
 
  
Infusion discontinued? 
  
Time from start of infusion: 
Bloods taken at termination of infusion   Yes/ No 
 
Other adverse effects? 
 
Patient withdrawal from study? 
 
Reason given? 
 
Other Notes: 
235 
8.8 Linkage disequilibrium CYP11B1 and CYP11B2 locus 
 
 
D’ values demonstrating linkage disequilibrium across the CYP11B1 and CYP11B2 
promoter region. Data pooled from genotyping described in chapter 3 and data 
from Imrie et al (Imrie et al., 2006) and Alvarez-Madrazo et al (Alvarez-Madrazo 
et al., 2009).  
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8.9 Table of polymorphisms  
 
 
 
NCBI SNP database 
 
http://www.ncbi.nlm. 
nih.gov/projects/SNP 
 
ENSMBL 
 
http://www.ensembl.org/Homo_sapiens
/Gene/Sequence?g=ENSG00000179142 
 
Ch Position Group 
Term 
 
Pos. 
from 
Exon1 
 
Pos.  
from 
5’ end 
 
Pos.  on 
plasmid  
Allele 1 Allele 2 rs number 
144000922 GRCh37 -1667 357 276 G C rs13254375 
144000906 GRCh37 -1651 373 292 T C rs13268025 
144000786 GRCh37 -1513 510 427 T C rs62524561 
144000727 GRCh37 -1472 551 468 A G rs62524560  
143999919 GRCh37 -663 1360 1269 T A rs28659182 
143999901 GRCh37 -645 1379 1287 C T rs11781082 
143999726 GRCh37 -470 1554 1462 T C rs10087214 
143999600 GRCh37 -344 1680 1590 C T rs1799998 
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8.10 Sequence of pGL3-CYP11B2 plasmid 
<Serial Cloner V2.0> -- <04 Mar 2010   14:44> 
Restriction map of pGL3_pCRscript_B2proCC_march 2010.xdna 
Showing restriction enzymes cutting maximum 1 time [using Serial Cloner Internal RE list as a Restriction Enzyme Library] 
 
        SacI          NheI 
        Eco53kI       BmtI       EcoRI 
  KpnI          AflIII           ApoI 
  Acc65I        MluI         >CdiI                                                               <SapI 
  |     |       |     |      |   |             • pGL3 plasmid                                    | 
  GGTACCGAGCTCTTACGCGTGCTAGCCCATCGAATTCCTGCAGCCCGGGGGATCCGCCCGATACAGGTCAGCAACCCTGAGCTACATAAAGAAAGGAAGA  < 100 
  CCATGGCTCGAGAATGCGCACGATCGGGTAGCTTAAGGACGTCGGGCCCCCTAGGCGGGCTATGTCCAGTCGTTGGGACTCGATGTATTTCTTTCCTTCT 
           10        20        30        40        50        60        70        80        90  
 
  GCATTTCAGAAGGAATCAGTAAAGAGAAAATGAAGTCTTTTATTTTTTCTTAATCTTAATTGATCTAAGAGTTTGCTAAAACAAAACAACAACAACAAAA  < 200 
  CGTAAAGTCTTCCTTAGTCATTTCTCTTTTACTTCAGAAAATAAAAAAGAATTAGAATTAACTAGATTCTCAAACGATTTTGTTTTGTTGTTGTTGTTTT 
           110       120       130       140       150       160       170       180       190  
 
                           >TstI 
                           |                T • C 
  ATAGGCCGGGCGCGGTGACTCACCACACCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACCTGAGGTCAGGAGTTCGAGACTAGCCTGGC  < 300 
  TATCCGGCCCGCGCCACTGAGTGGTGTGGACATTAGGGTCGTGAAACCCTCCGGCTCCACCCGTCTAGTGGACTCCAGTCCTCAAGCTCTGATCGGACCG 
           210       220       230       240       250       260       270       280       290  
 
                   
 
  CAACACGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGCACATGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCGGGAGG  < 400 
  GTTGTGCCACTTTGGGGCAGAGATGATTTTTATGTTTTTAATCGACCCGCACCACCGTGTACGGACATTAGGGTCGATGAACCCTCCGACTCCGCCCTCC 
           310       320       330       340       350       360       370       380       390  
 
                                      
  ATTGCTTGAACCCGGGAGACAGAGGTTGCAGTGAGCCGAGATCACACCATTGCACTCTAGCCTGGGCAACAGAGTGAGACTCTGTCTCAAAAATAAATAA  < 500 
  TAACGAACTTGGGCCCTCTGTCTCCAACGTCACTCGGCTCTAGTGTGGTAACGTGAGATCGGACCCGTTGTCTCACTCTGAGACAGAGTTTTTATTTATT 
           410       420       430       440       450       460       470       480       490  
 
 
   
  ATAAATAAATAAATAATAAAAATAAATAAATAAAAGCCAGAAAGTGTATTTGATGATCATAGTTATGTATATGTGAAATGAAGGACAGCAATGATGCAAG  < 600 
  TATTTATTTATTTATTATTTTTATTTATTTATTTTCGGTCTTTCACATAAACTACTAGTATCAATACATATACACTTTACTTCCTGTCGTTACTACGTTC 
           510       520       530       540       550       560       570       580       590  
 
                                                                                 
 
  GGATGGGTGAGTGGAATTAAAAATGTCTTATTATTTATTTATTTTGAGATGGAGTCTTGCTTTGCTGCCCAGGTTGGAGTGCAGTGGGATGATCTCAACT  < 700 
  CCTACCCACTCACCTTAATTTTTACAGAATAATAAATAAATAAAACTCTACCTCAGAACGAAACGACGGGTCCAACCTCACGTCACCCTACTAGAGTTGA 
           610       620       630       640       650       660       670       680       690  
 
 
238 
 
  CACTGCAACCTCCGCCTCCTTGATTCAAGCATTCATCTTGACTCAGCCTGCTGAGAAGCCgAGATTACAGGCATGCGCCACCACACCTGGCTAATTTTGT  < 800 
  GTGACGTTGGAGGCGGAGGAACTAAGTTCGTAAGTAGAACTGAGTCGGACGACTCTTCGGcTCTAATGTCCGTACGCGGTGGTGTGGACCGATTAAAACA 
           710       720       730       740       750       760       770       780       790  
 
                          
                          
  ATTTTTAGTAGAGACAGGGTTTTGCCATGTTGGCCAGGCTGGTCTCgAACTCCTGACCTCAGGTGATCCACCTGCATCAGCCTCCCAAAGTGCTGGGATG  < 900 
  TAAAAATCATCTCTGTCCCAAAACGGTACAACCGGTCCGACCAGAGcTTGAGGACTGGAGTCCACTAGGTGGACGTAGTCGGAGGGTTTCACGACCCTAC 
           810       820       830       840       850       860       870       880       890  
 
  ACAGACATGAGCCACTATGCCCAGCCTAAGAATATCTGATGATTATAAAGTGCTTGCATTACCTCTGAAGCTGTATAGTGTTATATGAAGGTGGAGTTGG  < 1000 
  TGTCTGTACTCGGTGATACGGGTCGGATTCTTATAGACTACTAATATTTCACGAACGTAATGGAGACTTCGACATATCACAATATACTTCCACCTCAACC 
           910       920       930       940       950       960       970       980       990  
 
                                                                   
                                                                   
  AGAGATGAGTTTTAAGCGTATATTGCAAACTCTAGGGCAACCACTAAAGAAGTGAGACCCAGCCTCTAGAAAAAAAAAAAAAAAGGAAATTAGCTATCAA  < 1100 
  TCTCTACTCAAAATTCGCATATAACGTTTGAGATCCCGTTGGTGATTTCTTCACTCTGGGTCGGAGATCTTTTTTTTTTTTTTTCCTTTAATCGATAGTT 
           1010      1020      1030      1040      1050      1060      1070      1080      1090  
 
                                              
                                              
  GCCACGAAAAGAAATGGAGGAACCTTAAACGCATATTACTAACTGAGATACGTCACTTTGAAAAGGCTACAAACGGTGTCATTCCAACTATACAACATTT  < 1200 
  CGGTGCTTTTCTTTACCTCCTTGGAATTTGCGTATAATGATTGACTCTATGCAGTGAAACTTTTCCGATGTTTGCCACAGTAAGGTTGATATGTTGTAAA 
           1110      1120      1130      1140      1150      1160      1170      1180      1190  
 
                                                                                                                              
          
  TGGAAAAGGCCAAAGCATGGTGATGATAAAAAGATCGGAGATGTCAGGGACTGGGGCAGGAGGGATGAGCTGGCAGAGCACAGGTTTTCTTTTCCTCTTT  < 1300 
  ACCTTTTCCGGTTTCGTACCACTACTATTTTTCTAGCCTCTACAGTCCCTGACCCCGTCCTCCCTACTCGACCGTCTCGTGTCCAAAAGAAAAGGAGAAA 
           1210      1220      1230      1240      1250      1260      1270      1280      1290  
 
                      
                      
  TTAAGACAGTGAAAATACTCCTAGGATCCTGCAAGGAGGGATACAAATTACATACATTTGTCAAAACCCACAGCATGTTGACCACCAGGAGGAGACCCCA  < 1400 
  AATTCTGTCACTTTTATGAGGATCCTAGGACGTTCCTCCCTATGTTTAATGTATGTAAACAGTTTTGGGTGTCGTACAACTGGTGGTCCTCCTCTGGGGT 
           1310      1320      1330      1340      1350      1360      1370      1380      1390  
 
                                                                                    
                                                                                    
  TGTGACTCCAGGACCCTGGTTGATAACAACGTATCGAGATTCCTCACATGGAACCAGTGCGCTTCTGTGGTGGAGGGTGTACCTGTGTCAGGGCAGGGGG  < 1500 
  ACACTGAGGTCCTGGGACCAACTATTGTTGCATAGCTCTAAGGAGTGTACCTTGGTCACGCGAAGACACCACCTCCCACATGGACACAGTCCCGTCCCCC 
           1410      1420      1430      1440      1450      1460      1470      1480      1490  
 
   
   
  TACGTGGACATTTTCTGCAGTTTTTGATCAATTTTGCAATGAACTAAATCTGTGGTATAAAAATAAAGTCTATTAAAAGAATCCAAGGCCCCCTCTCATC  < 1600 
  ATGCACCTGTAAAAGACGTCAAAAACTAGTTAAAACGTTACTTGATTTAGACACCATATTTTTATTTCAGATAATTTTCTTAGGTTCCGGGGGAGAGTAG 
           1510      1520      1530      1540      1550      1560      1570      1580      1590  
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  TCACGATAAGATAAAGTCCCCATCCATTTTACTCCTCTCAGCCCTGGAGAAAGGAGAGGCCAGGTCCCACCACCTTCCACCAGCATGGACCCCCAGTCCA  < 1700 
  AGTGCTATTCTATTTCAGGGGTAGGTAAAATGAGGAGAGTCGGGACCTCTTTCCTCTCCGGTCCAGGGTGGTGGAAGGTGGTCGTACCTGGGGGTCAGGT 
           1610      1620      1630      1640      1650      1660      1670      1680      1690  
 
                                    
                                    
                                    
  GACCCCACGCCTTTTCTCAGCATCCTCAGACCAGCAGGACTTGCAGCAATGGGGAATTAGGCACCTGACTTCTCCTTCATCTACCTTTGGCTGGGGGCCT  < 1800 
  CTGGGGTGCGGAAAAGAGTCGTAGGAGTCTGGTCGTCCTGAACGTCGTTACCCCTTAATCCGTGGACTGAAGAGGAAGTAGATGGAAACCGACCCCCGGA 
           1710      1720      1730      1740      1750      1760      1770      1780      1790  
 
                                                           
                                                           
  CCAGCCTTGACCTTCGCTCTGAGAGTCTCAGGCAGGTCCAGAGCCAGTTCTCCCATGACGTGATATGTTTCCAGAGCAGGTTCCTGGGTGAGATAAAAGG  < 1900 
  GGTCGGAACTGGAAGCGAGACTCTCAGAGTCCGTCCAGGTCTCGGTCAAGAGGGTACTGCACTATACAAAGGTCTCGTCCAAGGACCCACTCTATTTTCC 
           1810      1820      1830      1840      1850      1860      1870      1880      1890  
 
 
                                          
                                pGL3 plasmid•                                        
  ATTTGGGCTGAACAGGGTGGAGGGAGCATTGGGCTAGAGCGGCCGGGCTCGAGATCTGCGATCTAAGTAAGCTTGGCATTCCGGTACTGTTGGTAAAGCC  < 2000 
  TAAACCCGACTTGTCCCACCTCCCTCGTAACCCGATCTCGCCGGCCCGAGCTCTAGACGCTAGATTCATTCGAACCGTAAGGCCATGACAACCATTTCGG 
           1910      1920      1930      1940      1950      1960      1970      1980      1990  
 
 
    
  ACCATGGAAGACGCCAAAAACATAAAGAAAGGCCCGGCGCCATTCTATCCGCTGGAAGATGGAACCGCTGGAGAGCAACTGCATAAGGCTATGAAGAGAT  < 2100 
  TGGTACCTTCTGCGGTTTTTGTATTTCTTTCCGGGCCGCGGTAAGATAGGCGACCTTCTACCTTGGCGACCTCTCGTTGACGTATTCCGATACTTCTCTA 
           2010      2020      2030      2040      2050      2060      2070      2080      2090  
 
                                                                          
 
                     
  ACGCCCTGGTTCCTGGAACAATTGCTTTTACAGATGCACATATCGAGGTGGACATCACTTACGCTGAGTACTTCGAAATGTCCGTTCGGTTGGCAGAAGC  < 2200 
  TGCGGGACCAAGGACCTTGTTAACGAAAATGTCTACGTGTATAGCTCCACCTGTAGTGAATGCGACTCATGAAGCTTTACAGGCAAGCCAACCGTCTTCG 
           2110      2120      2130      2140      2150      2160      2170      2180      2190  
 
                                       
 
                                       
  TATGAAACGATATGGGCTGAATACAAATCACAGAATCGTCGTATGCAGTGAAAACTCTCTTCAATTCTTTATGCCGGTGTTGGGCGCGTTATTTATCGGA  < 2300 
  ATACTTTGCTATACCCGACTTATGTTTAGTGTCTTAGCAGCATACGTCACTTTTGAGAGAAGTTAAGAAATACGGCCACAACCCGCGCAATAAATAGCCT 
           2210      2220      2230      2240      2250      2260      2270      2280      2290  
 
 
   
  GTTGCAGTTGCGCCCGCGAAC  < 2321 
  CAACGTCAACGCGGGCGCTTG 
           2310     
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